document incorporate reference specify portion registrant proxy statement file commission pursuant regulation connection registrant annual meeting stockholder hold incorporate reference iii report base closing price share june exclude share registrant common stock hold executive officer director stockholder ownership exceed registrant common stock outstanding june exclusion share construe indicate person possess power direct indirect direct cause direction management policy registrant person control common control registrantgilead sciences inc annual report table content item business item risk factor item unresolved staff comment item property item legal proceeding item safety disclosure item market registrant common equity relate stockholder matter issuer purchase equity security item select financial datum item management discussion analysis financial condition result operation item quantitative qualitative disclosure market risk item financial statement supplementary datum item change disagreement accountant account financial disclosure item control procedure item information iii item director executive officer corporate governance item executive compensation item security ownership certain beneficial owner management relate stockholder matter item certain relationship relate transaction director independence item principal accountant fee service item exhibit financial statement schedule signature right trademark copyright trade name business include follow gilead gilead sciences stribild complera eviplera truvada viread hepsera ambisome emtriva vistide letairis volibris ranexa cayston rapiscan atripla register trademark belong bristolmyer squibb gilead sciences llc lexiscan register trademark belong astella llc macugen register trademark belong eyetech inc sustiva register trademark bristolmyers squibb pharma company tamiflu register trademark belong hoffmannla roche inc report include trademark service mark trade name companiesthis annual report include section entitle management discussion analysis financial condition result operation contain forwardlooke statement future event future result subject safe harbor create security act amend securities act securities exchange act amended exchange act word expect anticipate target goal project hope intend plan believe seek estimate continue variation word similar expression intend identify forwardlooke statement addition statement statement historical fact forward look statement include statement overall trend operate cost revenue trend liquidity capital need statement expectation belief future plan strategy anticipate event trend similar expression base forwardlooke statement current expectation future event statement guarantee future performance involve risk uncertainty assumption difficult predict actual result differ materially suggest forwardlooke statement reason include identify risk factor beginning give risk uncertainty caution place undue reliance forward look statement forwardlooke statement include report date hereof require federal security law rule regulation securities exchange commission sec undertake specifically decline obligation update statement publicly announce result revision forwardlooke statement distribution report result new information future event change assumption item business overview gilead sciences inc gilead incorporate delaware june researchbase biopharmaceutical company discover develop commercialize innovative medicine area unmet medical need new discovery experimental drug candidate seek improve care patient suffer lifethreatening disease world gilead primary area focus include human immunodeficiency virus hiv liver disease hepatitis virus hbv hepatitis virus hcv cardiovascular respiratory condition oncologyinflammation headquarter foster city california operations north america europe asia continue add exist portfolio product internal discovery clinical development program product acquisition inlicense strategy highlight past year execute strategy bring bestinclass drug market complete acquisition pharmasset inc pharmasset accelerate timeline develop alloral hcv regimen enter agreement acquire biosciences inc biosciences closed february expand grow oncologyinflammation pipeline expand single tablet regimen product offering treatment hiv launch stribild united states combine medicine oncedaily single tablet regimen expand worldwide access compleraeviplera available country advance research development pipeline active phase clinical trial end file marketing application component stribild elvitegravir cobicistat single agent hiv program substantial portion revenue derive market hiv product continue forefront advance hiv treatment development new single tablet regimen longterm goal ensure hiv patient option choose single tablet regiman right single tablet regimen allow patient adhere fully suppressive course therapy easily consistently critical successful management disease continue focus development new hiv medicine coformulation launch stribild united states compleraeviplera atripla single tablet regimen available submit marketing application united states european union elvitegravir integrase inhibitor treatment hiv infection treatmentexperience adult cobicistat pharmacoenhance boost agent increase blood level allow oncedaily dose certain hiv medicine food drug administration fda set target review date april prescription drug user fee act obtain fda approval oncedaily oral truvada combination safe sex practice preexposure prophylaxis prep reduce risk hiv infection uninfected adult truvada antiretroviral approve prevention hiv infection adult important progress clinical development tenofovir alafenamide taf know phase study show taf efficacious onetenth dose viread provide potential safety advantage base result phase trial evaluate single tablet regimen taf elvitegravir cobicistat emtricitabine treatment hiv infection treatmentnave adult commence early year agreement janssen ireland janssen conduct phase trial evaluate single tablet regimen taf cobicistat darunavir emtricitabine treatment hiv infection hcv program january acquire pharmasset acquisition acquire sofosbuvir know investigational nucleotide analog act inhibit replication hcv product candidate currently phase phase clinical trial hcv therapeutic market continues vastly underserve limitation available therapy small fraction individual infect hcv diagnose small fraction patient treat prior protease inhibitor approve half patient respond standard care combination pegylate interferon pegifn ribavirin addition protease inhibitor standard care result incremental response rate patient genotype infection regimen cause substantial effect fatigue bone marrow suppression potentially debilitate rash anemia neuropsychiatric effect discontinuation rate triple therapy combination significantly increase expect receive significant datum clinical trial evaluate sofosbuvir combination direct acting antiviral hcvinfecte individual genotype initial new drug application nda sofosbuvir support phase study name fission positron fusion neutrino fission study genotype treatment nave patient compare week sofosbuvir ribavirin current standard care week treatment interferon ribavirin positron compare week treatment sofosbuvir ribavirin genotype interferon intolerantineligible patient placebo fusion study explore week duration treatment sofosbuvir ribavirin genotype treatmentexperience patient neutrino single arm study evaluating week course sofosbuvir interferon ribavirin genotype infectedpatient announce datum study late quarter anticipate file regulatory approval sofosbuvir second quarter expect initial indication week treatment sofosbuvir ribavirin treatmentnaive interferonintolerant experienced genotype patient week treatment sofosbuvir peg ifn ribavirin treatmentnaive genotype patient parallel advance fixeddose combination sofosbuvir ledipasvir treatment genotype patient nda fix dose combination sofosbuvir ledipasvir support clinical trial study name ion evaluate fixeddose combination sofosbuvir ledipasvir ribavirin week treatmentnave genotype infect patient pende review result week arm initial enrollment patient second quarter expect enroll additional patient ion study assess fix dose combination sofosbuvir ledipasvir total individual january start screen patient second phase study name ion evaluate fixeddose combination ribavirin week ribavirin week therapy treatmentexperience genotype hcv patient risk factor entitle public announcement datum clinical study evaluate sofosbuvir fix dose combination sofosbuvir ledipasvir hcvinfecte patient likely cause significant volatility stock price oncologyinflammation year work advance oncology franchise idelalisib pik delta inhibitor antibody know advance phase trial compound evaluate treatment chronic lymphocytic leukemia indolent nonhodgkin lymphoma simtuzumab monoclonal antibody know evaluate phase trial treatment myelofibrosis colorectal cancer pancreatic cancer acquisition bioscience acquire momelotinib know cyt momelotinib jak inhibitor evaluate phase clinical trial treatment myelofibrosis expect advance compound phase trial later product hivaid stribild elvitegravir mgcobicistat mgemtricitabine mgtenofovir disoproxil fumarate complete oncedaily single tablet regimen hiv infection treatmentnaive adult stribild combine compound daily tablet approve fda august file marketing authorization application stribild european medicine agency ema december expect receive approval european commission second quarter compleraeviplera oral formulation dose day treatment hiv infection treatmentnave adult product market united states complera europe eviplera second complete single tablet regimen treatment hiv fixeddose combination antiretroviral medication viread tenofovir disoproxil fumarate emtriva emtricitabine janssen nonnucleoside reverse transcriptase inhibitor edurant rilpivirine atripla efavirenz mgemtricitabine mgtenofovir disoproxil fumarate oral formulation dose day treatment hiv infection adult atripla oncedaily single tablet regimen hiv intend stand therapy combination antiretroviral fixeddose combination antiretroviral medication viread emtriva bristol myerssquibb company non nucleoside reverse transcriptase inhibitor sustiva efavirenz truvada emtricitabine tenofovir disoproxil fumarate oral formulation dose day combination therapy treat hiv infection adult fixeddose combination antiretroviral medication viread emtriva fda approve truvada combination safe sex practice reduce risk sexually acquire hiv infection adult high risk strategy call preexposure prophylaxis prep viread oral formulation nucleotide analog reverse transcriptase inhibitor dose day combination therapy treat hiv infection patient year age old european commission approve use viread combination antiretroviral agent treatment hiv infect pediatric patient age year nucleoside reverse transcriptase inhibitor resistance toxicity precluding use line pediatric agent viread approve treatment chronic hbv adult emtriva oral formulation nucleoside analog reverse transcriptase inhibitor dose day combination therapy treat hiv infection adult united states europe emtriva available oral solution approve combination therapy treat hiv infection child liver disease viread oral formulation nucleotide analog reverse transcriptase inhibitor dose day treatment chronic hbv adult compensate decompensate liver disease license glaxosmithkline inc gsk right commercialize viread treatment chronic hbv china japan saudi arabia european commission approve use viread treatment chronic hbv infection adolescent patient age year compensate liver disease evidence immune active disease viread approve treatment hiv infection patient year age old combination antiretroviral agent hepsera adefovir dipivoxil oral formulation nucleotide analog polymerase inhibitor dose day treat chronic hbv patient year age old license gsk right commercialize hepsera treatment chronic hbv asia latin america certain territory cardiovascular letairis ambrisentan oral formulation endothelin receptor antagonist era indicate treatment pulmonary arterial hypertension pah group patients class iii symptom improve exercise capacity delay clinical worsen sublicense gsk right ambrisentan market gsk volibris ambrisentan pah territory outside united states ranexa ranolazine extendedrelease tablet treatment chronic angina licensed menarini international operation luxembourg rights ranexa territory outside united states lexiscanrapiscan regadenoson injection indicate use pharmacologic stress agent radionuclide myocardial perfusion image mpi test detect characterize coronary artery disease patient unable undergo adequate exercise stress astella llc exclusive right manufacture sell regadenoson lexiscan united states subject obligation pay royalty base sale lexiscan rapidscan pharma solutions inc rps hold exclusive right manufacture sell regadenoson rapiscan europe certain territory outside united states receive royalty astella rps sale territory respiratory cayston aztreonam inhalation solution inhale antibiotic treatment respiratory system cystic fibrosis patient year age old pseudomona aeruginosa aeruginosa tamiflu oseltamivir phosphate oral antiviral available capsule form treatment prevention influenza tamiflu approve treatment influenza child adult country include united states japan european union tamiflu approve prevention influenza child adults united states japan european union develop tamiflu hoffmannla roche ltd hoffmannla roche inc roche roche exclusive right manufacture sell tamiflu worldwide subject obligation pay royalty base percentage net sale tamiflu ambisome amphotericin liposome injection proprietary liposomal formulation amphotericin antifungal agent treat invasive fungal infection cause fungal specie adult corporate partner astella pharma inc promote sell ambisome united states canada promote sell ambisome europe australia new zealand vistide cidofovir injection antiviral injection treatment cytomegalovirus retinitis adult patient aid macugen pegaptanib sodium injection intravitreal injection antiangiogenic oligonucleotide treatment neovascular agerelate macular degeneration macugen develop eyetech inc eyetech technology license promote united states valeant pharmaceuticals inc valeant acquire eyetech valeant hold exclusive right manufacture sell macugen united states pfizer inc pfizer hold exclusive right manufacture sell macugen rest world receive royalty valeant pfizer base sale macugen worldwide sale antiviral product include product hivaid liver disease area describe billion billion billion represent total revenue sale product include letairis ranexa ambisome cayston billion billion million represent total revenue item management discussion analysis include annual report information revenue commercialization distribution international commercial sale operation marketing subsidiary australia austria belgium canada czech republic denmark finland france germany greece hong kong ireland italy japan netherlands new zealand norway poland portugal russia south korea spain sweden switzerland turkey united kingdom united states product market commercial team andor conjunction thirdparty distributor corporate partner commercial team promote product direct field contact physician hospital clinic healthcare provider generally grant thirdparty distributor exclusive right promote product territory specify period time agreement distributor provide collaborative effort distributor gilead obtain maintain regulatory approval product specify territory sell distribute stribild complera atripla truvada viread hepsera emtriva ranexa vistide united states exclusively wholesale channel product sale large wholesaler cardinal health inc mckesson corp amerisourcebergen corp account total revenue year end december combine basis wholesaler account approximately product sale united states approximately total worldwide revenue letairis cayston distribute exclusively specialty pharmacy specialty pharmacy dispense medication complex chronic condition require high level patient education ongoing counseling sell distribute compleraeviplera atripla truvada viread hepsera emtriva ambisome asia australia canada europe latin america middle east new zealand commercial team thirdparty distributor corporate partner access develop world gilead access program establish certain product treatment hiv chronic hbv visceral leishmaniasis available substantially reduce price develop world gilead deliver medicine country work regional business partner distribute brandname viread truvada price base country ability pay represent little profit gilead partnership india base company expand access generic version hiv medication leastdevelope country world work closely world health organization nongovernmental organization provide ambisome treatment leishmaniasis preferential price resource limited setting support numerous clinical study investigate role ambisome treat visceral cutaneous leishmaniasis develop country collaboration organization drug neglect disease initiative mdecin san frontire support clinical research study aim identify good treatment course visceral leishmaniasis donate ambisome support clinical study assess combination therapy costeffectiveness multiple visceral leishmaniasis treatment intervention december sign partnership agreement world health organization donate vial ambisome year donation treat patient resourcelimite country support clinical study donation product help define good treatment strategy develop world country example donate tenofovir centre aids programme research south africa caprisa microbicide trial assess effectiveness safety tenofovirbase microbicide gel prevention hiv infection south african woman provide drug number innovative international study investigate viread truvada prevent hiv transmission atrisk uninfected adult hiv prevention strategy call preexposure prophylaxis prep fda approval truvada agent indicate uninfected individual reduce risk acquire hiv sex enter number collaboration relate access product develop world include pharmachem technologies grand bahama ltd pharmachem pharmachem commercial manufacturing partner establish facility bahama manufacture tenofovir disoproxil fumarate active pharmaceutical ingredient viread active pharmaceutical ingredient atripla truvada resource limited country cooperative effort pharmachem grand bahama port authority aspen pharmacare holdings ltd aspen enter nonexclusive manufacturing distribution agreement aspen provide manufacture distribution viread truvada treatment hiv infection certain develop world country include gilead access program amend agreement aspen amend agreement aspen retain right manufacture distribute viread truvada treatment hiv infection develop world country aspen right purchase viread truvada unlabeled bottle distribution country right manufacture viread truvada active pharmaceutical ingredient purchase aspen supplier approve aspen grant right manufacture distribute generic version emtricitabine tenofovir disoproxil fumarate include version tenofovir disoproxil fumarate combination emtricitabine treatment hiv infection aspen require pay royalty net sale viread truvada royaltie net sale generic version tenofovir disoproxil fumarate include version tenofovir disoproxil fumarate combination generic version emtricitabine manufacture distribute aspen license generic manufacturer enter nonexclusive license agreement indian generic manufacturer grant right produce distribute generic version tenofovir disoproxil fumarate treatment hiv infection low income country world include india low income country gilead access program agreement require generic manufacturer meet certain national international regulatory quality standard include technology transfer enable expeditious production large volume high quality generic version tenofovir disoproxil fumarate addition agreement allow manufacture commercial quantity active pharmaceutical ingredient finish product expand nonexclusive license agreement increase number country include license include right stribild future product candidate elvitegravir investigational integrase inhibitor cobicistat pharmacoenhance boost agent increase blood level allow oncedaily dose certain hiv medicine expand access viread treatment hbv treatment develop country include nonexclusive license agreement ability manufacture distribute generic version tenofovir disoproxil fumarate treatment hbv country authorize sell generic version tenofovir disoproxil fumarate hiv august announce new collaboration indian partner produce distribute generic emtricitabine develop world include single tablet regimen contain emtricitabine fixeddose combination emtricitabine coformulate gilead hiv medicines merck enter agreement affiliate merck pursuant gilead merck provide atripla substantially reduce price hiv infect patient develop country africa caribbean latin america southeast asia agreement manufacture atripla efavirenz supply merck merck handle distribution product country cover agreement international partnership microbicide ipm conrad enter agreement grant right ipm conrad cooperate agency agency international development commit improve reproductive health expand contraceptive choice woman man develop manufacture prove efficacious arrange distribution resource limited country certain formulation tenofovir use topical microbicide prevent hiv infection medicine patent pool pool enter agreement pool organization establish united nations increase global access highquality lowcost antiretroviral therapy sharing patent grant pool nonexclusive license identify generic pharmaceutical manufacturer india specialize highquality production generic medicine grant sublicense indian manufacturer manufacture distribute generic version antiretroviral develop world sublicensee pool free develop combination product pediatric formulation hiv medicine grant pool right grant sublicense generic version stribild product candidate elvitegravir cobicistat generic pharmaceutical manufacturer india distribution develop world janssen expand agreement janssen tibotec pharmaceutical provide distribution compleraeviplera treatment hiv develop country enable commercialization generic version product competition market product target number area include viral cardiovascular respiratory fungal disease commercially available product treatment disease company institution make substantial investment develop additional product treat disease product compete available product base primarily efficacy safety tolerability acceptance doctor ease patient compliance patent protection ease use price insurance reimbursement coverage distribution marketing hiv product hiv landscape competitive complex treatment trend continue evolve grow number hiv drug currently sell advanced stage clinical development competition current expect competitor erode revenue receive sale hiv product brand hiv drug available united states product primarily compete fixeddose combination product nucleotidenucleoside reverse transcriptase inhibitor nrti class include combivir lamivudinezidovudine epzicomkivexa abacavirlamivudine trizivir abacavirlamivudinezidovudine sell joint venture viiv establish november gsk pfizer focus hiv therapie hiv product compete broadly hiv product abbott laboratories inc boehringer ingelheim gmbh merck roche janssen bms videx didanosine ddi generic hiv product united states gsk retrovir zidovudine face generic competition united states result launch generic zidovudine bms zerit stavudine face generic competition united states result launch generic stavudine epivir lamivudine market viiv competitive emtricitabine active pharmaceutical ingredient emtriva component atripla truvada compleraeviplera stribild compound patent cover epivir lamivudine expire united states europe generic lamivudine available united states spain portugal italy expect generic version lamivudine launch country european union generic version combivir lamivudine zidovudine approve recently launch united states addition late generic tenofovir available turkey result increase rebate viread turkey date significant impact generic didanosine zidovudine stavudine lamivudine generic version combivir generic tenofovir turkey price hiv product price decrease hiv product result long term currently expect competition generic version sustiva efavirenz component atripla available europe canada united states negatively impact sale hiv product expect launch dolutegravir integrase inhibitor fourth quarter gsk impact sale hiv product liver disease product hbv product viread hepsera face significant competition exist expect therapy treat patient chronic hbv erode revenue receive sale hbv product hbv product face competition baraclude entecavir oral nucleoside analog develop bms launch united states europe tyzekasebivo telbivudine oral nucleoside analog develop novartis pharmaceutical corporation novartis sale united states european union china hbv product compete epivirhbvzeffix lamivudine develop gsk collaboration shire pharmaceuticals group plc sell major country north south america europe asia viread hepsera treatment chronic hbv compete establish immunomodulatory therapy include introna interferon alfab sell schere plough corporation major country north south america europe asia pegasys pegylate interferon alfaa injectable drug similar introna sell roche treatment chronic hbv cardiovascular product letairis compete directly tracleer bosentan sell actelion pharmaceutical inc actelion indirectly adcirca tadalafil united therapeutics corporation ranexa compete predominantly generic compound distinct class drug treatment chronic angina united states include generic andor brand betablocker calcium channel blocker longacte nitrate addition surgical treatment intervention coronary artery bypass graft percutaneous coronary intervention option angina patient perceive healthcare practitioner prefer method treat cardiovascular disease underlie cause angina numerous market generic andor brand pharmacologic stress agent compete lexiscanrapiscan respiratory product cayston compete primarily tobi tobramycin inhalation solution inhale medication sell novartis treatment patient lung contain aeruginosa bacterial infection tamiflu compete relenza zanamivir antiinfluenza drug sell gsk relenza neuraminidase inhibitor deliver orallyinhale dry powder generic competitor include amantadine rimantadine oral tablet inhibit replication influenza virus biocryst pharmaceuticals inc develop injectable formulation peramivir influenza neuraminidase inhibitor treatment influenza currently approve japan south korea product ambisome face strong competition current expect competitor ambisome face competition vfend voriconazole develop pfizer caspofungin product develop merck market cancidas united states caspofungin ambisome compete lipidbase amphotericin product include abelcet amphotericin lipid complex injection sell enzon pharmaceuticals inc united states canada japan zeneus pharma ltd europe amphotec amphotericin cholesteryl sulfate complex injection sell river pharmaceutical llc worldwide anfogen amphotericin liposomal sell genpharma argentina bms numerous generic manufacturer sell conventional amphotericin compete ambisome aware lipid formulation claim similarity ambisome available outside united state include possible entry formulation greece taiwan formulation reduce market demand ambisome manufacture lipid formulation amphotericin complex formulation find unsafe sale ambisome negatively impact association vistide compete number drug treat cytomegalovirus retinitis include cytovene cytovene ganciclovir sell intravenous oral formulation respectively roche ocular implant bausch lomb incorporate valcyte valganciclovir market roche foscavir foscarnet intravenous drug sell astrazeneca plc vitravene fomivirsen drug inject directly eye sell cibavision macugen compete primarily visudyne verteporfin injection sell novartis connection photodynamic therapy lucentis ranibizumab sell genentech inc united states novartis territory outside united states number company pursue development technology competitive research program compete company include specialized pharmaceutical firm large pharmaceutical company act independently pharmaceutical company furthermore academic institution government agency public private organization conduct research seek patent protection establish collaborative arrangement competitive product program collaborative relationship business strategy establish collaboration company university medical research institution assist clinical development andor commercialization certain product product candidate provide support research program evaluate opportunity acquire product right product technology complementary business company university medical research institution information certain relationship include ongoing financial accounting impact business find item note consolidated financial statement include annual report form commercial collaboration currently number collaboration corporate partner govern manufacture sale distribution andor marketing product territory worldwide follow commercial collaboration significant financial statement perspective significant ongoing collaboration activity exist bms enter collaboration arrangement bms develop commercialize single tablet regimen truvada bms sustiva united states combination approve use united states sell brand atripla bms structure collaboration joint venture operate limited liability company name bristolmyers squibb gilead sciences llc consolidate bms grant royalty free sublicense joint venture use respective company own technology return grant license joint venture use intellectual property result collaboration joint venture collaboration agreement amend allow joint venture sell atripla canada economic interest joint venture hold bms include share revenue outofpocket expense base portion net selling price atripla attributable efavirenz truvada net selling price truvada change time relative net selling price efavirenz bms respective economic interest joint venture vary annually second quarter limited number activity jointly manage party long coordinate detail promotional activity united states party reduce joint promotional effort launch complera august stribild august agreement continue terminate mutual agreement party addition party terminate party participation collaboration day launch generic version party single agent product double agent product nonterminate party right continue sell atripla obligate pay terminate party certain royalty threeyear period follow effective date termination gilead sciences limit whollyowne subsidiary ireland bms enter collaboration agreement bms commercialize distribute atripla european union iceland liechtenstein norway switzerland collectively european territory party form limited liability company consolidate manufacture atripla distribution european territory efavirenz purchase bms bms estimate net selling price efavirenz european territory start quarter limited number activity jointly manage party long coordinate detail promotional activity region december efavirenz purchase bms bms estimate net selling price efavirenz european territory include inventory consolidate balance sheet agreement terminate expiration lasttoexpire patent afford market exclusivity atripla component european country cover agreement addition party terminate agreement reason termination effective later december calendar quarter notice termination nonterminate party right continue sell atripla obligate pay terminate party certain royalty threeyear period follow effective date termination event nonterminate party decide sell atripla effective date termination date atripla withdraw country date party assume distribution atripla whichever early gsk result acquisition myogen inc myogen assume right march license distribution supply agreement myogen gsk term license agreement gsk exclusive right market ambrisentan active pharmaceutical ingredient letairis volibris pulmonary arterial hypertension territory outside united states license agreement receive upfront payment million subject achievement specific milestone eligible receive total additional milestone payment million december receive million potential milestone payment addition receive royalty base net sale volibris gsk territory gsk option negotiate exclusive sublicense additional therapeutic use volibris gsk territory term license agreement agreement continue conduct bear expense clinical development activity believe required obtain maintain regulatory approval letairis volibris united states canada european economic area party conduct additional development activity territory expense party agree jointly develop ambrisentan new indication license field party pay share external cost associate joint development agreement gsk obligation pay royalty terminate countrybycountry basis early date generic equivalent sell country achieve certain percentage total prescription product plus generic equivalent fifteenth anniversary commercial launch country gsk terminate agreement reason termination right product revert party terminate agreement response material breach party janssen enter collaboration agreement janssen develop commercialize fixeddose combination truvada janssen rilpivirine combination approve united states european union sell brand complera united states eviplera european union agreement janssen grant exclusive license compleraeviplera worldwide exclude certain middle income develop world country japan party restrict combine drug drug december record million approximately million reimbursable expense incur janssen development rilpivirine maximum reimbursable term agreement responsible manufacturing compleraeviplera lead role registration distribution commercialization product license country janssen exercise right codetail combination product country gilead sell party july february amend collaboration agreement include distribution compleraeviplera rest world distribute product north america europe latin america argentina mexico australia new zealand janssen distribute product region include japan russia price product expect sum price truvada price rilpivirine purchase separately cost rilpivirine purchase janssen compleraeviplera approximate market price rilpivirine specified percentage major market party terminate collaboration agreement compleraeviplera withdraw market party materially breach agreement terminate agreement united states canada expiration expire patent tenofovir disoproxil fumarate united states terminate agreement country expiration expire patent tenofovir disoproxil fumarate country european union janssen terminate agreement united states canada expiration expire patent rilpivirine united states terminate agreement country expiration expire patent rilpivirine country european union research collaboration currently number collaboration corporate partner govern research development certain compound drug candidate research collaboration japan tobacco inc japan tobacco collaboration significant financial statement perspective significant ongoing collaboration activity exist japan tobacco enter licensing agreement japan tobacco japan tobacco grant exclusive right develop commercialize elvitegravir novel hiv integrase inhibitor country world exclude japan japan tobacco retain right agreement responsible seek regulatory approval territory require use diligent effort commercialize product treatment hiv infection bear cost expense associate commercialization effort term agreement pay upfront license fee million obligate total potential milestone payment million achievement certain clinical regulatory commercial objective additionally obligate pay royalty base net sale territory market product december total milestone payment million agreement obligation pay royalty japan tobacco terminate productbyproduct basis patent provide exclusivity product expire later tenth anniversary commercial launch product terminate agreement reason case license grant japan tobacco terminate party terminate agreement response material breach party research development research development philosophy strategy develop bestinclass drug improve safety efficacy unmet medical need intend continue commit significant resource research development opportunitie business development activity product development effort cover wide range medical condition include hivaid liver disease hbv hcv cardiovascular respiratory condition inflammationoncology research scientist foster city fremont palo alto san dimas oceanside california branford connecticut seattle washington mississauga ontario engage discovery development new molecule technology hope lead approval new medicine address unmet need development product candidate subject risk uncertaintie risk uncertainty include ability enroll patient clinical trial possibility unfavorable result clinical trial need modify delay clinical trial perform additional trial risk fail obtain regulatory approval result product candidate successfully commercialize drug development inherently risky product candidate fail drug development process summary key product candidate correspond current stage development additional information development pipeline visit website wwwgileadcom product candidate treatment hiv product candidate description marketing application pende stribild new drug application nda stribild oncedaily single tablet regimen elvitegravir cobicistat tenofovir disoproxil fumarate emtricitabine treatment hiv infection treatmentnave adult approve fda august file marketing authorization application stribild european medicine agency december expect receive approval european commission second quarter cobicistat cobicistat pharmacoenhance boost agent increase blood level allow oncedaily dose certain hiv medicine approve component stribild united states evaluation standalone boost agent certain hiv medicine treatmentnave patient received validation ema marketing authorization application product june file nda approval product single agent elvitegravir elvitegravir oral integrase inhibitor approve component stribild united states evaluate standalone agent hiv treatmentexperience patient june submit nda product receive validation ema marketing authorization application june file nda product single agent product phase single tablet regimen tenofovir alafenamide single tablet regimen taf nucleotide reverse transcriptase inhibitor know taf elvitegravir cobicistat emtricitabine elvitegravir cobicistat emtricitabine evaluate treatment hiv infection treatmentnave adult product phase single tablet regimen taf darunavir agreement janssen ireland enter single tablet regimen taf darunavir cobicistat emtricitabine cobicistat emtricitabine evaluate treatment hiv infection product candidate treatment liver disease product candidate description product phase sofosbuvir sofosbuvir nucleotide nsb inhibitor evaluation phase phase trial treatment hcv single tablet regimen sofosbuvir single tablet regimen sofosbuvir ledipasvir oral nsa inhibitor take ribavirin ledipasvir evaluation phase trial treatment hcv product phase oral protease inhibitor evaluate treatment hepatitis nonnucleoside nsb polymerase inhibitor evaluation treatment hcv simtuzumab simtuzumab monoclonal antibody evaluate treatment liver fibrosis nonalcoholic steatohepatitis primary sclerose cholangitis product phase pangenotypic nsa inhibitor evaluate treatment hcv oral tlr agonist evaluate treatment hbv hcv taf taf nucleoside reverse transcriptase inhibitor evaluation treatment hbv product candidate treatment cardiovascular disease product candidate description product phase ranolazine ranolazine late sodium current inhibitor approve treatment chronic angina evaluate treatment incomplete revascularization postpercutaneous coronary intervention treatment type diabetes product phase ranolazine ranolazine evaluate treatment paroxysmal atrial fibrillation product phase late sodium current inhibitor evaluate treatment ischemic heart disease arrhythmia product candidate treatment respiratory disease product candidate description product phase aztreonam inhalation solution aztreonam inhalation solution evaluate treatment bronchiectasis product phase inhalable small molecule antiviral fusion inhibitor evaluate treatment respiratory syncytial virus simtuzumab simtuzumab monoclonal antibody evaluate treatment idiopathic pulmonary fibrosis product candidate treatment oncology diseasesinflammation product candidate description product phase idelalisib idelalisib pik delta inhibitor antibody evaluate treatment chronic lymphocytic leukemia indolent nonhodgkin lymphoma product phase momelotinib gscyt momelotinib know cyt jak inhibitor evaluate treatment myelofibrosis simtuzumab simtuzumab monoclonal antibody evaluate treatment myelofibrosis colorectal cancer pancreatic cancer product phase pik delta inhibitor evaluate potential treatment lymphoid malignancy combination idelalisib syk inhibitor evaluate combination idelalisib potential treatment hematological malignancy total expense billion compare billion billion addition internal discovery clinical development program seek add portfolio product product acquisition collaboration follow table show recent acquisition year company therapeutic area therapeutics inc cardiovascular disorder cgi pharmaceuticals inc inflammatory disease arresto biosciences inc fibrotic disease cancer calistoga pharmaceuticals inc cancer inflammatory disease pharmasset chronic hcv biosciences inc hematological immune cell disorder inflammatory disease cancer large transaction acquisition pharmasset january billion pharmasset clinicalstage pharmaceutical company locate princeton new jersey commit discover develop commercialize novel drug treat viral infection pharmasset primary focus development oral therapeutic treatment hcv infection acquisition pharmasset gain ownership sofosbuvir currently phase trial treatment hcv risk factor entitle public announcement datum clinical study evaluate sofosbuvir fixeddose combination sofosbuvir ledipasvir hcvinfecte patient likely cause significant volatility stock price patent proprietary right european patent expiration number foreign patent patent application right patent relate compound product technology certain issue patent enforceable provide adequate protection pende patent application result issue patent follow table show estimate expiration date include patent term extension supplementary protection certificate andor pediatric exclusivity grant united states europe primary typically compound patent phase product candidate patent cover ranolazine compound instead discover sustained release formulation ranolazine achieve therapeutic plasma level patent obtain formulation characteristic plasma level achieve date parenthesis reflect estimate expiration date patent issue currently pende application estimate expiration date include potential additional exclusivity patent term extension supplementary protection certificate pediatric exclusivity grant product candidate single tablet regimen estimate patent expiration date provide correspond late expiring compound patent active ingredient single tablet regimen phase product candidate patent expiration product candidate treatment hiv cobicistat elvitegravir single tablet regimen taf elvitegravir cobicistat emtricitabine product candidate treatment liver disease sofosbuvir treatment hepatitis single tablet regimen sofosbuvir ledipasvir treatment hepatitis product candidate treatment respiratory disease aztreonam inhalation solution treatment bronchiectasis product candidate treatment cardiovascular disease ranolazine treatment incomplete revascularization postpercutaneous coronary intervention treatment type diabetes product candidate treatment oncologyinflammation idelalisib treatment chronic lymphocytic leukemia indolent nonhodgkin lymphoma follow table show actual estimate expiration date include patent term extension supplementary protection certificate andor pediatric exclusivity grant united states europe primary typically compound patent market product patent cover ranolazine compound instead discover sustained release formulation ranolazine achieve therapeutic plasma level patent obtain formulation characteristic plasma level achieve date parenthesis reflect estimate expiration date patent issue currently pende application expiration date include potential additional exclusivity patent term extension supplementary protection certificate pediatric exclusivity product single tablet regimen truvada atripla complera stribild estimate patent expiration date provide correspond late expiring compound patent active ingredient single tablet regimen product patent expiration vistide hepsera ambisome macugen tamiflu letairis viread ranexa atripla cayston emtriva truvada lexiscan compleraeviplera stribild february gilead teva reach agreement principle settle ongoing patent litigation concern patent protect tenofovir disoproxil fumarate viread truvada atripla product agreement teva allow launch generic version viread december settlement agreement file federal trade commission department justice review final patent protection certain challenge patent proprietary right important business properly draft enforceable patent difficult competitor use technology create competitive product difficult competitor obtain patent prevent technology create business strategy actively seek patent protection united states internationally file additional patent application appropriate cover improvement compound product technology rely trade secret internal knowhow technological innovation agreement party develop maintain protect competitive position ability competitive depend success strategy patent cover active pharmaceutical ingredient stribild compleraeviplera atripla truvada viread emtriva hepsera letairis vistide lexiscan hold party acquire exclusive right patent agreement party patent cover ranolazine compound active ingredient ranexa instead discover sustained release formulation ranolazine achieve therapeutic plasma level patent obtain formulation characteristic plasma level achieve patent cover active ingredient ambisome instead hold patent liposomal formulation compound protect formulation trade secret addition patent filing china certain asian country cover form adefovir dipivoxil active ingredient hepsera asia major market therapie hbv indication hepsera develop obtain patent certain product year marketing approval obtain product patent limited life begin run prior commercial sale relate product commercial value patent limit able apply patent term extension example extension patent supplementary protection certificate product grant united states number european country compensate delay obtain marketing approval similar patent term extension available product develop certain obtain country important infringe valid patent proprietary right violate agreement grant proprietary right infringe valid patent violate agreement prevent commercialize product process cover patent agreement require obtain license party allow use technology unable obtain alternative technology require license reasonable term fail obtain license alternative technology unable develop commercialize product example aware body patent relate operation letairis education access program leap restrict distribution program design support letairis patent claim sofosbuvir chemical entity metabolite existence issue patent guarantee right practice patent technology commercialize patent product party obtain right patent claim prevent attempt prevent commercialize patented product candidate obtain pharmasset acquisition example aware patent patent application own party allege cover use sofosbuvir party successful obtain valid enforceable patent establish infringement patent prevent sell sofosbuvir able obtain license patent license need available commercially reasonable term gilead successor pharmasset party collaboration agreement roche develop psi cytidine analog prodrug treatment chronic hcv infection collaborative research effort agreement end december roche later ask pharmasset consider roche contributed inventorship sofosbuvir pharmasset comply confidentiality provision collaboration agreement pharmasset advise carefully consider issue raise roche believe issue merit consider issue reach conclusion roche recently contact assert roche exclusive license sofosbuvir pursuant collaboration agreement roche allege sofosbuvir prodrug uridine monophosphate analog prodrug psi roche exclusive license believe roche claim merit roche successfully establish inventorship exclusive license right sofosbuvir expect revenue earning sale sofosbuvir adversely affect patent application confidential period time patent issue know competitor file patent application technology cover pende application invent file application direct technology subject patent application competitor file patent application receive patent obtain additional patent proprietary right block compete product addition competitor file patent application cover technology participate interferencederivation proceeding litigation determine right patent litigation interferencederivation proceeding unpredictable expensive ultimately successful result operation adversely affect event patent relate pharmaceutical biopharmaceutical biotechnology product compound process cover exist compound product process likely file future provide complete adequate protection future litigation examination proceeding enforcement validity exist patent future patent invalidate patent substantially reduce protection time time certain individual entity challenge patent example public patent foundation file request examination patent trademark office pto challenge patent relate tenofovir disoproxil fumarate active ingredient atripla truvada compleraeviplera stribild viread pto grant request pto confirm patentability patent time time involved dispute inventor patent example march jeremy clark employee pharmasset acquire january inventor patent file demand arbitration lawsuit pharmasset raymond schinazi clark initially file lawsuit pharmasset schinazi february seek void assignment provision employment agreement assert ownership patent claim metabolite sofosbuvir december court order stay litigation pende outcome arbitration proceeding require clark employment agreement instead proceed arbitration clark file additional lawsuit september june subsequently dismiss court september clark file motion seek reconsideration court december order deny court december clark file motion appoint special prosecutor february court issue order require clark enter arbitration risk dismissal case clark file demand arbitration march arbitration panel set hearing date april predict outcome arbitration clark prior assignment patent pharmasset voided arbitration panel ultimately find owner patent determine infringe patent require obtain license pay royalty clark commercialize sofosbuvir instance require defend right patent invention interference proceed pto interference administrative proceeding pto design determine invent subject matter claim party february receive notice pto declare interference patent idenix pharmaceuticals inc idenix pende patent application patent cover metabolite sofosbuvir idenix attempt claim class compound include metabolite pende patent application course proceed party call submit evidence date conceive respective invention interference determine invent compound entitle patent claim compound administrative law judge determine idenix entitle patent claim determine infringe claim require obtain license pay royalty idenix commercialize sofosbuvir determination judge appeal party federal district court june meet idenix mandatory settlement discussion party unable settle interference widely divergent view strength respective position need license idenix patent idenix need license gilead patent develop manufacture pipeline product believe idenix application involve interference similar foreign patent claim compound metabolite invalid result file impeachment action canadian federal court invalidate idenix patent canadian patent correspond idenix patent idenix patent application subject interference file similar legal action federal court norway seek invalidate correspond norwegian patent file similar legal action federal court australia seek invalidate correspond australian patent bring similar action country idenix award patent compound metabolite european country japan china event patent issue expect challenge proceeding similar invoke canada norway australia pende patent application patent application file collaborative partner result issuance patent result patent provide adequate protection result able prevent party develop compound product closely relate developed develop addition certain country africa asia include china provide effective enforcement patent thirdparty manufacturer able sell generic version product country litigation generic manufacturer approval process product fda grant new chemical entity nce exclusivity period manufacturer application approval generic version product grant generic manufacturer challenge patent protect product grant exclusivity year prior end exclusivity period generic manufacturer seek continue seek fda approval similar identical drug anda application form typically manufacturer seek approval generic drug tenofovir disoproxil fumarate emtricitabine fixeddose combination emtricitabine tenofovir disoproxil fumarate efavirenz example november receive notice teva pharmaceutical teva submit anda fda request permission manufacture market generic version truvada notice teva allege patent associate emtricitabine own emory university license exclusively invalid unenforceable andor infringe teva manufacture use sale generic fixeddose combination emtricitabine tenofovir disoproxil fumarate december file lawsuit teva infringement emtricitabine patent march receive notice teva submit anda fda request permission manufacture market generic fixeddose combination emtricitabine tenofovir disoproxil fumarate efavirenz notice teva challenge emtricitabine patent file lawsuit teva infringement emtricitabine patent lawsuit consolidated lawsuit file december january receive notice teva submit anda fda request permission manufacture market generic version viread notice teva challenge tenofovir disoproxil fumarate patent protect viread january receive notice teva amend anda relate generic version atripla truvada product notice relate teva anda generic version atripla teva challenge patent relate tenofovir disoproxil fumarate additional patent relate emtricitabine patent relate efavirenz notice relate teva anda generic version truvada teva challenge patent relate tenofovir disoproxil fumarate additional patent relate emtricitabine march file lawsuit teva infringement viread patent additional emtricitabine patent march bristolmyers squibb company merck inc file lawsuit teva infringement patent relate efavirenz file lawsuit requisite day period provide hatch waxman act stay prevent fda approval teva andas month court decision adverse patent month stay teva anda expire july result court scheduling order teva prohibit launch risk expiration month stay february gilead teva reach agreement principle settle ongoing patent litigation concern patent protect tenofovir disoproxil fumarate viread truvada atripla product trial litigation schedule begin february adjourn pende completion activity necessary finalize settlement agreement teva allow launch generic version viread december settlement agreement file federal trade commission department justice review final november receive notice teva submit abbreviate new drug submission ands canadian ministry health request permission manufacture market generic fixeddose combination emtricitabine tenofovir disoproxil fumarate notice teva allege patent associate truvada invalid unenforceable andor infringe teva manufacture use sale generic version truvada january file lawsuit teva seek order prohibition approval and december receive notice teva submit ands canadian ministry health request permission manufacture market generic fixeddose combination emtricitabine tenofovir disoproxil fumarate efavirenz notice teva allege patent associate atripla merck patent associate atripla invalid unenforceable andor infringe teva manufacture use sale generic fixeddose combination emtricitabine tenofovir disoproxil fumarate efavirenz february file lawsuit teva seek order prohibition approval ands july receive notice lupin limited lupin submit anda fda request permission manufacture market generic version truvada notice lupin allege patent associate emtricitabine patent associate tenofovir disoproxil fumarate invalid unenforceable andor infringe lupin manufacture use sale generic version fixeddose combination emtricitabine tenofovir disoproxil fumarate august file lawsuit lupin infringement patent july receive notice cipla ltd submit anda fda request permission manufacture market generic version emtriva generic version viread notice cipla allege patent associate emtricitabine invalid unenforceable andor infringe cipla manufacture use sale generic version emtricitabine patent associate tenofovir disoproxil fumarate invalid unenforceable andor infringe cipla manufacture use sale generic version tenofovir disoproxil fumarate august file lawsuit cipla infringement patent august receive notice teva submit ands canadian ministry health request permission manufacture market generic version tenofovir disoproxil fumarate notice teva allege patent associate viread invalid unenforceable andor infringe teva manufacture use sale generic version viread september file lawsuit teva seek order prohibition approval and august teva file impeachment action canadian federal court seek invalidation canadian patent associate viread currently defend impeachment action october receive notice lupin submit anda fda request permission manufacture market generic version viread notice lupin allege patent associate tenofovir disoproxil fumarate invalid unenforceable andor infringe lupin manufacture use sale generic version tenofovir disoproxil fumarate october file lawsuit lupin infringement patent ranolazine june receive notice lupin submit anda fda request permission manufacture market generic version sustain release ranolazine notice lupin allege patent associate ranexa invalid unenforceable andor infringe lupin manufacture use sale generic version ranexa july file lawsuit lupin infringement patent ranexa fda approve lupin anda receive court decision expiration court automatic stay july court schedule trial begin april court find patent protect ranexa formulation infringe andor invalid lupin receive final approval product lupin able launch generic version ranexa product risk issuance decision adefovir disoproxil august receive notice sigmapharm lab sigmapharm submit anda fda request permission manufacture market generic adefovir dipivoxil notice sigmapharm allege patent associate hepsera invalid unenforceable andor infringe sigmapharm manufacture use sale generic version hepsera september file lawsuit sigmapharm infringement patent fda approve sigmapharm anda receive court decision expiration court automatic stay february court set trial date case anticipate trial occur mid expiry month stay february sigmapharm obtain final fda approval product fda elect launch generic product risk infringe patent prior decision court patent challenge sigmapharm challenge ranbaxy inc ranbaxy pursuant notice receive october patent challenge ranbaxy expire july option filing lawsuit time believe ranbaxy infringe patent tamiflu february receive notice natco pharma ltd natco submit anda fda request permission manufacture market generic oseltamivir phosphate notice natco allege patent associate tamiflu invalid unenforceable andor infringe natco manufacture use sale generic version tamiflu march hoffmannla roche ltd file lawsuit natco infringement patent associate tamiflu december court issue rule favor gilead roche patent invalid reason state natco notice letter predict ultimate outcome action spend significant resource enforce defend patent unsuccessful lawsuit original claim patent narrow invalidated patent protection atripla truvada viread hepsera ranexa tamiflu united states atripla truvada viread canada substantially shorten patent cover product invalidate fda canadian ministry health approve request manufacture generic version products united states canada respectively prior expiration date patent sale generic version product hepsera early patent expiration significant negative effect revenue result operation trade secret rely unpatented trade secret improvement unpatente internal knowhow technological innovation particular great deal liposomal manufacturing expertise key component liposomal technology cover patent instead protect trade secret protect right mainly confidentiality agreement corporate partner employee consultant vendor agreement provide confidential information develop known individual course relationship keep confidential disclose party specify circumstance case employee agreement provide invention individual employ exclusive property certain party comply confidentiality agreement adequate remedy breach trade secret know independently discover competitor agreement invention jointly own corporate partner case exclusive property party certain circumstance difficult determine own particular invention dispute arise invention manufacture raw material manufacturing strategy contract party manufacture majority active pharmaceutical ingredient solid dose product rely corporate partner manufacture certain product additionally lease manufacturing facility san dimas california edmonton alberta canada cork ireland oceanside california manufacture certain product active pharmaceutical ingredient clinical commercial use manufacturing product contract party manufacture certain product clinical commercial purpose include stribild compleraeviplera atripla truvada viread hepsera emtriva ranexa vistide use multiple thirdparty contract manufacturer manufacture tenofovir disoproxil fumarate active pharmaceutical ingredient viread active pharmaceutical ingredient stribild compleraeviplera atripla truvada emtricitabine active pharmaceutical ingredient emtriva active pharmaceutical ingredient atripla truvada compleraeviplera stribild rely single party manufacturer manufacture active pharmaceutical ingredient cayston exclusive manufacturer active pharmaceutical ingredient hepsera letairis vistide rely thirdparty contract manufacturer tablet capsulate product example use multiple thirdparty contract manufacturer tablet stribild compleraeviplera atripla truvada viread hepsera ranexa emtriva encapsulation complete thirdparty contract manufacturer rely single thirdparty supplier manufacture letairis tablet manufacture agreement corporate partner roche party responsible manufacturing tamiflu agreement roche joint manufacturing committee compose representative roche opportunity review roche exist manufacturing capacity tamiflu global plan manufacture tamiflu astella llc corporate partner lexiscan united states responsible commercial manufacture supply product united states dependent single supplier active pharmaceutical ingredient lexiscan pari pharma gmbh responsible manufacturing device require administer cayston lung patient device single supplier single site future product continue develop additional manufacturing capability establish additional thirdparty supplier manufacture sufficient quantity product candidate undertake clinical trial manufacture sufficient quantity product approve commercial sale unable develop manufacturing capability internally contract large scale manufacturing party acceptable term future product ability conduct large scale clinical trial meet customer demand commercial product adversely affect manufacturing facility san dimas california manufacturing facility manufacture fill package solid dosage form product manufacture cayston ambisome san dimas facility depend single supplier active pharmaceutical ingredient cayston high quality cholesterol manufacture ambisome fill package solid dosage form product include stribild compleraeviplera atripla truvada viread emtriva ranexa finish forms label hepsera facilities san dimas exclusive supplier ambisome event disaster include earthquake equipment failure difficulty unable replace manufacturing capacity timely manner unable manufacture ambisome meet market need fill package drug product stribild atripla truvada viread cayston finish forms label hepsera emtriva facilities cork ireland perform quality control testing final labeling packaging ambisome final release product european union facility utilize cork ireland facility primarily solid dose tablet manufacturing certain antiviral product product packaging activity distribute product european union international market dublin ireland site edmonton alberta facility canada carry process research scaleup clinical development candidate manufacture active pharmaceutical ingredient investigational commercial product conduct chemical development activity improve exist commercial manufacturing process manufacture active pharmaceutical ingredient hepsera letairis vistide exclusively edmonton site supplier qualify active pharmaceutical ingredient letairis oceanside california facility design equip produce biologic compound toxicological phase phase clinical study use facility process development manufacture simtuzumab investigational monoclonal antibody candidate development treatment certain cancer fibrotic disease antibody currently phase clinical trial thirdparty manufacturer thirdparty manufacturer corporate partner independent entity subject unique operational financial risk control thirdparty manufacturer corporate partner fail perform require impair ability deliver product timely basis receive royalty cause delay clinical trial application regulatory approval extent risk materialize affect performance obligation financial result adversely affect example unexpected delay qualify new external site expand cayston manufacturing san dimas unable supply cayston fulfill project demand february september suspend access patient new prescription cayston subject certain exception specific medical need exist result inability manufacture sufficient cayston meet demand revenue receive sale cayston reduce believe technology use manufacture product proprietary product manufacture thirdparty contract manufacturer disclose necessary aspect technology enable manufacture product agreement thirdparty manufacturer intend restrict manufacturer reveal technology certain thirdparty manufacturer comply restriction addition thirdparty manufacturer develop technology relate work perform need manufacture product require enter additional agreement thirdparty manufacturer want use technology allow manufacturer use technology thirdparty manufacturer refuse allow use technology demand term use technology acceptable regulation manufacturing process manufacturing process pharmaceutical product highly regulate regulator shut manufacturing facility believe comply regulation thirdparty manufacturer corporate partner subject current good manufacturing practice extensive regulation govern manufacturing process stability testing record keep quality standard define fda ema similar regulation effect country manufacture operation subject routine inspection regulatory agency example january february fda conduct routine inspection san dimas california manufacturing distribution facility manufacture ambisome cayston package solid dosage form product conclusion inspection fda issue form inspectional observation state concern maintenance aseptic processing condition manufacture suite ambisome product environmental maintenance issue san dimas warehousing facility batch sample timeliness completion annual product quality report september san dimas manufacturing facility receive warning letter fda detail fda concern ambisome manufacturing environment include control system monitor procedure prevent microbiological contamination preventative cleaning equipment maintenance reference certain viread lot letter state concern connect quality procedure control investigation procedure generalize concern effectiveness san dimas quality unit carry responsibility november december fda reinspecte san dimas facility reinspection close additional form observation august fda notify resolve issue raise fda warning letter access supply material need access certain supply product manufacture product delivery material supplier interrupt reason unable purchase sufficient quantity raw material manufacture product unable ship certain product commercial supply supply product candidate development clinical trial example significant portion raw material intermediate manufacture hiv product stribild compleraeviplera atripla truvada viread emtriva supply chinesebased company result international trade dispute china united states action chinese government limit prevent chinese company supply material adversely affect ability manufacture supply hiv product meet market need material adverse effect operating result seasonal operation backlog worldwide product sale reflect significant degree seasonality royalty revenue represent approximately total revenue include tamiflu royalty affect seasonality royalty revenue recognize roche sale tamiflu impact severity flu season product delivery response influenza pandemic operate market characterize short lead time absence significant backlog believe backlog information material business government regulation operation activity subject extensive regulation numerous government authority united states countries united states drug subject rigorous fda regulation federal food drug cosmetic act federal state statute regulation govern testing manufacture safety efficacy labeling storage record keeping approval advertising promotion product result regulation product development product approval process expensive time consume fda approve drug sell united states general process approval follow preclinical testing test drug candidate human study drug laboratory experiment animal generate datum support drug candidate potential benefit safety submit datum fda investigational new drug ind application seek approval test compound human clinical trial fda accept investigational new drug application drug candidate study human clinical trial determine drug candidate safe effective clinical trial involve separate phase overlap year expensive phase subject considerable regulation follow phase drug candidate give small number healthy human control subject patient suffer indicate disease test safety dose tolerance pharmacokinetic metabolism distribution excretion phase drug candidate give limited patient population determine effect drug candidate treat disease good dose drug candidate possible effect safety risk drug candidate uncommon drug candidate appear promise phase clinical trial fail rigorous phase clinical trial phase drug candidate appear effective safe phase clinical trial phase clinical trial commence confirm result phase clinical trial conduct long term involve significantly large population conduct numerous site different geographic region carefully design provide reliable conclusive datum safety benefit drug candidate uncommon drug candidate appear promise phase clinical trial fail rigorous extensive phase clinical trial fda approval process believe datum phase clinical trial adequate level safety efficacy submit appropriate filing usually form nda supplemental nda fda seek approval sell drug candidate particular use fda hold public hear independent advisory committee expert advisor ask additional question make recommendation drug candidate committee make recommendation fda binding generally follow fda fda agree compound meet require level safety efficacy particular use allow sell drug candidate united states use unusual fda reject application believe drug candidate safe efficacious believe datum submit reliable conclusive point process development drug candidate stop number reason include safety concern lack treatment benefit certain clinical trial currently conduct conduct future complete successfully specified time period choose fda require delay suspend clinical trial time appear patient expose unacceptable health risk drug candidate appear sufficient treatment benefit fda require phase nonregistrational study explore scientific question characterize safety efficacy commercial use drug fda require provide additional data information improve manufacturing process procedure facility require extensive surveillance monitor safety benefit product candidate determine file contain adequate evidence safety benefit drug addition fda approve drug limit use drug fda withdraw approval believe comply regulatory standard problem uncover occur approval addition obtain fda approval drug obtain fda approval manufacturing facility drug sell include company manufacture drug facility subject periodic inspection fda fda approve foreign establishment manufacture product sell united states facility subject periodic regulatory inspection manufacturing facility locate california include oceanside san dimas facility license state california compliance local regulatory requirement manufacture facility locate canada include edmonton alberta facility facility locate near dublin cork ireland obtain local license permit compliance local regulatory requirement drug treat life threaten disease condition adequately address exist drug development program design address unmet medical need designate fast track candidate fda eligible accelerate priority review drug treatment hiv infection designate use president emergency plan aid relief qualify expedite priority review atripla truvada viread complera receive accelerate approval priority review drug receive accelerated approval monitor postmarkete clinical trial order confirm safety benefit drug congress agree package tax federal spending proposal january absent congressional action automatic reduction federal spending sequestration effect march sequestration acrossthe board cut implement expect effect operation governmental agency include fda result fda unable review approve new drug application currently anticipate timeline significant delay time anticipate product approval reduce anticipate future revenue earning negatively affect stock price drug subject extensive regulation outside united states european union centralize approval procedure authorize marketing product country european union include major country europe centralize approval procedure approval country european union obtain approval country european union simplified application process mutual recognition procedure decentralize procedure rely principle mutual recognition receive regulatory approval european registration procedure separate pricing reimbursement approval require country european union requirement approval manufacturing facility product approve sale regulatory authority price reimbursement successful commercialization product depend availability governmental thirdparty payer reimbursement cost product relate treatment government health administration authority private health insurer organization generally provide reimbursement united states european union significant potentially significant market product product candidate government authority thirdparty payer increasingly attempt limit regulate price medical product service particularly new innovative product therapy result low average selling price significant portion sale majority product subject significant discount list price rebate obligations united states state aids drug assistant program adap purchase significant portion hiv product rely federal supplemental federal state funding help fund purchase product give current economic downturn experience shift payer mix patient previously cover private insurance public reimbursement program require rebate discount patient previously cover public reimbursement program public reimbursement program require great rebate discount result shift revenue growth lower prescription growth absent congressional action automatic reduction federal spending sequestration effect march sequestration acrossthe board cut implement potentially cut federal state fund support adap program federal state fund available amount sufficient support number patient rely adap sale hiv product negatively impact reduce revenue example quarter state budget crisis florida lead temporary movement patient previously cover florida adap industrysupporte patient assistance program prior quarter insufficiency federal state fund state reduce eligibility criterion see increase number patient state adap wait list similar increase future period result cut federal state adap support result sequestration patient enrol adap generally receive product industrysupporte patient assistance program unable access treatment increase emphasis manage healthcare united states country regional pricing reimbursement control european union additional pressure product pricing reimbursement usage adversely affect product sale profitability pressure arise rule practice manage care group judicial decision governmental law regulation relate medicare medicaid healthcare reform pharmaceutical reimbursement policy price general europe success commercialize product product candidate develop depend largely obtain maintain government reimbursement european country patient unlikely use prescription drug reimburse government addition negotiate price governmental authority delay commercialization month reimbursement policy adversely affect ability sell product profitable basis international market government control price prescription pharmaceutical include implementation reference pricing price cut rebate revenuerelate taxis profit control expect price prescription pharmaceutical decline life product volume increase recently country european union increase discount require product effort continue country attempt manage healthcare expenditure especially light severe fiscal debt crisis experience country european union example june spain impose incremental discount brand drug august germany increase rebate prescription pharmaceutical generic drug come market face price decrease product country european union cost containment pressure european union lead delay treatment patient delay pricing approval negatively impact commercialization new product government agency issue regulation guideline directly applicable product addition time time professional society practice management group private healthscience foundation organization publish guideline recommendation direct certain health care patient community recommendation guideline relate matter product usage dosage route administration use related compete therapy consequently result increase decrease usage product example recent hiv treatment guideline united states abroad endorse early diagnosis treatment united states healthcare reform legislative regulatory change government prescription drug procurement reimbursement program occur relatively frequently united states march healthcare reform legislation adopt united states result require rebate discount product reimburse pay public payer include medicaid entity eligible purchase discount product drug pricing program public health service act adap result legislation discount rebate fee impact include minimum base rebate owe medicaid product reimburse medicaid increase discount rebate owe adap public health service entity reimburse purchase product increase require extend rebate patient receive product medicaid manage care organization require provide discount product sell patient medicare donut hole pharmaceutical manufacturer brand drug product require pay portion new industry fee know pharmaceutical excise tax billion calculate base select government sale calendar year percentage total industry government sale industry fee impose pharmaceutical industry increase billion additional increase year peak billion year decrease billion industry fee increase product sale increase drug patent expire major drug company expect portion excise tax increase estimate portion pharmaceutical excise tax approximately million compare approximately million excise tax tax deductible address healthcare reform legislation discussion continue federal level legislation allow require federal government directly negotiate price concession pharmaceutical manufacturer set minimum requirement medicare pricing addition state medicaid program request additional supplemental rebate product result increase federal base medicaid rebate private insurer use enactment increase rebate exert pricing pressure product extent private insurer manage care program follow medicaid coverage payment development adverse effect magnify private insurer adopt low payment schedule health care fraud abuse law antibribery law subject federal state law pertain health care fraud abuse include antikickback law false claim law antikickback law illegal prescription drug manufacturer solicit offer receive pay remuneration exchange induce referral business include purchase prescription particular drug breadth statutory provision increase attention give law enforcement authority possible certain practice challenge antikickback similar law false claim law generally prohibit knowingly present cause present false fraudulent claim payment federal certain state payer include medicare medicaid knowingly make cause false record statement material false fraudulent claim sale marketing medical activity subject scrutiny law addition foreign corrupt practice act similar worldwide antibribery law generally prohibit company intermediary make improper payment purpose obtain retain business policy mandate compliance antibribery law operate part world experience governmental corruption degree certain circumstance strict compliance antibribery law conflict local custom practice require interact doctor hospital state control manner different local custom despite train compliance program internal control policy procedure protect reckless criminal act commit employee agent violation fraud abuse law antibribery law punishable criminal andor civil sanction include fine civil monetary penalty possibility exclusion federal health care program include medicare medicaid violation lead imposition corporate integrity agreement similar government oversight program government allege convict violate law disruption business material adverse effect result operation compulsory license number develop country government official interested group suggest pharmaceutical company drug hiv infection available low cost alternatively government develop country require grant compulsory license allow competitor manufacture sell version product reduce product sale example past certain office government brazil express concern affordability hiv product declare consider issue compulsory license permit manufacture patent product hiv infection include viread july brazilian patent authority reject patent application tenofovir disoproxil fumarate active pharmaceutical ingredient viread high level appeal available brazilian patent authority currently patent brazil brazilian government purchase supply tenofovir disoproxil fumarate generic manufacturer addition concern cost availability tamiflu relate potential avian flu pandemic influenza generate international discussion compulsory licensing tamiflu patent example canadian government consider allow canadian manufacturer manufacture export active ingredient tamiflu eligible develop develop country canada access medicine regime furthermore roche issue voluntary license permit thirdparty manufacturing tamiflu example roche grant sublicense shanghai pharmaceutical group ltd china sublicense india hetero drug limited india certain develop country compulsory license issue permit generic manufacturing override tamiflu patent roche issue additional voluntary license permit thirdparty manufacturing tamiflu development reduce royalty receive roche sale tamiflu certain country permit enforcement patent thirdparty manufacturer able sell generic version product country compulsory license sale generic version product significantly reduce sale adversely affect result operation particularly generic version product import territory exist commercial sale employee january approximately fulltime employee believe good relation employee environment health safety voluntarily assess publicly report greenhouse gas emission water usage begin action reduce emission usage example establish employee commuter program evaluate energy efficiency building instal lowflow water fixture law regulation implement consideration mitigate effect climate change cause greenhouse gas emission example california air resources board process draft regulation meet state emission target base current information subject finalization propose regulation believe primary risk relate climate change risk increase energy cost energy intensive business anticipate subject cap trade system mitigation measure likely material capital expenditure result operation competitive position subject federal state local regulation workplace safety protection environment use hazardous material chemical viruse radioactive compound activity eliminate risk accidental contamination injury material certain misuse accident involve material lead significant litigation fine penalty implement proactive program reduce minimize risk hazardous material incident information subject information requirement exchange act file periodic report proxy statement information sec report proxy statement information obtain visit public reference room sec street washington call sec sec send electronic message sec publicinfosecgov send fax sec addition sec maintain website wwwsecgov contain report proxy information statement information issuer file electronically mail address headquarters lakeside drive foster city california telephone number location website wwwgileadcom link investors section website sec filings financial information section available follow filing soon reasonably practicable electronically file furnished sec annual report quarterly report form current report form amendment report file furnish pursuant section exchange act filing available free charge request transaction iran discuss access develop world item business commit provide access certain hiv product develop world connection provide medical education relate treatment hiv country accordance commitment january nonus subsidiary gilead base greece greek sub sponsor hiv conference abu dhabi uae strategies treatment prevention hiv discuss party distributor gilead north africa middle east include iran invite greek sub behalf doctor region include iranian doctor appear official iranian national aids program gilead sciences europe limited reimburse distributor travelrelate expense iranian doctor attend hiv conference expense iranian doctor total cover cost visa fee airline ticket transportation understand distributor turn transfer reimburse iranian entity act subdistributor iran distributor subdistributor affiliate gilead knowledge agency instrumentality control government iran sale product iran subdistributor available gilead access program sell notforprofit price activity describe involved nonus affiliate gilead occur prior enactment iran threat reduction syria human rights act august subject usiran sanction regime current intention engage activity describe future directly pursuant nonus subsidiary future time gilead include subsidiary engage activity obtain license department treasury office foreign asset control rely applicable exemption usiran sanction regime item risk factor evaluate business carefully consider follow risk addition information annual report manifestation follow risk materially adversely affect business result operation financial condition note factor investor permit private security litigation reform act possible predict identify factor consider follow risk complete statement potential risk uncertainty face public announcement datum clinical study evaluate sofosbuvir fixeddose combination sofosbuvir ledipasvir hcvinfecte patient likely cause significant volatility stock price development sofosbuvir combination ledipasvir delay discontinued stock price decline significantly expect receive significant datum clinical trial evaluate sofosbuvir investigational nucleotide analog acquire purchase pharmasset inc pharmasset combination direct acting antiviral hepatitis virus hcvinfecte individual genotype initial new drug application nda sofosbuvir support phase study name fission positron fusion neutrino fission study genotype treatment nave patient compare week sofosbuvir ribavirin current standard care week treatment interferon ribavirin february announce topline result fission study study meet primary efficacy endpoint noninferiority sofosbuvir plus ribavirin pegylate interferon pegifn plus ribavirin find patient achieve sustain viral response svr sofosbuvir plus ribavirin treatment group versus pegifn plus ribavirin treatment group positron compare week treatment sofosbuvir ribavirin genotype interferon intolerantineligible patient placebo november announce topline result positron study study find patient achieve svr week complete therapy neutrino single arm study evaluate week course sofosbuvir interferon ribavirin genotype infectedpatients february announce topline result neutrino study study meet primary efficacy endpoint superiority compare predefine historic control svr rate show patient achieve svr week complete therapy fusion study explore week duration treatment sofosbuvir ribavirin genotype treatmentexperience patient february announce topline result fusion study study meet primary efficacy endpoint superiority compare predefine historic control svr rate show patient week arm patient week arm achieve svr week complete therapy anticipate file regulatory approval sofosbuvir second quarter expect initial indication week treatment sofosbuvir ribavirin treatmentnaive interferonintolerant experienced genotype patient week treatment sofosbuvir peg ifn ribavirin treatmentnaive genotype patient parallel advance fixeddose combination sofosbuvir ledipasvir treatment genotype patient nda fix dose combination sofosbuvir ledipasvir support clinical trial study name ion evaluate fixeddose combination sofosbuvir ledipasvir ribavirin week treatmentnave genotype infect patient pende review result week arm initial enrollment patient second quarter expect enroll additional patient ion study assess fix dose combination sofosbuvir ledipasvir total individual january start screen patient phase study name ion evaluate fixeddose combination ribavirin week ribavirin week therapy treatmentexperience genotype hcv patient announcement datum clinical study evaluate sofosbuvir fixeddose combination sofosbuvir ledipasvir likely cause significant volatility stock price announcement negative unexpected datum discontinuation development sofosbuvir fixeddose combination sofosbuvir ledipasvir delay anticipated timeline file regulatory approval likely cause stock price decline significantly substantial portion revenue derive sale hiv product particularly atripla truvada unable maintain continue increase sale product result operation adversely affect currently dependent sale product treatment hiv infection particularly atripla truvada support exist operation hiv product contain tenofovir disoproxil fumarate andor emtricitabine belong nucleoside class antiviral therapeutic treatment paradigm hiv change cause nucleosidebased therapeutic fall favor unable maintain continue increase hiv product sale result operation likely suffer likely need scale operation include spend research development effort year end december atripla truvada product sale billion total revenue able sustain increase growth rate sale hiv product especially stribild compleraeviplera atripla truvada number reason include limited follow hiv product long period time patient combination product additional study conduct new issue respect safety resistance interaction drug arise cause provide additional warning contraindication label narrow approve indication halt sale product reduce revenue hiv product mature private insurer government payer reduce reimburse patient product increase pressure reduce price large market hiv product consist patient take hiv drug successful encourage physician change patient regimen include hiv product sale hiv product limit generic hiv product introduce major market ability maintain pricing market share affect fail commercialize new product expand indication exist product prospect future revenue adversely affect introduce new product market increase sale exist product able increase maintain total revenue continue expand effort drug development inherently risky product candidate fail drug development process example january announce decision terminate phase clinical trial ambrisentan patient idiopathic pulmonary fibrosis ipf april announce decision terminate phase clinical trial aztreonam inhalation solution treatment cystic fibrosis patient burkholderia spp addition marketing application single tablet regimen elvitegravir cobicistat tenofovir disoproxil fumarate emtricitabine treatment hiv treatmentnave patient approve european medicine agency ema foreign regulatory agency new drug application elvitegravir treatment hiv treatmentexperience patient cobicistat pharmacoenhance boost agent approve food drug administration fda ema foreign regulatory authority market approval grant product significant limitation use unable file marketing application new product include sofosbuvir fixeddose combination sofosbuvir ledipasvir currently anticipate timeline marketing approval product grant congress agree package tax federal spending proposal january absent congressional action automatic reduction federal spending sequestration effect march sequestration acrossthe board cut implement expect effect operation governmental agency include fda result fda unable review approve new drug application currently anticipate timeline significant delay time anticipate product approval reduce anticipate future revenue earning negatively affect stock price result operation adversely affect current potential future healthcare reform legislative regulatory change government prescription drug procurement reimbursement program occur relatively frequently united states foreign jurisdiction march healthcare reform legislation adopt united states result require rebate discount product reimburse pay public payer include medicaid entity eligible purchase discount product drug pricing program public health service act aids drug assistance program adaps result legislation discount rebate fee impact include minimum base rebate owe medicaid product reimburse medicaid increase discount rebate owe adap public health service entity reimburse purchase product increase require extend rebate patient receive product medicaid manage care organization require provide discount product sell patient medicare donut hole pharmaceutical manufacturer brand drug product require pay portion new industry fee know pharmaceutical excise tax billion calculate base select government sale calendar year percentage total industry government sale industry fee impose pharmaceutical industry increase billion additional increase year peak billion year decrease billion industry fee increase product sale increase drug patent expire major drug company expect portion excise tax increase estimate portion pharmaceutical excise tax approximately million compare approximately million excise tax tax deductible address healthcare reform legislation discussion continue federal level legislation allow require federal government directly negotiate price concession pharmaceutical manufacturer set minimum requirement medicare pricing addition state medicaid program request additional supplemental rebate product result increase federal base medicaid rebate private insurer use enactment increase rebate exert pricing pressure product extent private insurer manage care program follow medicaid coverage payment development adverse effect magnify private insurer adopt low payment schedule exist product subject reimbursement government agency party pharmaceutical pricing reimbursement pressure reduce profitability successful commercialization product depend availability governmental thirdparty payer reimbursement cost product relate treatment government health administration authority private health insurer organization generally provide reimbursement united states european union significant potentially significant market product product candidate government authority thirdparty payer increasingly attempt limit regulate price medical product service particularly new innovative product therapy result low average selling price significant portion sale majority product subject significant discount list price rebate obligations united states state adap purchase significant portion hiv product rely federal supplemental federal state funding help fund purchase product give current economic downturn experience shift payer mix patient previously cover private insurance public reimbursement program require rebate discount patient previously cover public reimbursement program public reimbursement program require great rebate discount result shift revenue growth lower prescription growth absent congressional action automatic reduction federal spending sequestration effect march sequestration acrossthe board cut implement reduce federal state fund support adap program federal state fund available amount sufficient support number patient rely adap sale hiv product negatively impact reduce revenue example quarter state budget crisis florida lead temporary movement patient previously cover florida adap industrysupporte patient assistance program prior quarter insufficiency federal state fund state reduce eligibility criterion see increase number patient state adap wait list similar increase future period result reduction federal state adap support result sequestration patient enrol adap generally receive product industrysupporte patient assistance program unable access treatment increase emphasis manage healthcare united states country regional pricing reimbursement control european union additional pressure product pricing reimbursement usage adversely affect product sale profitability pressure arise rule practice manage care group judicial decision governmental law regulation relate medicare medicaid healthcare reform pharmaceutical reimbursement policy price general europe success commercialize product product candidate develop depend largely obtain maintain government reimbursement european country patient unlikely use prescription drug reimburse government addition negotiate price governmental authority delay commercialization month reimbursement policy adversely affect ability sell product profitable basis international market government control price prescription pharmaceutical include implementation reference pricing price cut rebate revenuerelate taxis profit control expect price prescription pharmaceutical decline life product volume increase recently country european union increase discount require product effort continue country attempt manage healthcare expenditure especially light severe fiscal debt crisis experience country european union example june spain impose incremental discount brand drug august germany increase rebate prescription pharmaceutical generic drug come market face price decrease product country european union cost containment pressure european union lead delay treatment patient delay pricing approval negatively impact commercialization new product approximately product sale occur outside united states currency fluctuation hedging expense cause earning fluctuate adversely affect stock price significant percentage product sale denominate foreign currency primarily euro face exposure adverse movement foreign currency exchange rate dollar strengthen foreign currency relative value sale respective foreign currency decrease conversely dollar weaken currency relative value sale increase overall net receiver foreign currency benefit weak dollar adversely affect strong dollar relative foreign currency transact significant amount business use foreign currency exchange forward option contract hedge percentage forecast international sale primarily denominate euro hedge certain monetary asset liability denominate foreign currency reduce eliminate exposure currency fluctuation date transaction record date cash collect pay predict future fluctuation foreign currency exchange rate dollar dollar appreciate significantly certain currency hedge program sufficiently offset effect appreciation result operation adversely affect stock price decline additionally expense recognize relation hedging activity cause earning fluctuate level hedging expense recognize particular period impact change interest rate spread foreign currency hedge dollar inability accurately estimate demand product sale fluctuation result inventory level hold wholesaler pharmacie non retail customer difficult accurately forecast sale cause earning fluctuate adversely affect financial result stock price approximately product sale united states wholesaler cardinal health inc mckesson corp amerisourcebergen corp wholesaler enter inventory management agreement estimate determine end user demand completely effective match inventory level actual end user demand result change inventory level hold wholesaler cause operating result fluctuate unexpectedly sale wholesaler match end user demand addition inventory hold retail pharmacy nonwholesale location inventory management agreement control buy pattern adverse change economic condition factor cause retail pharmacy reduce inventory product reduce order wholesaler consequently wholesaler order end user demand change example fourth quarter wholesaler increase inventory level antiviral product quarter wholesaler draw inventory inventory level antiviral product move low end contractual boundary set inventory management agreement inventory distribution channel fluctuate quarter quarter continue fluctuation earning mismatch prescription demand product revenue addition nonretail sector united states include government institution include state adap correctional facility large health maintenance organization tend consistent term buy pattern cause quarter quarter fluctuation necessarily mirror patient demand federal state budget pressure annual grant cycle federal state adap fund cause adap purchasing pattern reflect patient demand example second quarter observe large nonretail purchase number state adap exceed patient demand believe purchase drive grant cycle federal adap fund early communication ryan white federal fund desire state adap reduce patient wait list lead significant reduction adap purchasing quarter observe large nonretail purchase fourth quarter drive issue result expect continue experience fluctuation purchase pattern nonretail customer result fluctuation product sale revenue earning future light global economic downturn budget crisis face european country observe variation purchase pattern induce cost containment measure europe believe measure cause government agency purchaser reduce inventory product distribution channel decrease revenue cause fluctuation product sale earning continue trend future face significant competition face significant competition large pharmaceutical biotechnology company substantially great resource addition competitor product operate field compete long hiv product compete primarily product joint venture establish glaxosmithkline inc gsk pfizer inc pfizer market fixeddose combination product compete stribild compleraeviplera atripla truvada example lamivudine market joint venture competitive emtricitabine active pharmaceutical ingredient emtriva component compleraeviplera atripla truvada face competition generic hiv product compound patent cover epivir lamivudine expire united states generic lamivudine available united states spain portugal italy expect generic version lamivudine launch country european union generic version combivir lamivudine zidovudine approve recently launch united states addition late generic tenofovir available turkey result increase rebate viread turkey currently expect competition generic version sustiva efavirenz component atripla available europe canada united states negatively impact sale hiv product expect launch dolutegravir integrase inhibitor fourth quarter gsk impact sale hiv product viread hepsera treatment chronic hbv compete primarily product produce gsk bms novartis pharmaceutical corporation novartis united states european union china ambisome compete primarily product produce merck inc merck pfizer addition aware lipid formulation claim similarity ambisome available outside united state include possible entry formulation greece taiwan formulation reduce market demand ambisome furthermore manufacture lipid formulation amphotericin complex formulation find unsafe sale ambisome negatively impact association letairis compete directly product produce actelion pharmaceutical inc indirectly pulmonary arterial hypertension product united therapeutics corporation pfizer ranexa compete predominantly generic compound distinct class drug betablocker calcium channel blocker longacte nitrate treatment chronic angina united states cayston competes product market novartis tamiflu compete product sell gsk generic competitor addition number company pursue development technology competitive exist product research program compete company include specialized pharmaceutical firm large pharmaceutical company act independently pharmaceutical company furthermore academic institution government agency public private organization conduct research seek patent protection establish collaborative arrangement competitive product program significant safety issue arise market product product candidate future sale reduce adversely affect result operation datum support marketing approval product form basis safety warning product label obtain control clinical trial limit duration case postapproval use product long period time patient underlie health problem take numerous medicine expect continue find new issue safety resistance drug interaction issue require provide additional warning contraindication label narrow approve indication reduce market acceptance product product letairis approve fda june member class compound call endothelin receptor antagonist era pose specific risk include risk birth defect risk letairis available letairis education access program leap restrict distribution program intend help physician patient learn risk associate product assure appropriate use product product additional patient discover new risk associate letairis result change distribution program additional restriction use letairis decrease demand product regulatory authority move active transparent pharmacovigilance make great amount standalone safety information directly available public website mean periodic safety update report summarie risk management plan summarie adverse event datum safety information appropriate context expertise misinterpret lead misperception legal action potentially cause product sale stock price decline safety resistance drug interaction issue arise market product sale product limit halt regulatory authority result operation adversely affect operation depend compliance complex fda comparable international regulation failure obtain broad approval timely basis maintain compliance delay halt commercialization product product develop approve marketing sale regulatory authority approve subject extensive regulation fda ema comparable regulatory agency country continue clinical trial stribild compleraeviplera atripla truvada viread hepsera emtriva letairis ranexa ambisome cayston currently approve additional use anticipate file marketing approval additional country additional indication product year product fail receive marketing approval timely basis market product manufacture sell product subject extensive regulation review discovery previously unknown problem market product problem manufacture promotional activity result restriction product include withdrawal product market fail comply applicable regulatory requirement include related promotion manufacturing subject penalty include fine suspension regulatory approval product recall seizure product criminal prosecution example fda rule require conduct postapproval clinical study assess know risk signal risk identify unexpected risk implement risk evaluation mitigation strategy product include medication guide patient package insert communication plan healthcare provider element fda deem necessary assure safe use drug include impose certain restriction distribution use product failure comply requirement impose sponsor fda result significant civil monetary penalty operating result adversely affect result anticipate timeline clinical trial uncertain support continue development product pipeline adversely affect prospect future revenue growth require demonstrate safety efficacy product develop intend use extensive preclinical study clinical trial result preclinical early clinical study accurately predict result later largescale clinical trial successfully complete largescale clinical trial result marketable product product candidate fails achieve primary endpoint clinical trial safety issue arise result clinical trial inadequate support regulatory approval product candidate commercialization product candidate delay halt example january announce decision terminate phase clinical trial ambrisentan patient ipf april announce decision terminate phase clinical trial aztreonam inhalation solution treatment patient burkholderia spp addition face challenge clinical trial protocol design clinical trial product candidate pipeline delay terminate prospect future revenue growth adversely impact example face numerous risk uncertaintie product candidate include sofosbuvir fixeddose combination sofosbuvir ledipasvir treatment hepatitis aztreonam inhalation solution treatment bronchiectasis ranolazine treatment incomplete revascularization postpercutaneous coronary intervention type diabete idelalisib treatment chronic lymphocytic leukemia currently phase clinical trial prevent completion development product candidate risk include ability enroll patient clinical trial possibility unfavorable result clinical trial need modify delay clinical trial perform additional trial risk fail obtain fda regulatory body approval result product candidate successfully commercialize strategic decision discontinue development product candidate example believe commercialization difficult relative opportunity pipeline program pipeline complete timely basis prospect future revenue growth adversely impact addition clinical trial involve commercial product raise new safety issue exist product turn decrease revenue harm business reliance thirdparty contract research organization conduct clinical trial unable directly control timing conduct expense quality clinical trial extensively outsource clinical trial activity usually perform small portion startup activity inhouse rely independent party contract research organization cro perform clinical study include document preparation site identification screen preparation prestudy visit training program management bioanalytical analysis important aspect service perform cros direct control dispute disruption relationship cro clinical trial delay regulatory submission rely quality validity clinical work perform thirdparty cro cro process methodology result determine invalid inadequate clinical data result relate regulatory approval adversely impact expense associate clinical trial cause earning fluctuate adversely affect stock price clinical trial require regulatory approval product clinical trial require conduct approval expensive difficult accurately predict control timing expense quarter quarter fda andor regulatory agency require clinical testing originally anticipate uneven unexpected spending program include clinical trial necessary advance sofosbuvir fixeddose combination sofosbuvir ledipasvir product candidate treatment hcv oncology cause operating result fluctuate quarter quarter volatility stock price depend relationship company sale marketing performance development commercialization product candidate revenue failure maintain relationship poor performance company dispute company negatively impact business rely number significant collaborative relationship major pharmaceutical company sale marketing performance certain territory include collaboration bms atripla united states europe canada hoffmannla roche ltd hoffmannla roche inc roche tamiflu worldwide gsk ambrisentan territory outside united states country rely international distributor sale truvada viread hepsera emtriva ambisome relationship involve clinical development product partner reliance collaborative relationship pose number risk include risk unable control resource corporate partner devote program product dispute arise respect ownership right technology develop corporate partner disagreement corporate partner cause delay termination research development commercialization product candidate result litigation arbitration contract corporate partner fail provide significant protection fail effectively enforce partner fails perform corporate partner considerable discretion elect pursue development additional product pursue alternative technology product collaboration competitor corporate partner marketing right choose pursue compete technology devote few resource marketing product product development distributor corporate partner unable pay particularly light current economic condition give risk great deal uncertainty success current future collaborative effort effort fail product development commercialization new product delay revenue product decline rely collaborative relationship major pharmaceutical company development commercialization certain product candidate gilead successor pharmasset party october collaboration agreement roche agreement grant roche right develop psi cytidine analog prodrug treatment chronic hcv infection collaborative research effort agreement end december roche later ask pharmasset consider roche contributed inventorship sofosbuvir pharmasset comply confidentiality provision collaboration agreement pharmasset advise carefully consider issue raise roche believe issue merit consider issue reach conclusion roche recently contact gilead assert roche exclusive license sofosbuvir pursuant collaboration agreement roche allege sofosbuvir prodrug uridine monophosphate analog prodrug psi roche exclusive license believe roche claim merit roche successfully establish inventorship exclusive license right sofosbuvir expect revenue earning sale sofosbuvir adversely affect april licensing agreement gsk give gsk right control clinical regulatory development commercialization hepsera territories asia africa latin america include major market hepsera china japan taiwan south korea november enter agreement gsk provide gsk exclusive commercialization right registration responsibility viread treatment chronic hbv china october grant similar right gsk japan saudi arabia success hepsera viread treatment chronic hbv territory depend entirely effort gsk regard gsk promote epivirhbvzeffix product compete hepsera viread treatment chronic hbv consequently gsk marketing strategy hepsera viread treatment chronic hepatitis influence promotion epivirhbvzeffix receive royalty gsk equal percentage gsk net sale hepsera viread treatment chronic hbv net sale gsk epivirhbvzeffix gsk fail devote sufficient resource succeed develop commercialize hepsera viread treatment chronic hbv territory potential revenue territory substantially reduce addition cayston letairis distribute thirdparty specialty pharmacy pharmacie specialize dispense medication complex chronic condition require high level patient education ongoing counseling use specialty pharmacy require significant coordination sale marketing medical affair regulatory affair legal finance organization involve risk include limited risk specialty pharmacy provide accurate timely information inventory patient data safety complaint effectively sell support cayston letairis devote resource necessary sell cayston letairis volume time frame expect able satisfy financial obligation cease operation rely party administer leap restrict distribution program design support letairis party provide information education prescriber patient risk letairis confirm insurance coverage investigate alternative source reimbursement assistance ensure fulfillment risk management requirement mandate letairis fda coordinates control dispense patient party specialty pharmacy failure party specialty pharmacy distribute letairis perform expect result regulatory action fda decrease letairis sale harm business cayston take patient specific inhalation device deliver drug lung patient ongoing distribution cayston entirely reliant manufacturer device example manufacturer encounter issue regulatory agency relate device unable supply sufficient quantity device addition manufacturer able provide adequate warranty support device distribute patient respect distribution drug device patient reliant capability specialty pharmacy example distribution channel drug device complicated require coordination reimbursement approval process associate drug device similarly complex device manufacturer unable obtain reimbursement approval receive approval lowerthanexpecte price sale cayston adversely affect previously describe issue limit sale cayston adversely affect financial result success depend significant degree ability protect patent intellectual property right domestically internationally able obtain effective patent protect technology use competitor patent company require stop pay use require technology patent proprietary right important business success depend significant degree ability obtain patent license patent right preserve trade secret defend infringement effort invalidate patent operate infringe property properly draft enforceable patent difficult competitor use technology create competitive product difficult competitor obtain patent prevent technology create business strategy actively seek patent protection united states internationally file additional patent application appropriate cover improvement compound product technology number foreign patent patent application right patent relate compound product technology certain issue patent enforceable provide adequate protection pende patent application result issue patent patent application confidential period time patent issue result know competitor file patent application technology cover pende application invent file application direct technology subject patent application competitor file patent application receive patent obtain additional patent proprietary right block compete product addition competitor file patent application cover technology participate interferencederivation proceeding litigation determine right patent litigation interferencederivation proceeding unpredictable expensive ultimately successful result operation adversely affect event time time certain individual entity challenge patent example public patent foundation file request reexamination patent trademark office pto challenge patent relate tenofovir disoproxil fumarate active ingredient stribild compleraeviplera atripla truvada viread pto grant request pto confirm patentability patent time time involved dispute inventor patent example march jeremy clark employee pharmasset acquire january inventor patent file demand arbitration lawsuit pharmasset raymond schinazi clark initially file lawsuit pharmasset schinazi february seek void assignment provision employment agreement assert ownership patent claim metabolite sofosbuvir december court order stay litigation pende outcome arbitration proceeding require clark employment agreement instead proceed arbitration clark file additional lawsuit september june subsequently dismiss court september clark file motion seek reconsideration court december order deny court december clark file motion appoint special prosecutor february court issue order require clark enter arbitration risk dismissal case clark file demand arbitration march arbitration panel set hearing date april predict outcome arbitration clark prior assignment patent pharmasset voided arbitration panel ultimately find owner patent determine infringe patent require obtain license pay royalty clark commercialize sofosbuvir patent cover ranolazine compound active ingredient ranexa instead discover sustained release formulation ranolazine achieve therapeutic plasma level patent obtain formulation characteristic plasma level achieve patent cover active ingredient ambisome addition patent filing china certain asian country cover form adefovir dipivoxil active ingredient hepsera asia major market therapie hbv indication hepsera develop obtain patent certain product year marketing approval obtain product patent limited life begin run prior commercial sale relate product commercial value patent limit able apply patent term extension supplementary protection certificate country generic manufacturer seek continue seek fda approval market generic version product anda application form typically manufacturer seek approval generic drug description anda litigation legal proceeding begin risk factor entitle litigation generic manufacturer reduce continue reduce earning unsuccessful lawsuit original claim patent narrow invalidated begin success depend large ability operate infringe patent proprietary right party infringe valid patent prevent commercialize product require obtain license party able obtain alternative technology require license reasonable term fail obtain license alternative technology unable develop commercialize product example aware body patent relate operation leap restrict distribution program design support letairis patent claim sofosbuvir chemical entity metabolite existence issue patent guarantee right practice patent technology commercialize patent product party obtain right patent claim prevent attempt prevent commercialize patented product candidate obtain pharmasset acquisition example aware patent patent application own party allege cover use sofosbuvir party successful obtain valid enforceable patent establish infringement patent prevent sell sofosbuvir able obtain license patent license need available commercially reasonable term instance require defend right patent invention interference proceed pto interference administrative proceeding pto design determine invent subject matter claim party february receive notice pto declare interference patent idenix pharmaceuticals inc idenix pende patent application patent cover metabolite sofosbuvir idenix attempt claim class compound include metabolite pende patent application course proceed party call submit evidence date conceive respective invention interference determine invent compound entitle patent claim compound administrative law judge determine idenix entitle patent claim determine infringe claim require obtain license pay royalty idenix commercialize sofosbuvir determination judge appeal party federal court june meet idenix mandatory settlement discussion party unable settle interference widely divergent view strength respective position need license idenix patent idenix need license gilead patent develop manufacture pipeline product believe idenix application involve interference similar foreign patent claim compound metabolite invalid result file impeachment action canadian federal court invalidate idenix patent canadian patent correspond idenix patent idenix patent application subject interference file similar legal action federal court norway seek invalidate correspond norwegian patent file similar legal action federal court australia seek invalidate correspond australian patent bring similar action country idenix award patent compound metabolite european country japan china event patent issue expect challenge proceeding similar invoke canada norway australia furthermore use significant proprietary technology rely unpatented trade secret proprietary knowhow protect certain aspect production technology trade secret know independently discover competitor manufacturing problem include thirdparty manufacturer corporate partner cause inventory shortage delay product shipment regulatory approval adversely affect result operation order generate revenue product able produce sufficient quantity product satisfy demand product result complex manufacturing process manufacturing process pharmaceutical product highly regulate regulator shut manufacturing facility believe comply regulation product manufacture facility thirdparty manufacturer corporate partner depend party perform manufacturing activity effectively timely basis majority solid dose product addition roche party responsible manufacturing tamiflu thirdparty manufacturer corporate partner subject current good manufacturing practice gmp extensive regulation govern manufacturing process stability testing record keep quality standard define fda ema similar regulation effect country thirdparty manufacturer corporate partner independent entity subject unique operational financial risk control thirdparty manufacturer corporate partner fail perform require impair ability deliver product timely basis receive royalty cause delay clinical trial application regulatory approval extent risk materialize affect performance obligation financial result adversely affect addition thirdparty manufacturer corporate partner able produce product limit number facility limited manufacturing capacity certain product example unexpected delay qualify new external site expand cayston manufacturing san dimas unable supply cayston fulfill project demand february september suspend access patient new prescription cayston subject certain exception specific medical need exist result inability manufacture sufficient cayston meet demand revenue receive sale cayston reduce manufacturing operation subject routine inspection regulatory agency example january february fda conduct routine inspection san dimas manufacturing facility exclusively manufacture cayston ambisome conclusion inspection fda issue form inspectional observation state concern maintenance aseptic processing condition manufacture suite ambisome product environmental maintenance issue san dimas warehousing facility batch sample timeliness completion annual product quality report september san dimas manufacturing facility receive warning letter fda detail fda concern ambisome manufacturing environment include control system monitor procedure prevent microbiological contamination preventative cleaning equipment maintenance reference certain viread lot letter state concern connect quality procedure control investigation procedure generalize concern effectiveness san dimas quality unit carry responsibility november december fda reinspecte san dimas facility reinspection close additional form observation august fda notify resolve issue raise fda warning letter ability successfully manufacture commercialize cayston depend ability manufacture multiproduct facility aztreonam active pharmaceutical ingredient cayston monobactam gramnegative antibiotic manufacture cayston san dimas california party multiproduct manufacturing facility historically fda permit manufacture monobactam multiproduct manufacturing facility assurance fda continue allow practice currently singleproduct facility dedicated manufacture cayston engage contract manufacturer singleproduct facility cayston fda prohibit manufacture monobactam antibiotic like aztreonam multiproduct manufacturing facility future able procure singleproduct manufacturing facility timely manner adversely affect commercial supply cayston anticipate financial result attributable product able obtain material supply necessary conduct clinical trial manufacture sell product limit ability generate revenue need access certain supply product conduct clinical trial manufacture product light global economic downturn increase difficulty purchase certain raw material manufacturing process unable purchase sufficient quantity material find suitable alternate material timely manner development effort product candidate delay ability manufacture product limit limit ability generate revenue supplier key component material name nda file fda ema regulatory authority product candidate seek marketing approval significant delay occur qualification new supplier require manufacturer qualified regulatory authority manufacturer continue expend time money effort area production quality control ensure compliance gmp manufacturer subject regular periodic inspection regulatory authority follow initial approval result inspection regulatory authority determine equipment facility laboratory process comply applicable regulation condition product approval regulatory authority suspend manufacturing operation manufacture operation single supplier product suspend unable generate sufficient quantity commercial clinical supply product meet market demand turn decrease revenue harm business addition delivery material supplier interrupt reason unable ship certain product commercial supply supply product development clinical trial addition product material utilize operation facility example manufacture ambisome exclusively facility san dimas california event disaster include earthquake equipment failure difficulty unable replace manufacturing capacity timely manner unable manufacture ambisome meet market need cayston dependent different thirdparty singlesource supplier aztreonam active pharmaceutical ingredient cayston manufacture single supplier single site second administer lung patient device single supplier single site disruption delay single supplier adversely affect ability supply cayston sure alternative supplier identify timely manner risk factor entitle ability successfully manufacture commercialize cayston depend ability manufacture multiproduct facility addition depend single supplier highquality cholesterol manufacture ambisome rely single source active pharmaceutical ingredient hepsera letairis vistide tablete letairis astella llc markets lexiscan united states responsible commercial manufacture supply product united states dependent single supplier active pharmaceutical ingredient lexiscan problem single supplier depend negatively impact development commercialization effort significant portion raw material intermediate manufacture hiv product stribild compleraeviplera atripla truvada viread emtriva supply chinesebased company result international trade dispute china united states action chinese government limit prevent chinese company supply material adversely affect ability manufacture supply hiv product meet market need material adverse effect operating result litigation generic manufacturer reduce continue reduce earning unsuccessful lawsuit original claim patent narrow invalidated generic version product launch prior patent expiry approval process product fda grant new chemical entity nce exclusivity period manufacturer application approval generic version product grant generic manufacturer challenge patent protect product grant exclusivity year prior end exclusivity period generic manufacturer seek continue seek fda approval similar identical drug anda application form typically manufacturer seek approval generic drug receive notice generic manufacturer submit andas manufacture generic version atripla truvada viread hepsera ranexa tamiflu united states atripla truvada viread canada expect begin trial generic manufacturer february gilead teva reach agreement principle settle ongoing patent litigation concern patent protect tenofovir disoproxil fumarate viread truvada atripla product trial litigation adjourn pende completion activity necessary finalize settlement agreement teva allow launch generic version viread december settlement agreement file federal trade commission department justice review final trial relate patent associate ranexa schedule begin april anticipate trial relate patent relate hepsera begin mid trial relate patent protect emtricitabine patent atripla schedule begin october predict ultimate outcome action spend significant resource enforce defend patent unsuccessful lawsuit original claim patent narrow invalidated patent protection atripla truvada viread hepsera ranexa tamiflu united states atripla truvada viread canada substantially shorten patent cover product invalidate fda canadian ministry health approve request manufacture generic version products united states canada respectively prior expiration date patent sale generic version product hepsera early patent expiration significant negative effect revenue result operation face credit risk southern european customer adversely affect result operation european product sale governmentowne support customer southern europe specifically greece italy portugal spain historically continue subject significant payment delay government funding reimbursement practice result continue result day sale outstanding significantly high country average length time account receivable remain outstanding december account receivable country total approximately million million past great day million past great day follow thousand december greater great day past day past italy spain portugal greece total historically receivable balance certain publiclyowne hospital accumulate period time subsequently settle large lump sum payment pattern experience pharmaceutical company sell directly hospital significant change occur reimbursement practice european government government funding unavailable able collect amount customer result operation adversely affect collect million past account receivable customer base spain portugal include million proceed onetime factoring arrangement sell receivables spain greek government settle substantially outstanding receivables subject bond settlement zerocoupon bond trade discount face value march greek government restructure sovereign debt impact holder greek bond result record million loss revenue gross margin reduce import country product available low price price product base local market economic competition differ country country sale country relatively high price reduce product import country low price market case pharmaceutical product sell steeply discount price develop world reexporte european country resold high price happen product particularly truvada viread agree available substantially reduce price country participate gilead access program atripla merck distribute substantially reduce price hiv infect patient develop country agreement revenue adversely affect addition establish partnership thirteen indian generic manufacturer distribute highquality lowcost generic version tenofovir disoproxil fumarate develop world country include india generic version medication license reexporte united states europe market outside country revenue adversely affect addition purchase product country sell price relatively low resale country sell price relatively high adversely impact revenue gross margin cause sale fluctuate quarter quarter example european union require permit product purchase country sell country purchase product country sell price relatively low resale country sell price relatively high affect inventory level hold wholesaler cause relative sale level country fluctuate quarter quarter reflect actual consumer demand give quarter quarterly fluctuation impact earning adversely affect stock price harm business expensive litigation government investigation reduce continue reduce earning involve number litigation investigation disputerelate matter require expend substantial internal financial resource expect matter continue require high level internal financial resource foreseeable future matter reduce continue reduce earning description department justice investigation interference litigation proceeding idenix contract arbitration jeremy clark legal proceeding begin outcome lawsuit lawsuit brought investigation investigation initiate inherently uncertain adverse development outcome result significant expense monetary damage penalty injunctive relief significantly reduce earning cash flow harm business country require grant compulsory license product face generic competition product number develop country government official interested group suggest pharmaceutical company drug hiv infection available low cost alternatively government develop country require grant compulsory license allow competitor manufacture sell version product reduce product sale example past certain office government brazil express concern affordability hiv product declare consider issue compulsory license permit manufacture patent product hiv infection include viread july brazilian patent authority reject patent application tenofovir disoproxil fumarate active pharmaceutical ingredient viread high level appeal available brazilian patent authority currently patent brazil brazilian government purchase supply tenofovir disoproxil fumarate generic manufacturer addition concern cost availability tamiflu relate potential avian flu pandemic influenza generate international discussion compulsory licensing tamiflu patent example canadian government consider allow canadian manufacturer manufacture export active ingredient tamiflu eligible develop develop country canada access medicine regime furthermore roche issue voluntary license permit thirdparty manufacturing tamiflu example roche grant sublicense shanghai pharmaceutical group ltd china sublicense india hetero drug limited india certain develop country compulsory license issue permit generic manufacturing override tamiflu patent roche issue additional voluntary license permit thirdparty manufacturing tamiflu development reduce royalty receive roche sale tamiflu certain country permit enforcement patent thirdparty manufacturer able sell generic version product country compulsory license sale generic version product significantly reduce sale adversely affect result operation particularly generic version product import territory exist commercial sale change royalty revenue disproportionately affect pretax income earning share gross margin portion revenue derive royalty revenue recognize collaboration agreement party royalty revenue impact pretax income earning share gross margin disproportionately contribution revenue increase decrease royalty revenue material significantly impact operating result example roche tamiflu sale unpredictable variability strong relationship seasonal influenza global pandemic planning effort tamiflu royalty increase sharply quarter primarily result pandemic planning initiative worldwide tamiflu royalty second quarter decrease decline pandemic planning initiative worldwide period royalty revenue tamiflu increase disproportionate increase pretax income earning share gross margin similarly period royalty tamiflu decrease disproportionate decrease pretax income earning share gross margin face significant liability result product cover insurance successful claim materially reduce earning testing manufacturing marketing use commercial product product candidate development involve substantial risk product liability claim claim directly consumer healthcare provider pharmaceutical company recent year coverage availability costeffective product liability insurance decrease unable maintain sufficient coverage product liability arise addition cost defend lawsuit pay damage product liability claim exceed coverage unable maintain adequate coverage claim exceed coverage financial condition ability clinically test product candidate market product adversely impact addition negative publicity associate claim regardless merit decrease future demand product impair financial condition business disruption natural manmade disaster harm future revenue worldwide operation subject business interruption stem natural manmade disaster selfinsure corporate headquarters fremont location house majority research development activity san dima oceanside manufacture facility locate california seismically active region carry earthquake insurance significant recovery time require resume operation financial condition operating result materially adversely affect event major earthquake change effective income tax rate reduce earning factor favorable unfavorable effect income tax rate factor include limited interpretation exist tax law change tax law rate portion nondeductible pharmaceutical excise tax accounting stock option sharebase payment merger acquisition future level spending change accounting standard change mix earning tax jurisdiction operate change overall level pretax earning resolution federal state foreign income tax audits impact income tax provision result mention factor significant negative impact net income income tax return audit federal state foreign tax authority currently examination internal revenue service tax year state foreign jurisdiction differ interpretation tax law regulation result significant dispute arise tax authority involve issue time deduction allocation income tax jurisdiction resolution exposure report period material impact result operation period fail attract retain highly qualified personnel unable successfully develop new product candidate conduct clinical trial commercialize product candidate future success depend large continue ability attract retain highly qualified scientific technical management personnel personnel expertise clinical testing governmental regulation commercialization face competition personnel company university public private research institution government entity organization competition qualified personnel biopharmaceutical field intense limited pool qualified potential employee recruit able attract retain quality personnel acceptable term unsuccessful recruitment retention effort business harm item unresolved staff comment applicable item property lease facility foster city fremont palo alto san dimas california house manufacturing warehousing activity addition lease facility branford connecticut seattle washington house administrative activity order expand corporate headquarters complete purchase office building locate velocity way foster city associate real property international headquarter include commercial medical administrative facility locate lease london area united kingdom manufacturing facility cork ireland primarily use solid dose tablet manufacturing antiviral product product packaging activity lease facility cork share service lease facility dublin area ireland house distribution activity manufacturing facility edmonton alberta canada primarily use conduct process research scaleup clinical development candidate manufacture active pharmaceutical ingredient investigational commercial product chemical development activity improve exist commercial manufacturing process manufacture facility oceanside california design equipped produce biologic compound toxicological phase phase clinical study use facility process development manufacture simtuzumab investigational monoclonal antibody candidate development treatment certain cancer fibrotic disease antibody lease additional facility house commercial medical administrative activity australia austria belgium canada czech republic france germany greece hong kong ireland italy netherlands poland portugal russia spain south korea sweden switzerland turkey united kingdom lease office shanghai china provide source manufacturing support primarily relate commercial purchase active pharmaceutical ingredient believe exist property include own lease site good condition suitable conduct business believe capital resource sufficient purchase lease construct additional facility require meet expect longterm growth need item legal proceeding litigation generic manufacturer tenofovir disoproxil fumarate emtricitabine fixeddose combination emtricitabine tenofovir disoproxil fumarate efavirenz november receive notice teva pharmaceutical teva submit abbreviate new drug application anda drug administration fda request permission manufacture market generic version truvada notice teva allege patent associate emtricitabine own emory university license exclusively invalid unenforceable andor infringe teva manufacture use sale generic fixeddose combination emtricitabine tenofovir disoproxil fumarate december file lawsuit district court new york teva infringement emtricitabine patent march receive notice teva submit anda fda request permission manufacture market generic fixeddose combination emtricitabine tenofovir disoproxil fumarate efavirenz notice teva challenge emtricitabine patent file lawsuit district court new york teva infringement emtricitabine patent lawsuit consolidated lawsuit file december january receive notice teva submit anda fda request permission manufacture market generic version viread notice teva challenge tenofovir disoproxil fumarate patent protect viread january receive notice teva amend anda relate generic version atripla truvada product notice relate teva anda generic version atripla teva challenge patent relate tenofovir disoproxil fumarate additional patent relate emtricitabine patent relate efavirenz notice relate teva anda generic version truvada teva challenge patent relate tenofovir disoproxil fumarate additional patent relate emtricitabine march file lawsuit teva infringement viread patent additional emtricitabine patent march bristolmyers squibb company merck inc file lawsuit teva infringement patent relate efavirenz file lawsuit requisite day period provide hatch waxman act stay prevent fda approval teva andas month district court decision adverse patent month stay teva anda expire july result court scheduling order teva prohibit launch risk expiration month stay gilead teva reach agreement principle settle ongoing patent litigation concern patent protect tenofovir disoproxil fumarate viread truvada atripla product trial litigation schedule begin february adjourn pende completion activity necessary finalize settlement agreement teva allow launch generic version viread december settlement agreement file federal trade commission department justice review final november receive notice teva submit abbreviate new drug submission ands canadian ministry health request permission manufacture market generic fixeddose combination emtricitabine tenofovir disoproxil fumarate notice teva allege patent associate truvada invalid unenforceable andor infringe teva manufacture use sale generic version truvada january file lawsuit teva canadian federal court seek order prohibition approval and december receive notice teva submit ands canadian ministry health request permission manufacture market generic fixeddose combination emtricitabine tenofovir disoproxil fumarate efavirenz notice teva allege patent associate atripla merck patent associate atripla invalid unenforceable andor infringe teva manufacture use sale generic fixeddose combination emtricitabine tenofovir disoproxil fumarate efavirenz february file lawsuit teva canadian federal court seek order prohibition approval ands july receive notice lupin limited lupin submit anda fda request permission manufacture market generic version truvada notice lupin allege patent associate emtricitabine patent associate tenofovir disoproxil fumarate invalid unenforceable andor infringe lupin manufacture use sale generic version fixeddose combination emtricitabine tenofovir disoproxil fumarate august file lawsuit lupin district court new york infringement patent july receive notice cipla ltd submit anda fda request permission manufacture market generic version emtriva generic version viread notice cipla allege patent associate emtricitabine invalid unenforceable andor infringe cipla manufacture use sale generic version emtricitabine patent associate tenofovir disoproxil fumarate invalid unenforceable andor infringe cipla manufacture use sale generic version tenofovir disoproxil fumarate august file lawsuit cipla district court new york infringement patent august receive notice teva submit ands canadian ministry health request permission manufacture market generic version tenofovir disoproxil fumarate notice teva allege patent associate viread invalid unenforceable andor infringe teva manufacture use sale generic version viread september file lawsuit teva canadian federal court seek order prohibition approval and august teva file impeachment action canadian federal court seek invalidation canadian patent associate viread currently defend impeachment action october receive notice lupin submit anda fda request permission manufacture market generic version viread notice lupin allege patent associate tenofovir disoproxil fumarate invalid unenforceable andor infringe lupin manufacture use sale generic version tenofovir disoproxil fumarate october file lawsuit lupin district court new york infringement patent ranolazine june receive notice lupin submit anda fda request permission manufacture market generic version sustain release ranolazine notice lupin allege patent associate ranexa invalid unenforceable andor infringe lupin manufacture use sale generic version ranexa july file lawsuit lupin district court new jersey infringement patent ranexa fda approve lupin anda receive district court decision expiration court automatic stay july court schedule trial begin april court find patent protect ranexa formulation infringe andor invalid lupin receive final approval product lupin able launch generic version ranexa product risk issuance decision adefovir disoproxil fumarate august receive notice sigmapharm lab sigmapharm submit anda fda request permission manufacture market generic adefovir dipivoxil notice sigmapharm allege patent associate hepsera invalid unenforceable andor infringe sigmapharm manufacture use sale generic version hepsera september file lawsuit sigmapharm district court new jersey infringement patent fda approve sigmapharm anda receive district court decision expiration court automatic stay february court set trial date case anticipate trial occur mid expiry month stay february sigmapharm obtain final fda approval product fda elect launch generic product risk infringe patent prior decision court patent challenge sigmapharm challenge ranbaxy inc ranbaxy pursuant notice receive october patent challenge ranbaxy expire july option filing lawsuit time believe ranbaxy infringe patent tamiflu february receive notice natco pharma ltd natco submit anda fda request permission manufacture market generic oseltamivir phosphate notice natco allege patent associate tamiflu invalid unenforceable andor infringe natco manufacture use sale generic version tamiflu march hoffmannla roche ltd file lawsuit natco district court new jersey infringement patent associate tamiflu december court issue rule favor gilead roche patent invalid reason state natco notice letter predict ultimate outcome action spend significant resource enforce defend patent unsuccessful lawsuit original claim patent narrow invalidated patent protection atripla truvada viread hepsera ranexa tamiflu united states atripla truvada viread canada substantially shorten patent cover product invalidate fda canadian ministry health approve request manufacture generic version products united states canada respectively prior expiration date patent sale generic version product hepsera early patent expiration significant negative effect revenue result operation department justice investigation june receive subpoena attorney office northern district california request document relate manufacture relate quality distribution practice complera atripla truvada viread emtriva hepsera letairis cooperating continue cooperate governmental inquiry interference proceeding litigation idenix pharmaceuticals inc february receive notice patent trademark office pto declare interference patent idenix pharmaceuticals inc idenix pende patent application interference administrative proceeding pto design determine invent subject matter claim party patent cover metabolite sofosbuvir idenix attempt claim class compound include metabolite pende patent application course proceed party call submit evidence date conceive respective invention interference determine invent compound entitle patent claim compound administrative law judge determine idenix entitle patent claim determine infringe claim require obtain license pay royalty idenix commercialize sofosbuvir determination pto appeal party federal court june meet idenix mandatory settlement discussion party unable settle interference widely divergent view strength respective position need license idenix patent idenix need license gilead patent develop manufacture pipeline product believe idenix application involve interference similar foreign patent claim compound metabolite invalid result file impeachment action canadian federal court invalidate idenix patent canadian patent correspond idenix patent idenix patent application subject interference file similar legal action federal court norway seek invalidate correspond norwegian patent file similar legal action federal court australia seek invalidate correspond australian patent bring similar action country idenix award patent compound metabolite european country japan china event patent issue expect challenge proceeding similar invoke canada norway australia contract arbitration march jeremy clark employee pharmasset inc pharmasset acquire january inventor patent file demand arbitration lawsuit pharmasset raymond schinazi clark initially file lawsuit pharmasset schinazi alabama district court february seek void assignment provision employment agreement assert ownership patent claim metabolite sofosbuvir december court order stay litigation pende outcome arbitration proceeding require clark employment agreement instead proceed arbitration clark file additional lawsuit september june subsequently dismiss court september clark file motion seek reconsideration court december order deny court december clark file motion appoint special prosecutor february alabama court issue order require clark enter arbitration risk dismissal case clark file demand arbitration march arbitration panel set hearing date april predict outcome arbitration clark prior assignment patent pharmasset voided arbitration panel ultimately find owner patent determine infringe patent require obtain license pay royalty clark commercialize sofosbuvir matter party legal action arise ordinary course business believe legal action material adverse impact consolidate business financial position result operation item safety disclosure applicable item market registrant common equity relate stockholder matter issuer purchase equity security common stock trade nasdaq global select market symbol gild follow table set forth high low intraday sale price share common stock nasdaq global select market period indicate price represent quotation dealer adjustment retail markup markdown commission represent price actual transaction high low quarter second quarter quarter fourth quarter quarter second quarter quarter fourth quarter february share common stock outstanding hold approximately stockholder record include share hold broker bank nominee pay cash dividend common stock inception expect retain earning primarily use operation expansion business anticipate pay cash dividend near future effort continue return value stockholder minimize dilution stock issuance january board directors board authorize threeyear billion stock repurchase program commence september completion stock repurchase program december repurchase billion common stock january stock repurchase program spend total million repurchase retire million share common stock average purchase price share suspend share repurchase half order focus debt repayment item note consolidated financial statement include annual report information stock repurchase program performance graph follow graph compare total stockholder return past year index standard poor stock index label index nasdaq biotechnology index label nbi index total return index assume reinvestment dividend pay company include index calculate december year composite member index nbi index intend use indice comparator stock performance purpose follow graph go forward composite member index require applicable regulation use index comparator believe nbi index relevant comparator compose peer company linesofbusiness similar stockholder return show graph necessarily indicative future performance endorse prediction future stockholder return comparison cumulative total return investment past year section soliciting material deem file sec incorporate reference filing securities act exchange act date hereof irrespective general incorporation language filing show cumulative return investment assume investment common stock nbi index index december issuer purchase equity security december repurchase billion common stock january threeyear billion stock repurchase program spend total million repurchase retire million share common stock average purchase price share suspend share repurchase half order focus debt repayment item note consolidated financial statement include annual report information stock repurchase program table summarize stock repurchase activity month end december thousands share amount total number maximum fair share purchase value share publicly total number average price announce purchase share purchase pay share program program october october november november december december total january announce board authorize threeyear billion stock repurchase program expire january difference total number share purchase total number share purchase publicly announce program share common stock withhold employee restrict stock award order satisfy applicable tax withholding obligation item select financial datum gilead sciences inc select consolidated financial datum thousand share datum year end december consolidated statement income datum total revenue total cost expense income operation provision income taxis net income attributable gilead net income share attributable gilead common stockholdersbasic share share calculationbasic net income share attributable gilead common stockholdersdilute share share calculationdilute december consolidated balance sheet datum cash cash equivalent marketable security work capital total asset longterm obligation convertible senior note senior unsecured note credit facility retain earning total stockholder equity record million million stockbase compensation research development expense sell general administrative expense respectively relate acquisition pharmasset record million impairment charge expense relate certain inprocess research development iprd asset acquire cgi pharmaceuticals inc record million impairment charge expense relate certain iprd asset acquire therapeutics inc therapeutic complete acquisition asset navita asset llc relate cicletanine business aggregate purchase price million record iprd expense net income share number share share calculation period present reflect twoforone stock split form stock dividend effective january complete acquisition pharmasset recognize consideration transfer billion primarily record intangible asset finance transaction approximately billion cash hand billion bank debt issue january billion senior unsecured note issue december complete acquisition therapeutic recognize consideration transfer billion primarily record intangible asset borrow million fiveyear revolve credit facility credit agreement issue billion principal senior unsecured note register offering issue billion principal convertible senior note private placement item management discussion analysis financial condition result operation follow management discussion analysis financial condition result operation mda intend help reader understand result operation financial condition mda provide supplement read conjunction audit consolidated financial statement accompany note consolidated financial statement disclosure include annual report include disclosure item risk factor consolidate financial statement prepare accordance generally accept accounting principle present dollar management overview gilead sciences inc gilead incorporate delaware june researchbase biopharmaceutical company discover develop commercialize innovative medicine area unmet medical need new discovery experimental drug candidate seek improve care patient suffer lifethreatening disease world gilead primary area focus include human immunodeficiency virus hiv liver disease hepatitis virus hbv hepatitis virus hcv cardiovascular respiratory condition oncologyinflammation headquarter foster city california operations north america europe asia continue add exist portfolio product internal discovery clinical development program product acquisition inlicense strategy product portfolio comprise stribild compleraeviplera atripla truvada viread hepsera emtriva letairis ranexa ambisome cayston vistide international commercial sale operation marketing subsidiary north america europe asia addition sell distribute certain product corporate partner royaltypaye collaborative agreement business highlight continue advance pipeline therapeutic area believe combination exist internal research program recent acquisition partnership allow continue bring innovative therapy individual live unmet medical need summary key accomplishment complete billion acquisition pharmasset inc pharmasset acquire lead compound know sofosbuvir nucleotide analog evaluate treatment hcv infection accelerate timeline develop alloral hcv regiman result acquisition expand worldwide access compleraeviplera available country expand research development pipeline active phase clinical study end submit marketing application united states european union elvitegravir integrase inhibitor treatment hiv infection treatmentexperience adult cobicistat pharmacoenhance boost agent increase blood level allow oncedaily dose certain hiv medicine food drug administration fda set target review date april prescription drug user fee act obtain fda approval launch stribild single tablet regimen treatment hiv united states announce acquisition biosciences closed february expand grow oncologyinflammation pipeline obtain fda approval oncedaily oral truvada combination safe sex practice preexposure prophylaxis prep reduce risk hiv infection uninfected adult outlook operating objective include increase market share commercial product continue strengthen pipeline internally develop andor externally inlicense purchase opportunity strengthen key alliance perspective continue advance grow product pipeline focus progress effort file marketing application sofosbuvir treatment hcv develop additional innovative hiv single tablet regimen advance new product candidate treatment oncology inflammation disease result expect forward number important latestage clinical study relate hiv hcv oncology inflammation commercial perspective number initiative promote continue growth franchise hiv area scientific support early diagnosis treatment use single tablet regimen remain compelling medically practically anticipation receive regulatory approval sofosbuvir begin build commercial organization support expect launch product launch stribild single tablet regimen treatment hiv united states expect continue strong uptake stribild united states marketing application stribild currently review european medicine agency approve expect product available second quarter hbv area continue support educational promotional activity focus asian community united states highlight need screen diagnose link patient care cardiovascular area continue effort raise awareness gilead pulmonary arterial hypertension cardiology community mindful condition current macroeconomic environment affect ability achieve goal factor affect business include change legislation delay impact funding adap united states continuation worsen economic condition certain key market particularly europe patent expiration competitive product launch generic competitor continue government pricing pressure internationally potential volatility foreign currency exchange rate continue monitor condition adjust business process appropriate attempt mitigate risk business believe success experienced enable continue build financially sound business model allow continue expand commercial activity maintain quality compliance continue grow business remain focused profitable revenue growth prudent expense management believe enable solid execution operating objective financial highlight total revenue grow billion drive strong underlying demand product total product sale billion increase primarily growth antiviral franchise increase billion compare prior year sale letairis ranexa ambisome surpass billion mark reach billion increase compare prior year royalty revenue collaboration corporate partner million increase compare prior year expense increase billion progress invest expansion product pipeline continue investing phase clinical study particularly liver disease oncology sell general administrative sga expense billion increase million reflective ongoing growth business increase pharmaceutical excise tax result healthcare reform net income billion diluted share decrease billion diluted share primarily continued progression investment product pipeline increase effective tax rate result shift geographic mix earning expiration federal research tax credit increase acquisitionrelate expense receive tax benefit december cash cash equivalent marketable security total billion decrease billion december january complete pharmasset acquisition finance approximately billion cash hand billion senior unsecured note issue december billion bank debt issue january generate billion operating cash flow repay approximately billion debt financing repurchase retire share common stock million result operation total revenue total revenue include product sale royalty revenue contract revenue total revenue billion billion billion increase total revenue drive growth product sale product sale total product sale billion increase total product sale billion primarily drive continued growth sale antiviral product include atripla truvada compleraeviplera increase reflect sale growth product primarily letairis ranexa ambisome reach billion compare million total product sale increase compare billion primarily drive growth atripla truvada product sale generate outside united states result face exposure adverse movement foreign currency exchange rate primarily euro foreign currency exchange forward contract hedge percentage foreign currency exposure foreign currency exchange net hedge unfavorable impact million revenue compare favorable impact million revenue compare product sale united states increase billion compare billion primarily drive high underlying demand antiviral product launch stribild august product sale therapeutic area contribute growth letairis sale total million increase compare ranexa sale total million increase compare ambisome sale total million increase compare product sale europe increase billion compare billion primarily drive high underlying demand antiviral franchise antiviral product sale europe total billion increase compare billion primarily drive sale atripla truvada foreign currency exchange net hedge unfavorable impact million european product sale compare total product sale expect grow realize year impact sale stribild continue growth compleraeviplera product cardiovascular franchise believe growth temper uncertainty time approval federal budget possibility automatic reduction federal spending sequestration march unavailability delay aids drug assistance program adap funding challenge economic environment europe result subject continue potential volatility foreign currency exchange rate follow table summarize period period change product sale thousand change change antiviral product atripla truvada viread compleraeviplera stribild hepsera emtriva total antiviral product letairis ranexa ambisome total product sale antiviral product antiviral product sale increase compare compare atripla atripla sale drive primarily sale volume growth united states atripla sale drive primarily sale volume growth europe united states atripla sale account total antiviral product sale respectively efavirenz component atripla gross margin zero comprise billion billion billion atripla sale respectively truvada truvada sales drive primarily sale volume growth united states truvada sales drive primarily sale volume growth europe united states truvada sale account total antiviral product sale respectively compleraeviplera sale compleraeviplera increase primarily sale volume growth united states complera approve united states august eviplera approve european union november stribild stribild approve united states august product sale product include letairis ranexa ambisome increase primarily sale volume growth label update march sales letairis continue grow result high enrollment increase ambisome product sale united states canada relate solely sale ambisome astella pharma inc record manufacturing cost royalty revenue follow table summarize period period change royalty revenue thousand change change royalty revenue royalty revenue increase compare drive primarily high royalty revenue glaxosmithkline japan tobacco astellas partially offset low tamiflu royalty roche second quarter tamiflu royalty decrease decline flu planning initiative worldwide significant source royalty revenue sale tamiflu roche royalty revenue decline compare primarily low tamiflu royalty roche tamiflu royalty roche contribute million million million total royalty revenue respectively recognize royalty tamiflu sale roche quarter follow quarter correspond sale occur cost good sell product gross margin follow table summarize period period change product sale thousand cost good sell thousand product gross margin change change total product sale cost good sell product gross margin product gross margin consistent product gross margin product gross margin decrease compare primarily annual selling price adjustment percentage share atripla pay partner efavirenz component research development expense change change research development manage expense identify activity anticipate perform give period prioritize effort base scientific datum probability successful development market potential available human capital resource consideration continually review pipeline status development necessary reallocate resource portfolio believe good support future growth business expense summarize consist primarily clinical study perform contract research organization cro material supply license fee milestone payment collaboration arrangement personnel cost include salary benefit stockbase compensation overhead allocation consist support facilitiesrelate cost follow table provide breakout expense major cost type thousand clinical study outside service personnel expense facility cost iprd impairment charge total compare clinical study outside service increase million progression expansion phase study particularly liver disease oncology personnel expense increase million high headcount support product pipeline study progression compare clinical study outside service increase million study progression liver disease hiv new investment oncology inflammation new inlicense agreement milestone ongoing collaboration personnel expense increase million high headcount facility cost increase million support ongoing growth business increase partially offset million decrease iprd impairment charge record million impairment charge relate certain iprd asset acquire cgi pharmaceuticals inc cgi impairment charge result change anticipate market share relate syk compound record million impairment charge relate certain iprd asset acquire therapeutics inc majority impairment charge relate program product candidate phase clinical study treatment diabetes hypertriglyceridemia terminate fourth quarter unfavorable result pharmacokinetic pharmacodynamic test demonstrate limited effectiveness compound patient expect expense increase level continued investment internal collaborative effort advancement product pipeline drive primarily progression phase clinical study liver disease oncology area sell general administrative expense change change sell general administrative sga expense relate sale marketing finance human resource legal administrative activity expense primarily comprise facility overhead cost outside marketing advertising legal expense general administrative cost compare sga expense increase million increase primarily million increase cost associate growth business include personnel headcountrelate expense million increase stockbase compensation expense primarily result acquisition pharmasset increase million pharmaceutical excise tax result healthcare reform increase partially offset reduction bad debt provision million include gain million relate sale account receivables balance spain second quarter compare sga expense increase million primarily increase contract legal professional service million pharmaceutical excise tax million increase compensation benefit expense million result high headcount support expand commercial activity promotional cost million drive expand sale marketing activity bad debt provision million associate slow collection southern european country expect sga expense increase support expansion business include prelaunch activity preparation anticipate nda file sofosbuvir half increase pharmaceutical excise tax expect bad debt provision return historical level include significant collection past account receivable spain portugal expect occur interest expense compare interest expense increase million increase primarily additional debt issue connection acquisition pharmasset include billion senior unsecured note issue december billion bank debt issue january compare interest expense increase million increase interest expense primarily issuance convertible senior note billion july issuance senior unsecured note billion march issuance senior unsecured note billion december increase partially offset maturity convertible senior note aggregate principal balance million income expense net income expense net net expense million compare income million million respectively decrease income expense net compare primarily decrease interest income result low cash marketable security balance yield million loss greek bond relate greece restructure sovereign debt quarter increase income expense net compare drive primarily favorable net foreign currency exchange impact increase interest income partially offset increase cost relate hedging activity provision income taxis provision income tax billion million billion respectively effective tax rate differ federal statutory rate primarily tax credit certain operating earning nonus subsidiary consider indefinitely reinveste partially offset state taxis stockbase compensation expense relate pharmasset acquisition contingent consideration expense relate certain acquisition receive tax benefit provide income taxis undistribute earning foreign operation intend indefinitely reinveste foreign subsidiary effective tax rate differ federal statutory rate primarily tax credit certain operating earning nonus subsidiary consider indefinitely reinveste partially offset state taxis nondeductible pharmaceutical excise tax effective tax rate differ federal statutory rate primarily tax credit certain operating earning nonus subsidiary consider indefinitely reinveste partially offset state taxis january congress pass american taxpayer relief act retroactively reinstate federal research tax credit result income tax provision quarter include discrete tax benefit relate federal research tax credit reduce effective tax rate quarter less extent annual effective tax rate acquisition pharmasset january complete acquisition pharmasset publiclyheld clinicalstage pharmaceutical company commit discover develop commercialize novel drug treat viral infection pharmasset primary focus development oral therapeutic treatment hcv infection pharmasset lead compound know sofosbuvir formally know nucleotide analog january evaluate phase phase clinical study treatment hcv infection genotype believe acquisition pharmasset provide opportunity complement exist hcv portfolio help advance effort develop alloral regimen treatment hcv acquire outstanding share common stock pharmasset share cash tender offer subsequent merger term agreement plan merger enter november aggregate cash payment acquire outstanding share common stock billion finance transaction approximately billion cash hand billion senior unsecured note issue december billion bank debt issue january pharmasset acquisition account business combination result operation pharmasset include consolidated statement income january date acquire approximately outstanding share common stock pharmasset cash consideration transfer result obtain effective control pharmasset acquisition complete january time pharmasset whollyowne subsidiary gilead integrate operation track earning result product candidate therapeutic area maintain separate earning result acquire pharmasset business follow table summarize component cash pay acquire pharmasset thousand total consideration transfer stockbase compensation expense total cash pay billion cash payment consist billion cash payment outstanding common stockholder million cash payment option holder pharmasset stock option plan billion cash payment outstanding common stockholder million cash payment vested option holder pharmasset stock option plan account consideration transfer remain million cash payment account stockbase compensation expense result accelerate vest pharmasset employee option immediately prior acquisition follow table summarize acquisition date fair value asset acquire liability assume consideration transfer thousand identifiable intangible asset cash cash equivalent asset acquire liability assume net total identifiable net asset goodwill total consideration transfer identifiable intangible asset acquire intangible asset primarily comprise sofosbuvir inprocess research development iprd compound estimate fair value billion date acquisition fair value determine probabilityweighte income approach discount expect future cash flow present value estimate net cash flow discount discount rate base estimate weightedaverage cost capital company profile similar pharmasset rate comparable estimate internal rate return acquisition represent rate market participant use value intangible asset project cash flow base key assumption estimate revenue operate profit relate project consider stage development acquisition date time resource need complete development approval product candidate life potential commercialize product associate risk include inherent difficulty uncertaintie develop product candidate obtain marketing approval fda regulatory agency risk related viability potential alternative treatment future target market intangible asset relate iprd project consider indefinitelive asset amortize completion abandonment associate effort goodwill million goodwill represent excess consideration transfer fair value asset acquire liability assume attributable synergy expect combine operation pharmasset goodwill expect deductible income tax purpose stockbase compensation expense stockbase compensation expense recognize accelerate vest employee option immediately prior acquisition report consolidated statement income follow thousands year end december research development expense sell general administrative expense total stockbase compensation expense cost cost incur connection acquisition include thousands year end december transaction cost investment advisory legal accounting fee bridge financing cost restructure cost total cost follow table summarize cost line item consolidate statement income cost recognize thousands year end december research development expense sell general administrative expense interest expense total cost liquidity capital resource believe exist capital resource supplement cash flow generate operating activity cash flow financing activity adequate satisfy capital need foreseeable future cash cash equivalent marketable security decrease significantly complete acquisition pharmasset january follow table summarize cash cash equivalent marketable security work capital cash flow activity end period present thousand december cash cash equivalent marketable security working capital year end december cash provide operating activity invest activity financing activity cash cash equivalent marketable security cash cash equivalent marketable security total billion december decrease billion december primarily acquisition pharmasset billion january generate billion cash flow operation cash cash equivalent marketable security total billion december increase billion december increase primarily attributable issuance senior unsecured note total net proceed billion cash provide operation billion increase partially offset billion repurchase common stock stock repurchase program million repay convertible senior note million acquisition arresto biosciences inc calistoga pharmaceuticals inc billion net proceed relate senior unsecured note issue december billion additional bank debt issue january fund billion acquisition pharmasset total cash cash equivalent marketable security december approximately billion generate operation foreign jurisdiction intend use foreign operation rely unrepatriate earning source fund domestic business expect sufficient cash flow borrowing capacity united states fund domestic operational strategic need work capital work capital billion december decrease billion work capital december primarily attributable billion cash pharmasset acquisition increase shortterm debt billion relate current portion bank debt issue finance pharmasset acquisition current portion convertible senior note work capital billion december increase billion work capital december increase primarily attributable increase billion cash cash equivalent shortterm marketable security result billion net issuance senior unsecured note december sale longterm marketable security anticipation acquisition pharmasset cash provide operating activity cash provide operating activity billion primarily related net income billion adjust noncash item million depreciation amortization expense million stockbase compensation expense million net cash inflow relate change operate asset liabilitie million tax benefit employee stock plan cash provide operating activity billion primarily related net income billion adjust noncash item million depreciation amortization expense million net cash inflow relate change operate asset liability million stockbase compensation expense cash provide operating activity billion primarily related net income billion adjust noncash item million depreciation amortization expense million stockbase compensation expense million iprd impairment expense million tax benefit employee stock plan partially offset million net cash outflow relate change operate asset liabilitie cash provide investing activity cash investing activity billion consist primarily billion acquisition pharmasset net stockbase compensation expense cash acquire million net purchase marketable security million capital expenditure relate primarily purchase office building million million increase construction progress associate new facility headquarters support ongoing growth business cash provide investing activity billion consist billion net proceed relate sale marketable security connection acquisition pharmasset partially offset million acquisition arresto calistoga million capital expenditure cash investing activity billion drive billion net purchase marketable security million acquisition cgi million capital expenditure cash provide financing activity cash provide financing activity million drive primarily net proceed billion issuance bank debt conjunction pharmasset acquisition proceed million issuance common stock employee stock plan million proceed receive related convertible note hedge cash proceed partially offset billion repay debt financing year million repurchase common stock stock repurchase program include commission upcoming maturity convertible note suspend share repurchase activity half cash provide financing activity billion drive primarily issuance billion senior unsecured note billion raise december partially fund pharmasset acquisition net issuance cost million proceed issuance common stock employee stock plan cash proceed partially offset billion repurchase common stock stock repurchase program include commission million repay convertible senior note cash financing activity billion drive primarily billion repurchase common stock stock repurchase program million purchase note hedge relate convertible senior note cash outflow partially offset billion net proceed issuance note million proceed issuance common stock employee stock plan million proceed sale warrant relate note longterm obligation bank debt january conjunction acquisition pharmasset enter fiveyear billion revolve credit facility credit agreement year revolve credit agreement million shortterm revolve credit facility credit agreement shortterm revolve credit agreement billion term loan facility term loan credit agreement borrow aggregate principal billion follow million fiveyear revolve credit agreement million shortterm revolve credit agreement billion term loan credit agreement close acquisition fully repay billion outstanding debt term loan credit agreement shortterm revolve credit agreement time agreement terminate fiveyear revolve credit agreement contain customary representation warranty affirmative negative financial maintenance covenant event default loan bear interest eurodollar rate plus applicable margin base rate plus applicable margin define credit agreement reduce commitment prepay loan time premium penalty fiveyear revolve credit agreement inclusive million swing line loan subfacility million letter credit subfacility december million letter credit outstanding fiveyear revolve credit agreement fiveyear revolve credit agreement terminate amount owe agreement shall payable january convertible senior note senior unsecured note portion convertible note convert repay million principal balance pay million cash relate conversion spread note represent conversion value excess principal receive million cash convertible note hedge relate note december issue senior unsecured note register offering aggregate principal billion partially fund acquisition pharmasset pay interest note fix annual rate range convertible senior note mature repay aggregate principal balance million pay million cash relate conversion spread mature note represent conversion value excess principal receive million cash relate convertible note hedge warrant relate convertible senior note expire august march issue senior unsecured note april register offering aggregate principal billion note pay interest fix annual rate december debttoebitda ratio repay billion debt financing plan continue repay debt decrease debttoebitda ratio follow summary borrowing financing arrangement thousand interest december type borrowing description issue date date rate convertible senior note april convertible senior note july convertible senior note july senior unsecured april note march april senior unsecured december note december december senior unsecured december note december december senior unsecured december note december december senior unsecured december note december december credit facility fiveyear revolver january january variable total debt net current portion total longterm debt net believe exist capital resource supplement cash generate operation adequate satisfy capital need foreseeable future future capital requirement depend factor include limited follow commercial performance current future product progress scope effort include preclinical study clinical trial cost timing outcome regulatory review expansion sale marketing capability administrative expense possibility acquire additional manufacturing capability office facility possibility acquire company new product cost associate settlement conversion convertible senior note relate warrant establishment additional collaborative relationship company cost associate defense settlement adverse result litigation government investigation future require additional funding form proceed equity debt financing fund require guarantee available favorable term critical accounting policy estimate judgment discussion analysis financial condition result operation base consolidated financial statement prepare accordance generally accept accounting principle preparation financial statement require estimate judgment affect report amount asset liability revenue expense related disclosure ongoing basis evaluate estimate include related revenue recognition allowance doubtful account valuation intangible asset contingent consideration liability result business combination tax provision base estimate historical experience market specific relevant assumption believe reasonable circumstance result form basis make judgment carry value asset liability readily apparent source actual result differ significantly estimate believe follow critical accounting policy reflect significant judgment estimate preparation consolidated financial statement revenue recognition product sale recognize revenue product sale persuasive evidence arrangement exist delivery customer occur price fix determinable collectability reasonably assure record estimate reduction revenue government rebate medicaid reimbursement customer incentive cash discount prompt payment distributor fee expect return expire product estimate deduct gross product sale time revenue recognize reduction gross product sale government rebate significantly impact report net product sale base certain estimate require complex significant judgment management government rebate allowance accrue government rebate estimate reduction revenue governmentmanage medicaid program certain qualify federal state foreign government program reimbursement portion retail price prescription fill cover program reduction settle invoice directly chargeback wholesaler government rebate invoice directly record accrue government rebate consolidated balance sheet qualified program purchase product wholesaler low contractual government price wholesaler charge difference acquisition cost low contractual government price record allowance account receivable pay rebate country outside united states date payment foreign government represent significant portion total government rebate government program united states estimate sale allowance base contractual term historical utilization rate new information change program regulation guideline impact actual rebate expectation future utilization rate program channel inventory datum obtain major wholesaler accordance inventory management agreement government rebate chargeback billion billion billion respectively represent total gross product sale respectively deduct gross product sale believe methodology use estimate sale allowance government price reduction reasonable appropriate give current fact circumstance actual result differ base current information available actual government rebate claim period vary estimate record period december accrue government rebate million million respectively accrue government rebate allowance government chargeback million million respectively record account receivable follow table summarize aggregate activity government rebate allowance accrue government rebate account balance deduct balance begin charge end year expense accrual year year end december government rebate allowance accrue government rebate activity relate sale activity relate sale prior total year end december government rebate allowance accrue government rebate activity relate sale activity relate sale prior total allowance doubtful account maintain allowance doubtful account estimate loss result inability customer require payment allowance base analysis factor include limited contractual payment term historical payment pattern customer individual customer circumstance analysis day sale outstanding geographic region review local economic environment potential impact government funding reimbursement practice financial condition customer economic environment operate deteriorate result inability payment additional allowance require believe allowance doubtful account adequate significant deterioration factor materially change expectation result increase allowance doubtful account december allowance doubtful account million million respectively valuation intangible asset contingent consideration liability result business combination conjunction business combination record intangible asset primarily relate iprd project record contingent consideration liability payable achievement specify development regulatory approval salesbase milestone event identifiable intangible asset contingent consideration liability measure respective fair value acquisition date model value intangible asset contingent consideration liability require use significant estimate assumption include limited estimate revenue operate profit relate product product candidate probability success unapproved product candidate consider stage development time resource need complete development approval product candidate life potential commercialize product associate risk include inherent difficulty uncertaintie develop product candidate obtain fda regulatory approval risk relate viability potential alternative treatment future target market intangible asset indefinite useful life review annually impairment fact circumstance suggest carry value asset recoverable revalue contingent consideration obligation quarter follow acquisition record increase decrease fair value expense consolidated statement income increase decrease fair value indefinitelive intangible asset contingent consideration liability result update assumption expect timing probability achieve specify milestone change project revenue change discount rate significant judgment employ determine assumption acquisition date subsequent period update assumption significant impact result operation give period actual result differ estimate december total intangible asset billion billion respectively contingent consideration liabilitie million million respectively tax provision estimate income tax provision include defer tax asset liability base significant management judgment evaluate realization portion defer tax asset quarterly basis record valuation allowance reduce defer tax asset amount likely realize consider future taxable income ongoing tax planning strategy historical financial performance assess need valuation allowance expect realize defer tax asset previously record valuation allowance reduce valuation allowance period determination factor favorable unfavorable effect income tax rate factor include limited interpretation exist tax law change tax law rate portion nondeductible pharmaceutical excise tax accounting stock option sharebase payment merger acquisition future level spending change accounting standard change mix earning tax jurisdiction operate change overall level pretax earning resolution federal state foreign income tax audits impact income tax provision result mention factor significant negative impact net income record liability relate uncertain tax position accordance guidance clarifie accounting uncertainty income taxis recognize enterprise financial statement prescribe minimum recognition threshold measurement attribute financial statement recognition measurement tax position take expect take tax return believe uncertain tax position currently pende material adverse effect consolidated financial statement adverse resolution uncertain tax position period material impact result operation period december total federal state foreign unrecognized tax benefit million million respectively total unrecognized tax benefit million million december respectively recognize reduce effective tax rate period recognition december believe reasonably possible unrecognized tax benefit significantly change month expect clarification irs tax authority uncertain tax position file federal state foreign income tax return jurisdiction unite states abroad federal income tax purpose statute limitation open onwards certain acquire entity statute limitation open year inception utilization net operating loss credit carry prior year california income tax purpose statute limitation open onwards income tax return audit federal state foreign tax authority currently examination irs tax year state foreign jurisdiction differ interpretation tax law regulation result significant dispute arise tax authority involve issue time deduction allocation income tax jurisdiction periodically evaluate exposure associate tax filing position balance sheet arrangement balance sheet arrangement define item aii regulation contractual obligation contractual obligation consist debt obligation operating lease capital commitment purchase obligation active pharmaceutical ingredient inventoryrelate item clinical trial contract follow table summarize significant enforceable legally bind obligation future commitment obligation relate contract likely continue regardless fact certain obligation cancelable december thousands payment period contractual obligation total year year year year longterm debt operating lease obligation capital commitment purchase obligation clinical trial total longterm debt obligation include future interest payment base fix rate convertible senior note respectively longterm debt obligation include future interest payment base fix rate senior unsecured note december december april december december respectively december aggregate carry value convertible note senior unsecured note billion billion respectively december firm capital project commitment approximately million primarily relate facility improvement project december firm purchase commitment relate active pharmaceutical ingredient certain inventoryrelate item amount include minimum purchase requirement actual purchase expect significantly exceed amount addition commit potential future milestone payment party license collaboration development arrangement payment agreement generally payable achievement certain developmental regulatory andor commercial milestone achievement milestone probable reasonably estimable contingency record consolidated balance sheet include table december clinical study clinical trial phase significant clinical trial expenditure cro material contract cro cancelable historically cancel contract amount reflect commitment base exist contract reflect future modification termination exist contract anticipate potential new contract total gross unrecognized tax benefit liability million december believe reasonably possible unrecognized tax benefit significantly change month expect clarification irs tax authority uncertain tax position unrecognize tax benefit include longterm income taxis payable noncurrent defer tax asset consolidate balance sheet include table recent accounting pronouncement july financial accounting standard board issue new accounting guidance intend simplify testing indefinitelive intangible asset impairment entity allow option perform qualitative assessment impairment indefinitelive intangible asset determine quantitative assessment necessary guidance effective impairment test perform interim annual period fiscal year begin september early adoption permit elect early adopt guidance december material impact consolidate financial statement item quantitative qualitative disclosure market risk expose market risk result change foreign currency exchange rate interest rate credit risk reduce certain risk enter type foreign currency interest rate derivative hedging transaction follow investment guideline monitor outstanding receivables risk management program foreign currency exchange risk operation include manufacture sale activity united states canada ireland sale activity country outside united states include europe asia result financial result significantly affect factor change foreign currency exchange rate weak economic condition foreign market distribute product operating result expose change foreign currency exchange rate dollar foreign currency significant euro dollar strengthen currency relative value sale respective foreign currency decrease conversely dollar weaken currency relative amount sale increase overall net receiver foreign currency benefit weak dollar adversely affect strong dollar relative foreign currency transact significant amount business product sale denominate foreign currency partially mitigate impact change currency exchange rate net cash flow foreign currency denominate sale enter foreign currency exchange forward option contract hedge certain monetary asset liability denominate foreign currency reduce eliminate exposure currency fluctuation date transaction record date cash collect pay general market risk contract offset correspond gain loss transaction hedge december open foreign currency forward contract notional amount billion billion respectively hypothetical adverse movement foreign currency exchange rate compare dollar relative exchange rate december resulted reduction fair value contract approximately million date realize negatively affect earning remain life contract hypothetical adverse movement foreign currency exchange rate compare dollar relative exchange rate december resulted reduction fair value contract approximately million date realize negatively affect earning remain life contract analysis consider impact hypothetical change foreign currency exchange rate anticipated transaction foreign currency sensitive instrument design offset interest rate risk portfolio availableforsale marketable security fix variable rate liability create exposure interest rate risk respect investment portfolio adhere investment policy require limit amount invest security base credit rating maturity industry group investment type issuer security issue government goal investment policy order priority follow safety preservation principal diversification risk liquidity investment sufficient meet cash flow requirement competitive aftertax rate return follow table summarize expect maturity average interest rate interestgenerate asset fix interestbeare liability december dollar thousand expect maturity total fair value total december asset available forsale debt security average interest rate liability longterm debt average interest rate december issue senior unsecured note december register offering note pay interest fix annual rate range march issue senior unsecured note april register offering note pay interest fix annual rate july issue convertible senior note private placement pursuant rule securities act amend note issued par bear interest rate respectively convert share common stock subject certain circumstance april issue convertible senior note private placement pursuant rule securities act amend note issue par bear interest rate convert share common stock subject certain circumstance quarter connection acquisition pharmasset enter credit agreement subject variable interest rate portion interest expense relate variable interest total million credit risk subject credit risk portfolio cash equivalent marketable security investment policy limit amount invest security credit rating maturity industry group investment type issuer security issue government expose significant concentration credit risk financial instrument goal investment policy order priority follow safety preservation principal diversification risk liquidity investment sufficient meet cash flow requirement competitive aftertax rate return subject credit risk account receivable relate product sale majority trade account receivable arise product sale united states europe second quarter receive payment million past account receivable customer base spain include proceed onetime factoring arrangement sell receivables carry value million net allowance doubtful account receive proceed million record gain million result primarily reversal relate allowance doubtful account gain record offset sga expense consolidate statement income subsequent transaction continue involvement transfer receivables derecognize time sale december account receivable southern europe specifically greece italy portugal spain total approximately million million past great day million past great day december account receivable southern europe specifically greece italy portugal spain total approximately billion million past great day million past great day date experience significant loss respect collection account receivable believe allowance doubtful account adequate december item financial statement supplementary datum financial statement require item set forth begin annual report incorporate reference item change disagreement accountant account financial disclosure applicable item control procedure evaluation disclosure control procedure evaluation december carry supervision participation management include chief executive officer chief financial officer effectiveness disclosure control procedure define rule securities exchange act amended exchange act control procedure company design ensure information require disclose company report file submit exchange act record process summarize report time period specify securities exchange commission rule form information accumulate communicate company management include chief executive officer chief financial officer appropriate allow timely decision require disclosure base evaluation chief executive officer chief financial officer conclude disclosure control procedure effective december management report internal control financial reporting management responsible establish maintain adequate internal control financial reporting term define rule exchange act internal control system design provide reasonable assurance preparation fair presentation financial statement external purpose accordance generally accept accounting principle internal control system matter design inherent limitation provide reasonable assurance objective internal control system meet supervision participation management include chief executive officer chief financial officer conduct evaluation effectiveness internal control financial reporting base criterion establish internal controlintegrate framework issue committee sponsor organization treadway commission coso base evaluation conclude internal control financial reporting effective december independent register public accounting firm ernst young llp audit consolidated financial statement include annual report issue report internal control financial reporting december report audit internal control financial reporting appear change internal control financial reporting management include chief executive officer chief financial officer evaluate change internal control financial reporting occur quarter end december conclude change quarter materially affect reasonably likely materially affect internal control financial reporting report independent register public accounting firm board director stockholder gilead sciences inc audit gilead sciences inc internal control financial reporting december base criterion establish internal control integrate framework issue committee sponsor organization treadway commission coso criterion gilead sciences inc management responsible maintain effective internal control financial reporting assessment effectiveness internal control financial reporting include accompany management report internal control financial reporting responsibility express opinion company internal control financial reporting base audit conduct audit accordance standard public company accounting oversight board united states standard require plan perform audit obtain reasonable assurance effective internal control financial reporting maintain material respect audit include obtain understand internal control financial reporting assess risk material weakness exist test evaluate design operating effectiveness internal control base assess risk perform procedure consider necessary circumstance believe audit provide reasonable basis opinion company internal control financial reporting process design provide reasonable assurance reliability financial reporting preparation financial statement external purpose accordance generally accept accounting principle company internal control financial reporting include policy procedure pertain maintenance record reasonable detail accurately fairly reflect transaction disposition asset company provide reasonable assurance transaction record necessary permit preparation financial statement accordance generally accept accounting principle receipt expenditure company accordance authorization management director company provide reasonable assurance prevention timely detection unauthorized acquisition use disposition company asset material effect financial statement inherent limitation internal control financial reporting prevent detect misstatement projection evaluation effectiveness future period subject risk control inadequate change condition degree compliance policy procedure deteriorate opinion gilead sciences inc maintain material respect effective internal control financial reporting december base coso criterion audit accordance standard public company accounting oversight board united states consolidated financial statement gilead sciences inc report date february express unqualified opinion thereon ernst young llp redwood city california february item information applicable iii item director executive officer corporate governance information require item concern director executive officer incorporate reference section definitive proxy statement file securities exchange commission pursuant regulation connection annual meeting stockholder proxy statement heading nominee director stand reelection board committee meeting executive officer section beneficial ownership reporting compliance write code ethic apply director employee include executive officer include limitation principal executive officer principal financial officer principal accounting officer controller person perform similar function code ethic available website httpwwwgileadcom investor section corporate governance change waiver code ethic disclose website intend satisfy disclosure requirement item form amendment waiver provision code ethic disclose information website item executive compensation information require item incorporate reference section proxy statement heading executive compensation compensation committee interlock insider participation compensation committee report compensation nonemployee board member item security ownership certain beneficial owner management relate stockholder matter information require item incorporate reference section proxy statement heading security ownership certain beneficial owner management security authorize issuance equity compensation plan item certain relationship relate transaction director independence information require item incorporate reference section proxy statement heading nominee director stand reelection certain relationship relate party transaction item principal accountant fee service information require item incorporate reference section proxy statement head principal accountant fee service item exhibit financial statement schedule follow document file annual report index list consolidate financial statement report independent register public accounting firm audit consolidated financial statement consolidate balance sheet consolidate statement income consolidate statement comprehensive income consolidate statement stockholder equity consolidate statement cash flow note consolidated financial statement schedule include report schedule omit require require information include financial statement note thereto exhibit follow exhibit file herewith incorporate reference item exhibit exhibit footnote exhibit number description document agreement plan merger registrant apex merger sub inc therapeutics inc date march agreement plan merger registrant merger sub pharmasset inc date november restate certificate incorporation registrant amend amend restate bylaw registrant amend restate reference exhibit exhibit indenture relate convertible senior note note registrant wells fargo bank national association trustee include form convertible senior note date april indenture relate convertible senior note note registrant wells fargo bank national association trustee include form convertible senior note date july indenture relate convertible senior note note registrant wells fargo bank national association trustee include form convertible senior note date july indenture relate senior note date march registrant wells fargo national association trustee supplemental indenture relate senior note date march registrant wells fargo national association trustee include form senior note second supplemental indenture relate senior note date december registrant wells fargo national association trustee include form note form note form note form note confirmation otc convertible note hedge relate note date april amend restate april registrant bank america confirmation otc warrant transaction date april amend restate april registrant bank america warrants expire confirmation otc convertible note hedge relate note date july registrant goldman sachs confirmation otc convertible note hedge relate note date july registrant jpmorgan chase bank national association confirmation otc convertible note hedge relate note date july registrant goldman sachs confirmation otc convertible note hedge relate note date july registrant jpmorgan chase bank national association confirmation otc warrant transaction date july registrant goldman sach warrant expire confirmation otc warrant transaction date july registrant jpmorgan chase bank national association warrants expire confirmation otc warrant transaction date july registrant goldman sach warrant expire confirmation otc warrant transaction date july registrant jpmorgan chase bank national association warrants expire confirmation otc additional convertible note hedge relate note date august registrant goldman sachs confirmation otc additional convertible note hedge relate note date august registrant jpmorgan chase bank national association confirmation otc additional convertible note hedge relate note date august registrant goldman sachs confirmation otc additional convertible note hedge relate note date august registrant jpmorgan chase bank national association confirmation otc additional warrant transaction date august registrant goldman sach warrant expire confirmation otc additional warrant transaction date august registrant jpmorgan chase bank national association warrants expire confirmation otc additional warrant transaction date august registrant goldman sach warrant expire confirmation otc additional warrant transaction date august registrant jpmorgan chase bank national association warrants expiring amendment confirmation otc convertible note hedge relate note date august registrant goldman sachs amendment confirmation otc convertible note hedge relate note date august registrant jpmorgan chase bank national association amendment confirmation otc convertible note hedge relate note date august registrant goldman sachs amendment confirmation otc convertible note hedge relate note date august registrant jpmorgan chase bank national association amendment confirmation otc additional convertible note hedge relate note date august registrant goldman sachs amendment confirmation otc additional convertible note hedge relate note date august registrant jpmorgan chase bank national association amendment confirmation otc additional convertible note hedge relate note date august registrant goldman sachs amendment confirmation otc additional convertible note hedge relate note date august registrant jpmorgan chase bank national association year revolve credit facility credit agreement registrant gilead biopharmaceutics ireland corporation borrowers bank america administrative agent swing line lender issuer certain lender party thereto barclays capital syndication agent goldman sachs bank usa jpmorgan chase bank royal bank canada wells fargo bank codocumentation agent date january parent guaranty agreement year revolve credit facility date january registrant gilead sciences inc stock option plan amend january form option agreement stock option plan gilead sciences inc nonemployee director stock option plan amend january form option agreement gilead sciences inc nonemployee director stock option plan gilead sciences inc equity incentive plan amend form employee stock option agreement equity incentive plan grant prior february form employee stock option agreement equity incentive plan grant february april form employee stock option agreement equity incentive plan grant commencing form employee stock option agreement equity incentive plan grant commence february form employee stock option agreement equity incentive plan subsequent year grant form nonemployee director stock option agreement equity incentive plan grant prior form nonemployee director option agreement equity incentive plan initial grant form nonemployee director option agreement equity incentive plan annual grant form nonemployee director option agreement equity incentive plan annual grant commencing form restrict stock unit issuance agreement equity incentive plan annual grant nonemployee director commence form restrict stock award agreement equity incentive plan annual grant certain nonemployee director prior form performance share award agreement equity incentive plan grant certain executive officer form performance share award agreement equity incentive plan grant certain executive officer form performance share award agreement equity incentive plan grant certain executive officer form performance share award agreement equity incentive plan grant certain executive officer form restrict stock unit issuance agreement equity incentive plan grant certain executive officer prior form restrict stock unit issuance agreement equity incentive plan grant certain executive officer commence form restrict stock unit issuance agreement equity incentive plan servicebase vest certain executive officer commence november form restrict stock unit issuance agreement equity incentive plan servicebase vest certain executive officer commence gilead sciences inc employee stock purchase plan amend restate november gilead sciences inc international employee stock purchase plan adopt november gilead sciences inc defer compensation planbasic plan document gilead sciences inc defer compensation planadoption agreement addendum gilead sciences inc defer compensation plan gilead sciences inc defer compensation plan amend restate october gilead sciences inc severance plan amend january gilead sciences inc corporate bonus plan amend restate gilead sciences inc code section bonus plan base salary name executive officer offer letter date april registrant robin washington form indemnity agreement enter registrant director executive officer form employee proprietary information invention agreement enter registrant certain officer key employee form employee proprietary information invention agreement enter registrant certain officer key employee revise september amend restate collaboration agreement registrant gilead holding llc bristolmyers squibb company squibb son llc bristolmyers squibb gilead sciences llc date september commercialization agreement gilead sciences limited bristolmyers squibb company date december amendment agreement date october registrant institute organic chemistry biochemistry iocb rega stichting vzw rega follow exhibit license agreement date december registrant iocb rega license agreement license agreement date october registrant iocb rega october license agreement license agreement date december registrant iocb rega december license agreement amendment agreement registrant iocbrega date december amend license agreement december license agreement sixth amendment agreement license agreement iocbrega registrant date august amend october license agreement december license agreement development license agreement registrant hoffmannla roche ltd hoffmannla roche inc date september amendment supplement date november development licensing agreement registrant hoffmannla roche ltd hoffmanla roche inc date september second amendment date december development licensing agreement registrant hoffmannla roche ltd hoffmanla roche inc date september amendment date october development licensing agreement registrant hoffmannla roche ltd hoffmanla roche inc date september exclusive license agreement registrant successor triangle pharmaceuticals inc glaxo group limited wellcome foundation limited glaxo wellcome inc emory university date royalty sale agreement registrant emory university investor trust custodial service ireland limit solely capacity trustee royalty pharma date july amend restate license agreement registrant emory university investor trust custodial service ireland limit solely capacity trustee royalty pharma date july license agreement japan tobacco inc registrant date march amendment license agreement japan tobacco inc registrant date second amendment license agreement japan tobacco inc registrant date amendment license agreement japan tobacco inc registrant date july fourth amendment license agreement japan tobacco inc registrant date july license agreement registrant successor myogen inc abbott deutschland holding gmbh date october license agreement registrant successor therapeutics inc roche palo alto llc successor interest merger syntex usa inc date march amendment license agreement registrant successor therapeutics inc roche palo alto llc successor interest merger syntex usa inc date july amendment license agreement registrant successor therapeutics inc roche palo alto llc successor interest merger syntex usa inc date november amendment license agreement registrant successor therapeutics inc roche palo alto llc successor interest merger syntex usa inc date june amendment license agreement registrant successor therapeutics inc roche palo alto llc successor interest merger syntex usa inc date december license collaboration agreement registrant gilead sciences limited janssen ireland tibotec pharmaceutical date july second amendment license collaboration agreement registrant gilead sciences limited janssen ireland tibotec pharmaceutical date july master clinical commercial supply agreement gilead world market limited registrant patheon inc date january tenofovir disoproxil fumarate manufacturing supply agreement gilead sciences limited pharmachem technologies grand bahama ltd date july addendum tenofovir disoproxil fumarate manufacturing supply agreement gilead sciences limited pharmachem technologies grand bahama ltd date addendum tenofovir disoproxil fumarate manufacturing supply agreement gilead sciences limited pharmachem technologies grand bahama ltd date december addendum tenofovir disoproxil fumarate manufacturing supply agreement gilead sciences limited pharmachem technologies grand bahama ltd date february tenofovir disoproxil fumarate manufacturing supply agreement gilead sciences limited ampac fine chemical llc date november restate amend toll manufacturing agreement gilead sciences limited registrant nycome gmbh altana pharma oranienburg gmbh date november emtricitabine manufacturing supply agreement gilead sciences limit evonik degussa gmbh know degussa date june amendment emtricitabine manufacture supply agreement gilead sciences limit evonik degussa gmbh know degussa date april purchase sale agreement joint escrow instruction electronics imaging inc registrant date july amendment date october purchase sale agreement joint escrow instruction electronics imaging inc registrant date july subsidiary registrant consent independent register public accounting firm power attorney reference signature certification chief executive officer require rule rule securities exchange act amend certification chief financial officer require rule rule securities exchange act amend certification chief executive officer chief financial officer require rule rule section chapter title united states code usc follow material registrant annual report year end december format extensible business report language xbrl include consolidated balance sheet december consolidated statement income year end december iii consolidated statement comprehensive income year end december consolidate statement stockholder equity year end december consolidate statement cash flow year end december note consolidated financial statement file exhibit registrant current report form file march incorporate reference file exhibit registrant current report form file november incorporate reference file exhibit registrant current report form file incorporate reference file exhibit registrant current report form file april incorporate reference file exhibit registrant current report form file august incorporate reference file exhibit registrant current report form file april incorporate reference file exhibit registrant current report form file december incorporate reference file exhibit registrant quarterly report form quarter end june incorporate reference file exhibit registrant quarterly report form quarter end june incorporate reference file exhibit registrant quarterly report form quarter end september incorporate reference file exhibit registrant current report form file january incorporate reference file exhibit registrant registration statement form file january incorporate reference file exhibit registrant registration statement form amend incorporate reference file exhibit registrant annual report fiscal year end december incorporate reference file exhibit registrant current report form file incorporate reference file exhibit registrant current report form file february incorporate reference file exhibit registrant annual report fiscal year end december incorporate reference file exhibit registrant quarterly report form quarter end june incorporate reference file exhibit registrant annual report fiscal year end december incorporate reference file exhibit registrant quarterly report form quarter end march incorporate reference file exhibit registrant quarterly report form quarter end june incorporate reference file exhibit registrant quarterly report form quarter end march incorporate reference file exhibit registrant current report form file december incorporate reference file exhibit registrant quarterly report form quarter end march incorporate reference file exhibit registrant registration statement form file december incorporate reference file exhibit registrant annual report fiscal year end december incorporate reference file exhibit registrant annual report fiscal year end december incorporate reference information include registrant current report form file february incorporate reference file exhibit registrant quarterly report form quarter end june incorporate reference file exhibit registrant quarterly report form quarter end september incorporate reference file exhibit registrant annual report fiscal year end march incorporate reference file exhibit registrant annual report fiscal year end december incorporate reference file exhibit registrant annual report fiscal year end december incorporate reference file exhibit registrant annual report fiscal year end december incorporate reference file exhibit triangle pharmaceuticals inc quarterly report form file november incorporate reference file exhibit registrant quarterly report form quarter end september incorporate reference file exhibit registrant quarterly report form quarter end march incorporate reference file exhibit registrant quarterly report form quarter end september incorporate reference file exhibit myogen inc registration statement form amend originally file august incorporate reference file exhibit therapeutics inc registration statement form amend originally file april incorporate reference file exhibit therapeutics inc quarterly report form quarter end june incorporate reference file exhibit registrant quarterly report form quarter end september incorporate reference file exhibit registrant annual report fiscal year end december incorporate reference file exhibit registrant current report form file august incorporate reference file exhibit registrant annual report fiscal year end december incorporate reference file exhibit registrant quarterly report form quarter end september incorporate reference agreement plan merger merger agreement contain representation warranty registrant apex merger sub inc therapeutics inc solely specific date representation warranty solely purpose merger agreement subject important qualification limitation agree registrant apex merger sub inc therapeutics inc representation warranty accurate complete specify date subject standard materiality provide merger agreement purpose allocate risk registrant apex merger sub inc therapeutics inc establish matter fact agreement plan merger pharmasset merger agreement contain representation warranty registrant merger sub pharmasset inc solely specific date representation warranty solely purpose pharmasset merger agreement subject important qualification limitation agree registrant merger sub pharmasset inc representation warranty accurate complete specify date subject standard materiality provide pharmasset merger agreement purpose allocate risk registrant merger sub pharmasset inc establish matter fact management contract compensatory plan arrangement certification accompanie relate deem file security exchange commission incorporate reference file registrant security act amend securities exchange act amend date irrespective general incorporation language contain filing xbrl information file herewith certain confidential portion exhibit omit mean mark portion asterisk mark exhibit file separately secretary sec mark pursuant registrant application request confidential treatment rule securities exchange act amend gilead sciences inc consolidated financial statement year end december content report independent register public accounting firm audit consolidated financial statement consolidate balance sheet consolidate statement income consolidate statement comprehensive income consolidate statement stockholder equity consolidate statement cash flow note consolidated financial statement report independent register public accounting firm board director stockholder gilead sciences inc audit accompany consolidated balance sheet gilead sciences inc december relate consolidated statement income comprehensive income stockholder equity cash flow year period end december audits include financial statement schedule list index item financial statement schedule responsibility company management responsibility express opinion financial statement schedule base audit conduct audits accordance standard public company accounting oversight board united states standard require plan perform audit obtain reasonable assurance financial statement free material misstatement audit include examine test basis evidence support amount disclosure financial statement audit include assess accounting principle significant estimate management evaluate overall financial statement presentation believe audits provide reasonable basis opinion opinion financial statement refer present fairly material respect consolidate financial position gilead sciences inc december consolidate result operation cash flow year period end december conformity generally accept accounting principle opinion relate financial statement schedule consider relation basic financial statement take present fairly material respect information set forth audit accordance standard public company accounting oversight board united states gilead sciences inc internal control financial reporting december base criterion establish internal controlintegrate framework issue committee sponsor organization treadway commission report date february express unqualified opinion thereon ernst young llp redwood city california february gilead sciences inc consolidated balance sheet thousand share amount december asset current asset cash cash equivalent shortterm marketable security account receivable net allowance december respectively inventory defer tax asset prepay taxis prepaid expense current asset total current asset property plant equipment net longterm portion prepay royalty longterm defer tax asset longterm marketable security intangible asset net goodwill longterm asset total asset liability stockholder equity current liability account payable accrue government rebate accrue compensation employee benefit income taxis payable accrue liability defer revenue current portion longterm debt obligation net total current liability longterm defer revenue longterm debt net longterm income taxis payable longterm obligation commitment contingency note stockholder equity prefer stock par value share share authorize outstanding common stock par value share share authorize share issue outstanding december respectively additional paidin capital accumulate comprehensive income loss retain earning total gilead stockholder equity noncontrolle interest total stockholder equity total liability stockholder equity number share period present reflect twoforone stock split form stock dividend declare december take effect january accompany note gilead sciences inc consolidated statement income thousand share amount year end december revenue product sale royalty revenue contract revenue total revenue cost expense cost good sell research development expense sell general administrative expense total cost expense income operation interest expense income expense net income provision income taxis provision income taxis net income net loss attributable noncontrolle interest net income attributable gilead net income share attributable gilead common stockholdersbasic share share calculationbasic net income share attributable gilead common stockholdersdilute share share calculationdilute net income share number share share calculation period present reflect twoforone stock split form stock dividend declare december take effect january accompany note gilead sciences inc consolidated statement comprehensive income thousand year end december net income comprehensive income loss net foreign currency translation gain loss availableforsale security net unrealize gain loss net tax impact year end december respectively reclassification net income net tax impact year end december respectively net change cash flow hedge net unrealized gain loss net tax impact year end december respectively reclassification net income net tax impact year end december respectively net change comprehensive income loss comprehensive income comprehensive loss attributable noncontrolle interest comprehensive income attributable gilead accompany note gilead sciences inc consolidated statement stockholder equity thousand gilead stockholder equity common stock accumulate additional total paidin comprehensive retain noncontrolle stockholder share capital income loss earning interest equity balance december contribution noncontrolle interest net income loss comprehensive income net tax issuance employee stock purchase plan stock option exercise net tax benefit employee stock plan stockbase compensation purchase convertible note hedge sale warrant defer tax asset convertible note hedge equity portion convertible note net issuance cost repurchase common stock balance december distribution noncontrolle interest net income loss comprehensive income net tax issuance employee stock purchase plan stock option exercise net tax benefit employee stock plan stockbase compensation repurchase common stock balance december contribution noncontrolle interest net income loss comprehensive loss net tax issuance employee stock purchase plan stock option exercise net tax benefit employee stock plan stockbase compensation repurchase common stock balance december common stock share period present reflect twoforone stock split form stock dividend declare december take effect january accompany note gilead sciences inc consolidated statement cash flow thousands year end december operating activity net income adjustment reconcile net income net cash provide operating activity depreciation expense amortization expense stockbase compensation expense inprocess research development impairment charge excess tax benefit stockbase compensation tax benefit employee stock plan defer income taxis change operate asset liability account receivable net inventory prepaid expense asset account payable income taxis payable accrue liability defer revenue net cash provide operating activity invest activity purchase marketable security proceed sale marketable security proceed maturitie marketable security purchase investment acquisition net cash acquire capital expenditure net cash provide investing activity financing activity proceed debt finance net issuance cost proceed convertible note hedge proceed sale warrant proceed issuance common stock purchase convertible note hedge repurchase common stock repayment debt financing repayment longterm obligation excess tax benefit stockbase compensation contribution distribution noncontrolle interest net cash provide financing activity effect exchange rate change cash net change cash cash equivalent cash cash equivalent begin period cash cash equivalent end period supplemental disclosure cash flow information interest pay net amount capitalize income taxis pay accompany note gilead sciences inc note consolidated financial statement organization summary significant accounting policy overview gilead sciences inc gilead incorporate delaware june researchbase biopharmaceutical company discover develop commercialize innovative medicine area unmet medical need new discovery experimental drug candidate seek improve care patient suffer lifethreatening disease world gilead primary area focus include human immunodeficiency virus hiv liver disease hepatitis virus hbv hepatitis virus hcv cardiovascular respiratory condition oncologyinflammation continue add exist portfolio product internal discovery clinical development program product acquisition inlicense strategy product portfolio comprise atripla truvada viread compleraeviplera stribild hepsera emtriva letairis ranexa ambisome cayston vistide international commercial sale operation marketing subsidiary north america europe asia addition sell distribute certain product corporate partner royaltypaye collaborative agreement basis presentation accompany consolidated financial statement include account gilead whollyowne subsidiary joint ventures bristolmyers squibb company bms primary beneficiary record noncontrolle interest consolidated financial statement reflect bms interest joint venture intercompany transaction eliminate consolidated financial statement include result company acquire date acquisition applicable reporting period january complete twoforone stock split form stock dividend stockholders record january declare december accordingly share share amount period present consolidated financial statement note adjust retroactively reflect stock split additionally certain prior period amount consolidated financial statement relate note reclassify conform current presentation significant accounting policy estimate judgment preparation consolidated financial statement require estimate judgment affect report amount asset liability revenue expense related disclosure ongoing basis management evaluate significant accounting policy estimate base estimate historical experience market specific relevant assumption believe reasonable circumstance result form basis make judgment carry value asset liability readily apparent source actual result differ significantly estimate revenue recognition product sale recognize revenue product sale persuasive evidence arrangement exist delivery customer occur price fix determinable collectability reasonably assure recognition revenue product sale provision government rebate medicaid reimbursement customer incentive cash discount prompt payment distributor fee expect return expire product appropriate item deduct gross product sale government rebate estimate reduction revenue governmentmanage medicaid program certain qualify federal state foreign government program base contractual term historical utilization rate new information change program regulation guideline impact actual rebate expectation future utilization rate program product sale channel inventory datum obtain major wholesaler accordance inventory management agreement government rebate invoice directly record accrue government rebate consolidated balance sheet qualified program purchase product wholesaler low contractual government price wholesaler charge difference acquisition cost low contractual government price record allowance account receivable cash discount estimate cash discount base contractual term historical utilization rate expectation future utilization rate distributor fee inventory management agreement significant wholesaler pay wholesaler fee primarily compliance certain contractually determine covenant maintenance agree inventory level distributor fee base contractually determine fix percentage sale product return provide customer general right product return permit return product damage defective receive customer case product sell united states certain country outside united states product expire accept return product expire month expire year expiration date estimate expect return expire product base primarily ongoing analysis historical return pattern royalty revenues royalty revenue sale product generally recognize receive generally quarter follow quarter correspond sale occur royalty revenue sale lexiscan ambisome astella llc astella pharma inc respectively recognize month follow month correspond sale occur contract revenue revenue nonrefundable upfront license fee milestone payment development collaboration obligation supply product recognize performance occur obligation complete accordance specific term obligation arrangement revenue recognize obligation fulfil ratably development manufacturing period revenue associate substantive atrisk milestone recognize base achievement milestone set forth respective agreement advance payment receive excess amount earn classified defer revenue consolidated balance sheet shipping handle cost shipping handling cost incur inventory purchase product shipment record cost good sell consolidated statement income research development expense expense consist primarily personnel cost include salary benefit stockbase compensation clinical study perform contract research organization cro material supply license fee milestone payment collaboration arrangement overhead allocation consist support facilitiesrelate cost charge cost include clinical study cost expense incur clinical study cost significant component expense clinical study perform thirdparty cro monitor level performance significant contract include extent patient enrollment activity communication cro accrue cost clinical study perform cro service period specify contract adjust estimate require base ongoing review level effort cost actually incur cro material cro contract terminable write notice generally liable actual service complete cro certain noncancelable expense incur point termination amount pay advance relate uncompleted service refund contract terminate advertising expense expense cost advertising include promotional expense incur advertising expense million million million net income share attributable gilead common stockholder follow table reconciliation numerator denominator calculation basic diluted net income share attributable gilead common stockholder thousand year end december numerator net income attributable gilead denominator weightedaverage share common stock outstanding calculation basic net income share attributable gilead common stockholder effect dilutive security stock option equivalent conversion spread relate note conversion spread relate note conversion spread relate note conversion spread relate note warrant relate convertible note weightedaverage share common stock outstanding calculation dilute net income share attributable gilead common stockholder basic net income share attributable gilead common stockholder calculate base weightedaverage number share common stock outstanding period dilute net income share attributable gilead common stockholder calculate base weightedaverage number share common stock outstanding dilutive security outstanding period potential dilutive share common stock result assume exercise outstanding stock option performance share assume exercise warrant relate convertible senior note note note note collectively convertible note determine treasury stock method principal convertible note settle cash conversion spread relate convertible note include calculation dilute net income share attributable gilead common stockholder common stock result assume settlement conversion spread convertible note dilutive effect average market price common stock period exceed conversion price note note note respectively convertible senior note note mature relate warrant expire result consider impact period outstanding net income share calculation common stock result assume settlement conversion spread note dilutive effect average market price common stock period exceed conversion price average market price common stock exceed conversion price note dilutive effect include accompany table warrant relate note dilutive effect average market price common stock period exceed warrant exercise price average market price common stock exceed exercise price warrant relate note warrant dilutive effect net income share period average market price common stock exceed conversion price note dilutive effect include accompany table portion note convert result consider impact period outstanding average market price common stock exceed conversion price note note dilutive effect include accompany table average market price common stock exceed conversion price note note note dilutive effect net income share period warrant relate note note note dilutive effect average market price common stock period exceed warrant exercise price respectively average market price common stock exceed warrant exercise price relating note dilutive effect include accompany table average market price common stock exceed warrant exercise price relate note note warrant dilutive effect net income share period average market price common stock exceed warrant exercise price relate convertible note warrant dilutive effect net income share period stock option purchase approximately million million million weightedaverage share common stock outstanding respectively include computation dilute net income share attributable gilead common stockholder effect antidilutive stockbase compensation sharebase payment employee director recognize consolidated statement income base fair value benefit tax deduction excess recognize compensation cost report consolidated statement cash flow financing activity calculate pool excess tax benefit record additional paidin capital apic cash cash equivalent consider highly liquid investment insignificant interest rate risk original maturity month purchase date cash equivalent eligible instrument investment policy include cash equivalent include commercial paper money market fund overnight repurchase agreement repos major bank authorize dealer bank obligation marketable nonmarketable security determine appropriate classification marketable security consist primarily debt security variable rate demand obligation time purchase reevaluate designation balance sheet date marketable security consider availableforsale carry estimate fair value report cash equivalent shortterm marketable security longterm marketable security unrealize gain loss availableforsale security exclude net income report accumulate comprehensive income loss separate component stockholder equity income expense net include interest dividend amortization purchase premium discount realize gain loss sale security otherthantemporary decline fair value security cost security sell base specific identification method regularly review investment otherthantemporary decline fair value review include consideration cause impairment include creditworthiness security issuer number security unrealize loss position severity duration unrealize loss intent sell security likely require sell security recovery amortize cost basis determine decline fair value investment accounting basis decline otherthantemporary reduce carry value security hold record loss decline result enter collaboration time time hold investment nonpublic company record nonmarketable security cost longterm asset amount otherthantemporary impairment regularly review security indicator impairment investment nonmarketable security material period present concentration risk subject credit risk portfolio cash equivalent marketable security investment policy limit amount invest security credit rating maturity industry group investment type issuer security issue government expose significant concentration credit risk financial instrument goal investment policy order priority follow safety preservation principal diversification risk liquidity investment sufficient meet cash flow requirement competitive aftertax rate return subject credit risk account receivable relate product sale majority trade account receivable arise product sale united states europe receive payment million past account receivable customer base spain include proceed onetime factoring arrangement sell receivables carry value million net allowance doubtful account receive proceed million record gain million result primarily reversal relate allowance doubtful account gain record offset sell general administrative sga expense consolidate statement income subsequent transaction continue involvement transfer receivables derecognize time sale december account receivable southern europe specifically greece italy portugal spain total approximately million million great day past million great day past date experience significant loss respect collection account receivable believe allowance doubtful account adequate december certain raw material component utilize operation obtain single supplier certain raw material utilize operation facility supplier key component raw material name new drug application nda file food drug administration fda product significant delay occur qualification new supplier require delivery material supplier interrupt reason unable ship commercial product supply product candidate clinical trial account receivable trade account receivable record net allowance wholesaler chargeback relate government rebate program cash discount prompt payment sale return doubtful account estimate wholesaler chargeback government rebate cash discount sale return base contractual term historical trend expectation utilization rate program estimate allowance doubtful account determine base exist contractual payment term historical payment pattern customer individual customer circumstance analysis day sale outstanding geographic region review local economic environment potential impact government funding reimbursement practice historically amount uncollectible account receivable write insignificant consistent management expectation inventory inventory record low cost market cost determine firstin firstout basis periodically review composition inventory order identify obsolete slowmoving unsaleable item unsaleable item observe alternate use inventory record writedown net realizable value period impairment recognize future commercialization consider probable future economic benefit expect realize base management judgment capitalize prelaunch inventory cost prior regulatory approval number factor take consideration include current status regulatory approval process potential impediment approval process safety efficacy anticipate research development initiative impact indication compound viability commercialization marketplace trend december prelaunch inventory consolidate balance sheet significant property plant equipment property plant equipment state cost accumulate depreciation amortization depreciation amortization recognize straight line method repair maintenance cost expense incur estimate useful life year follow description estimate useful life building improvement laboratory manufacturing equipment office computer equipment leasehold improvement short useful life lease term office computer equipment include capitalize software unamortize capitalize software cost million million consolidated balance sheet december respectively leasehold improvement capitalize lease equipment amortize short lease term asset useful life amortization capitalize lease equipment include depreciation expense capitalize interest construction inprogress include property plant equipment interest capitalize significant goodwill intangible asset goodwill represent excess consideration transfer estimate fair value asset acquire liability assume business combination intangible asset indefinite useful life relate purchase inprocess research development iprd project measure respective fair value acquisition date amortize goodwill intangible asset indefinite useful life test goodwill indefinite live intangible asset impairment annual basis annual test aware event change indicate reduction fair value asset carry amount intangible asset relate iprd project consider indefinitelive completion abandonment associate effort period asset consider indefinitelive amortize test impairment annual basis annual test aware event change indicate reduction fair value iprd project respective carrying amount development complete generally occur regulatory approval market product obtain associate asset deem finitelived amortize base respective estimate useful life point time intangible asset finite useful life amortize estimate useful life intangible asset finite useful life review impairment fact circumstance suggest carry value asset recoverable impairment longlive asset carry value longlive asset review regular basis existence fact circumstance internally externally suggest impairment specific potential indicator impairment include significant decrease fair value asset significant change extent manner asset significant physical change asset significant adverse change legal factor business climate affect value asset adverse action assessment fda regulator accumulation cost significantly excess originally expect acquire construct asset operate cash flow loss combine history operate cash flow loss projection forecast demonstrate continue loss associate income produce asset indication impairment test recoverability compare estimate undiscounted future cash flow expect result use asset asset group eventual disposition carry asset asset group excess carrying value asset asset group estimate fair value recognize impairment loss valuation contingent consideration result business combination connection certain acquisition require pay future consideration contingent achievement specify development regulatory approval salesbase milestone event record contingent consideration result business combination fair value acquisition date quarter revalue obligation record increase decrease fair value expense consolidated statement income time relate product candidate receive marketing approval increase decrease fair value contingent consideration liability result update assumption expect timing probability achieve specify milestone change project revenue change discount rate significant judgment employ determine assumption acquisition date subsequent period update assumption significant impact result operation give period actual result differ estimate foreign currency translation transaction contract operation nonus entity record functional currency entity financial reporting purpose functional currency entity currency environment entity primarily generate expend cash result operation nonus dollar functional currency entity translate functional currency dollar average currency rate month approximate result obtain actual currency rate date individual transaction asset liability translate currency rate end period adjustment result translate financial statement foreign entity dollar exclude determination net income record component comprehensive income loss separate component stockholder equity transaction gain loss record income expense net consolidated statement income net transaction loss total million million million respectively hedge portion foreign currency exposure related outstanding monetary asset liability forecast product sale foreign currency exchange forward option contract general market risk relate contract offset correspond gain loss hedge transaction credit risk associate contract drive change interest currency exchange rate result vary time work major bank closely monitor current market condition limit risk counterpartie contract unable perform limit risk loss enter contract permit net settlement maturity overall risk loss event counterparty default limit unrecognized gain outstanding contract contract positive fair value date default enter derivative contract trading purpose hedge net investment foreign subsidiary fair value financial instrument financial instrument consist principally cash cash equivalent marketable security account receivable foreign currency exchange forward option contract account payable shortterm longterm debt cash cash equivalent marketable security foreign currency exchange contract hedge account receivable forecast sale report respective fair value consolidate balance sheet carry value fair value convertible note billion billion respectively december carry value fair value convertible note billion billion respectively december issue senior unsecured note april april note register offering aggregate principal billion carrying value fair value april note million billion respectively december carry value fair value april note million billion respectively december issue senior unsecured note december december note december december note december december note december december note aggregate principal billion carrying value fair value note billion billion respectively december carry value fair value note billion billion respectively december fair value convertible note senior unsecured note determine level input base quote market value remain financial instrument report consolidated balance sheet amount approximate current fair value income taxis income tax provision compute liability method defer tax asset liability determine base difference financial statement tax basis asset liability enact tax rate effect year difference expect reverse significant estimate require determine provision income taxis estimate base interpretation exist tax law regulation factor favorable unfavorable effect income tax rate factor include limited interpretation exist tax law change tax law rate portion nontax deductible pharmaceutical excise tax accounting stock option sharebase payment merger acquisition future level spending change accounting standard change mix earning tax jurisdiction operate change overall level pretax earning resolution federal state foreign income tax audits impact income tax provision result mention factor significant negative impact consolidate net income record liability relate uncertain tax position accordance guidance clarifie accounting uncertainty income taxis recognize enterprise financial statement prescribe minimum recognition threshold measurement attribute financial statement recognition measurement tax position take expect take tax return believe uncertain tax position currently pende material adverse effect consolidated financial statement adverse resolution uncertain tax position period material impact result operation period recent accounting pronouncement july financial accounting standard board issue new accounting guidance intend simplify testing indefinitelive intangible asset impairment entity allow option perform qualitative assessment impairment indefinitelive intangible asset determine quantitative assessment necessary guidance effective impairment test perform interim annual period fiscal year begin september early adoption permit elect early adopt guidance december material impact consolidate financial statement fair value measurement determine fair value financial nonfinancial asset liability fair value hierarchy establish level input measure fair value follow level input include quote price active market identical asset liability level input include observable input level input quote price similar asset liability quote price identical similar asset liability market active input observable corroborate observable market datum substantially term asset liability marketable security review trading activity pricing measurement date sufficient quote price identical security available use market pricing observable market input similar security obtain thirdparty datum provider input represent quote price similar asset active market derive observable market datum level input include unobservable input support little market activity significant fair value underlie asset liability level asset liability include fair value measurement determine pricing model discount cash flow methodology similar valuation technique significant management judgment estimation follow table summarize asset liability record fair value respective fair value classification level input fair value hierarchy define thousand december december level level level total level level level total asset debt security treasury security money market fund certificate deposit government agency security municipal debt security nonus government security corporate debt security residential mortgage asset back security student loanbacke security total debt security equity security derivative liabilitie contingent consideration derivative level input estimate fair value government relate debt corporate debt residential mortgage assetbacked security take consideration valuation obtain thirdparty pricing service pricing service utilize industry standard valuation model include income marketbase approach significant input observable directly indirectly estimate fair value input include report trade brokerdealer quote similar security issuer credit spread benchmark security prepaymentdefault projection base historical datum observable input substantially foreign currency derivative contract maturity primarily month time horizon counterpartie minimum credit rating equivalent standard poor moody investors service inc fitch inc estimate fair value contract take consideration valuation obtain thirdparty valuation service utilize incomebase industry standard valuation model significant input observable directly indirectly input include foreign currency rate london interbank offer rate libor swap rate input applicable commonly quote interval level input asset measure fair value level input comprise auction rate security greek bond availableforsale investment portfolio policy recognize transfer level classification actual date event change circumstance cause transfer december hold asset measure level input follow table provide rollforward change fair value asset measure level input thousand year end december fair value beginning period total realize unrealized gain loss include income expense net comprehensive income loss net sale marketable security transfer level fair value end period auction rate security underlie asset auction rate security consist student loan auction rate security typically measure level input failure auction lack market activity liquidity experience begin require security measure level input fair value auction rate security determine discount cash flow model consider project cash flow issue trust underlie collateral expect yield project cash flow estimate base underlying loan principal bond outstanding payout formula weightedaverage life cash flow project consider collateral composition security relate historical project prepayment quarter sell remain portfolio auction rate security result sale receive total proceed million result million loss recognize income expense net consolidated statement income december auction rate security record longterm marketable security consolidate balance sheet greek government bond greek government agree settle majority age outstanding account receivable zerocoupon bond expect trade discount face value estimate fair value greek zerocoupon bond level input current lack market activity liquidity discount rate fair value model bond base credit default swap rate march greek government restructure sovereign debt impact holder greek bond result record million loss relate debt restructure income expense net consolidated statement income exchange greek governmentissue bond new security liquidate quarter december greek governmentissue bond record shortterm longterm marketable security consolidate balance sheet contingent consideration liability connection certain acquisition require pay future consideration contingent achievement specify development regulatory approval salesbase milestone event estimate fair value contingent consideration liability acquisition date report period probabilityweighte income approach reflect probability time future payment fair value measurement base significant level input anticipate timeline probability achieve development regulatory approval salesbase milestone event project revenue result probabilityweighte cash flow discount creditrisk adjust interest rate report period revalue obligation perform review assumption list record increase decrease fair value contingent consideration obligation expense consolidated statement income time relate product candidate receive marketing approval absence significant change key assumption quarterly determination fair value contingent consideration obligation primarily reflect passage time significant judgment employ determine level input fair value measurement acquisition date subsequent period update assumption significant impact result operation give period actual result differ estimate example significant increase probability achieve milestone project revenue result significantly high fair value measurement significant decrease estimate probability achieve milestone project revenue result significantly low fair value measurement significant increase discount rate anticipate timeline result significantly low fair value measurement significant decrease discount rate anticipate timeline result significantly high fair value measurement potential contingent consideration payment result development regulatory approval base milestone relate cgi pharmaceuticals inc cgi calistoga pharmaceutical acquisition range payment milestone achieve estimate maximum million undiscounted accrue million december million december potential future payment result acquisition arresto biosciences inc arresto relate royalty obligation future sale specify salesbased milestone achieve follow table provide rollforward contingent consideration liability record longterm obligation consolidate balance sheet thousand year end december balance beginning period addition new acquisition net change valuation balance end period availableforsale security follow table summary availableforsale debt equity security record cash cash equivalent marketable security consolidate balance sheet quarter liquidate portion investment portfolio partially fund acquisition pharmasset inc pharmasset complete january estimate fair value availableforsale security generally base price obtain commercial pricing service thousands december december gross gross gross gross amortize unrealize unrealized estimate amortize unrealize unrealized estimate cost gain loss fair value cost gain loss fair value debt security treasury security money market fund certificate deposit government agency security municipal debt security nonus government security corporate debt security residential mortgage assetbacke security student loan back security total debt security equity security total follow table summarize classification availableforsale debt equity security consolidate balance sheet thousand december december cash cash equivalent shortterm marketable security longterm marketable security total cash cash equivalent table exclude cash million million december respectively follow table summarize portfolio availableforsale debt security contractual maturity thousand december december amortize cost fair value amortize cost fair value year great year year great year year great year total conform current presentation reclassify billion amortize cost fair value balance december great year year contractual maturity follow table summarize gross realize gain loss relate sale marketable security thousand year end december gross realize gain sale gross realize loss sale cost security sell determine base specific identification method follow table summarize availableforsale debt security continuous unrealized loss position deem otherthan temporarily impair thousand month month great total gross gross gross unrealize estimate unrealized estimate unrealized estimate loss fair value loss fair value loss fair value december debt security treasury security government agency security municipal debt security nonus government security corporate debt security certificate deposit residential mortgage asset back security student loanbacke security total december debt security treasury security government agency security municipal debt security nonus government security corporate debt security certificate deposit residential mortgage asset back security student loanbacke security total december hold total security respectively unrealize loss position base review security believe otherthantemporary impairment security december intend sell security likely require sell security recovery amortize cost basis derivative financial instrument operate foreign country expose market risk associate foreign currency exchange rate fluctuation dollar foreign currency significant euro order manage risk hedge portion foreign currency exposure related outstanding monetary asset liability forecast product sale foreign currency exchange forward option contract general market risk relate contract offset correspond gain loss hedge transaction credit risk associate contract drive change interest currency exchange rate result vary time work major bank closely monitor current market condition limit risk counterpartie contract unable perform limit risk loss enter contract permit net settlement maturity overall risk loss event counterparty default limit unrecognized gain outstanding contract contract positive fair value date default enter derivative contract trading purpose hedge net investment foreign subsidiary hedge exposure foreign currency exchange rate fluctuation certain monetary asset liability foreign subsidiary denominate nonfunctional currency derivative instrument use hedge exposure designate hedge result change fair value record income expense net consolidated statement income hedge exposure foreign currency exchange rate fluctuation forecast product sale denominate nonfunctional currency derivative instrument use hedge exposure designate cash flow hedge maturity date month execute hedge contract quarterly assess prospective hedge effectiveness regression analysis calculate change cash flow result hedge instrument monthly basis assess retrospective hedge effectiveness dollar offset approach exclude time value effectiveness testing recognize change time value hedge income expense net effective component hedge record unrealized gain loss hedge instrument accumulate comprehensive income oci stockholder equity hedge forecast transaction occur hedge dedesignate unrealized gain loss reclassify product sale majority gain loss relate hedged forecast transaction report accumulate oci december reclassify product sale month cash flow effect derivative contract year end december include net cash provide operating activity consolidate statement cash flow notional amount foreign currency exchange contract outstanding billion billion december respectively follow table summarize information fair value derivative instrument consolidate balance sheet thousand december asset derivative liability derivative classification fair value classification fair value derivative designate hedge foreign currency exchange contract current asset accrue liability foreign currency exchange contract longterm asset longterm obligation total derivative designate hedge derivative designate hedge foreign currency exchange contract current asset accrue liability total derivative designate hedge total derivative december asset derivative liability derivatives classification fair value classification fair value derivative designate hedge foreign currency exchange contract current asset accrue liability foreign currency exchange contract longterm asset longterm obligation total derivative designate hedge derivative designate hedge foreign currency exchange contract current asset accrue liability total derivative designate hedge total derivative follow table summarize effect foreign currency exchange contract consolidate statement income thousands year end december derivative designate hedge net gain loss recognize oci effective portion net gain loss reclassify accumulated oci product sale effective portion gain loss recognize income expense net ineffective portion amount exclude effectiveness testing derivative designate hedge net gain loss recognize income expense net material amount record income expense net year end december result discontinuance cash flow hedge balance accumulate comprehensive income loss net taxis report consolidated balance sheet consist follow component thousand december net unrealized gain loss availableforsale security net unrealize gain loss cash flow hedge cumulative foreign currency translation adjustment accumulate comprehensive income loss acquisition pharmasset inc january complete acquisition pharmasset publiclyheld clinicalstage pharmaceutical company commit discover develop commercialize novel drug treat viral infection pharmasset primary focus development oral therapeutic treatment hcv infection pharmasset lead compound know sofosbuvir formally refer nucleotide analog january evaluate phase phase clinical study treatment hcv infection genotype believe acquisition pharmasset provide opportunity complement exist hcv portfolio help advance effort develop alloral regimen treatment hcv acquire outstanding share common stock pharmasset share cash tender offer subsequent merger term agreement plan merger enter november aggregate cash payment acquire outstanding share common stock billion finance transaction approximately billion cash hand billion senior unsecured note issue december billion bank debt issue january pharmasset acquisition account business combination result operation pharmasset include consolidated statement income january date acquire approximately outstanding share common stock pharmasset cash consideration transfer result obtain effective control pharmasset acquisition complete january time pharmasset whollyowne subsidiary gilead integrate operation track earning result product candidate therapeutic area maintain separate earning result acquire pharmasset business follow table summarize component cash pay acquire pharmasset thousand total consideration transfer stockbase compensation expense total cash pay billion cash payment consist billion cash payment outstanding common stockholder million cash payment option holder pharmasset stock option plan billion cash payment outstanding common stockholder million cash payment vested option holder pharmasset stock option plan account consideration transfer remain million cash payment account stockbase compensation expense result accelerate vest pharmasset employee option immediately prior acquisition follow table summarize acquisition date fair value asset acquire liability assume consideration transfer thousand identifiable intangible asset cash cash equivalent asset acquire liability assume net total identifiable net asset goodwill total consideration transfer identifiable intangible asset acquire intangible asset primarily comprise sofosbuvir iprd compound estimate fair value billion date acquisition fair value asset determine probabilityweighte income approach discount expect future cash flow present value estimate net cash flow discount discount rate base estimate weightedaverage cost capital company profile similar pharmasset rate comparable estimate internal rate return acquisition represent rate market participant use value intangible asset project cash flow sofosbuvir base key assumption estimate revenue operate profit relate project consider stage development acquisition date time resource need complete development approval product candidate life potential commercialize product associate risk include inherent difficulty uncertaintie develop product candidate obtain marketing approval fda regulatory agency risk related viability potential alternative treatment future target market intangible asset relate iprd project consider indefinitelive asset completion abandonment associate effort goodwill million goodwill represent excess consideration transfer fair value asset acquire liability assume attributable synergy expect combine operation pharmasset goodwill expect deductible income tax purpose stockbase compensation expense stockbase compensation expense recognize accelerate vest employee option immediately prior acquisition report consolidated statement income follow thousands year end december research development expense sell general administrative expense total stockbase compensation expense cost cost incur connection acquisition include thousands year end december transaction cost investment advisory legal accounting fee bridge financing cost restructure cost total cost follow table summarize cost line item consolidate statement income cost recognize thousands year end december research development expense sell general administrative expense interest expense total cost pro forma information follow unaudited pro forma information present combine result operation gilead pharmasset acquisition pharmasset complete january adjustment effect pro forma event directly attributable acquisition unaudite pro forma result reflect operating efficiency potential cost saving result consolidation operation gilead pharmasset accordingly unaudite pro forma result present informational purpose necessarily indicative actual result operation combine company acquisition occur begin period present indicative future result operation thousands year end december total revenue net income attributable gilead unaudited pro forma consolidated result include nonrecurre pro forma adjustment assume acquisition occur january stock base compensation expense million incur include net income attributable gilead year end december cost million incur year end december include net income attributable gilead year end december calistoga pharmaceuticals inc february enter agreement acquire calistoga million plus potential payment million base achievement certain milestone transaction close april time calistoga whollyowne subsidiary calistoga privatelyheld biotechnology company base seattle washington focus development medicine treat cancer inflammatory disease acquisition provide portfolio proprietary compound selectively target isoform phosphoinositide kinase pik lead product candidate idelalisib refer firstinclass specific inhibitor pik delta isoform pik delta preferentially express leukocyte involve variety inflammatory autoimmune disease hematological cancer acquisition account business combination calistoga result operation april include consolidated statement income significant acquisitiondate fair value total consideration transfer acquire calistoga million consist cash pay prior closing million contingent consideration million follow table summarize fair value asset acquire liability assume april thousand iprd net liability assume total identifiable asset goodwill total consideration transfer iprd intangible asset associate iprd project relate idelalisib product candidate management determine estimate acquisitiondate fair value intangible asset relate iprd million estimate fair value determine income approach discount expect future cash flow present value estimate fair value present value discount rate consider estimate weightedaverage cost capital company profile substantially similar calistoga acquirer estimate weightedaverage cost capital believe appropriate give unique characteristic acquisition include competitive bidding process rate comparable estimate internal rate return acquisition represent rate market participant use value intangible asset project cash flow iprd project base key assumption estimate revenue operate profit relate project consider stage development acquisition date time resource need complete development approval product candidate life potential commercialize product associate risk include inherent difficulty uncertaintie develop product candidate obtain marketing approval fda regulatory agency risk related viability potential alternative treatment future target market intangible asset relate iprd project consider indefinitelive completion abandonment associate effort goodwill excess consideration transfer fair value assign asset acquire liability assume million represent goodwill result calistoga acquisition management believe goodwill mainly represent synergy expect combine operation acquire calistoga assemble workforce intangible asset qualify separate recognition consider calistoga acquisition material business combination disclose pro forma result operation require material business combination arresto biosciences inc december enter agreement acquire arresto million plus potential future payment base achievement certain sale target transaction close january time arresto whollyowne subsidiary arresto privatelyheld developmentstage biotechnology company base palo alto california focus develop antibody potential treatment fibrotic disease cancer lead product acquisition arresto simtuzumab refer humanize monoclonal antibody mab target human lysyl oxidaselike loxl protein addition ongoing phase study simtuzumab patient advance solid tumor time acquisition phase study initiate evaluate simtuzumab patient idiopathic pulmonary fibrosis acquisition account business combination arresto result operation january include consolidated statement income significant acquisitiondate fair value total consideration transfer acquire arresto million consist cash pay prior closing million contingent consideration million follow table summarize fair value asset acquire liability assume january thousand iprd defer tax asset defer tax liability net liability assume total identifiable net asset goodwill total consideration transfer iprd intangible asset associate iprd project relate simtuzumab product candidate management determine estimate acquisitiondate fair value intangible asset relate iprd million estimate fair value determine income approach discount expect future cash flow present value estimate fair value present value discount rate base estimate weightedaverage cost capital company profile substantially similar arresto comparable estimate internal rate return acquisition represent rate market participant use value intangible asset project cash flow iprd project base key assumption estimate revenue operate profit relate project consider stage development acquisition date time resource need complete development approval product candidate life potential commercialize product associate risk include inherent difficulty uncertaintie develop product candidate obtain marketing approval fda regulatory agency risk related viability potential alternative treatment future target market intangible asset relate iprd project consider indefinitelive completion abandonment associate effort goodwill excess consideration transfer fair value assign asset acquire liability assume million represent goodwill result arresto acquisition management believe goodwill mainly represent synergy expect combine operation acquire arresto assemble workforce intangible asset qualify separate recognition consider arresto acquisition material business combination disclose pro forma result operation require material business combination cgi pharmaceuticals inc june enter agreement acquire cgi million cash consist million upfront payment million contingent consideration payable base achievement clinical development milestone transaction close july time cgi whollyowne subsidiary cgi privatelyheld development stage pharmaceutical company base branford connecticut primarily focus small molecule chemistry protein kinase biology lead preclinical compound cgi library proprietary small molecule kinase inhibitor target spleen tyrosine kinase syk unique application treatment inflammatory disease include rheumatoid arthritis cgi acquisition account business combination result operation cgi july include consolidated statement income significant acquisitiondate fair value total consideration transfer acquire cgi million consist cash pay prior closing million contingent consideration million follow table summarize fair value asset acquire liability assume july thousand iprd defer tax asset defer tax liability net liability assume total identifiable net asset goodwill total consideration transfer iprd intangible asset associate iprd project relate preclinical syk product candidate management estimate acquisitiondate fair value intangible asset relate iprd million estimate fair value determine income approach discount expect future cash flow present value estimate fair value present value discount rate base estimate weightedaverage cost capital company profile substantially similar cgi comparable estimate internal rate return cgi operation represent rate market participant use value intangible asset project cash flow iprd project base key assumption estimate revenue operate profit relate project consider stage development time resource need complete development approval product candidate life potential commercialize product associate risk include inherent difficulty uncertaintie develop drug compound obtain marketing approval fda regulatory agency risk related viability potential alternative treatment future target market intangible asset relate iprd project consider indefinitelive completion abandonment associate effort fourth quarter record million impairment charge expense relate syk iprd asset acquire cgi impairment charge result change anticipate market share relate syk compound goodwill excess consideration transfer fair value assign asset acquire liability assume million represent goodwill result cgi acquisition management believe goodwill mainly represent synergy expect combine operation acquire cgi assemble workforce intangible asset qualify separate recognition inventory inventory summarize follow thousand december raw material work process finish good total december joint venture form gilead bms note include consolidated financial statement hold billion million inventory respectively efavirenz active pharmaceutical ingredient purchase bms bms estimate net selling price efavirenz property plant equipment property plant equipment summarize follow thousand december property plant equipment net building improvement include leasehold improvement laboratory manufacturing equipment office computer equipment capitalize lease equipment construction progress subtotal accumulate depreciation amortization include relate capitalize lease equipment respectively subtotal land total november acquire land office building total approximately square foot locate foster city california aggregate purchase price million construction progress increase million compare primarily new lab building expect complete intangible asset goodwill follow table summarize carry intangible asset goodwill thousand december indefinitelive intangible asset finitelive intangible asset total intangible asset goodwill total intangible asset goodwill indefinitelive intangible asset december indefinitelive intangible asset billion consist primarily purchase iprd acquisition pharmasset note december indefinitelive intangible asset million consist million million purchase iprd acquisition arresto calistoga respectively probabilityweighte income approach estimate current fair value record million impairment charge relate certain iprd asset acquire cgi impairment charge result change anticipate market share relate syk compound include expense consolidated statement income million purchase iprd project therapeutics inc complete reclassify finitelived intangible asset currently amortize estimate useful life finitelive intangible asset follow table summarize finitelive intangible asset thousand december december gross carry accumulate gross carry accumulate amortization amortization intangible asset ranexa intangible asset lexiscan total amortization expense relate finitelived intangible asset include cost good sell consolidated statement income total million million million year end december respectively weightedaverage amortization period intangible asset approximately year december estimate future amortization expense associate intangible asset succeed fiscal year follow thousands fiscal year total goodwill follow table summarize change carry goodwill thousand balance december goodwill result acquisition pharmasset balance december collaborative arrangement time time result enter strategic collaboration hold investment nonpublic company review interest investee company consolidation andor appropriate disclosure base applicable guidance variable interest entity vie require consolidate entity contractual term arrangement essentially provide control entity majority voting interest assess primary beneficiary vie base power direct activity vie significantly impact vie economic performance obligation absorb loss right receive benefit vie potentially significant vie december determine certain investee company vie respect joint venture bms primary beneficiary consolidate investee bristolmyers squibb company north america enter collaboration arrangement bms united states develop commercialize single tablet regimen contain truvada bms sustiva efavirenz combination approve use united states sell brand atripla bms structure collaboration joint venture operate limited liability company name bristolmyers squibb gilead sciences llc consolidate term collaboration bms grant royalty free sublicense joint venture use respective company own technology return grant license joint venture use intellectual property result collaboration bms amend joint venture collaboration agreement allow joint venture sell atripla canada economic interest joint venture hold bms include share revenue outofpocket expense base portion net selling price atripla attributable efavirenz truvada net selling price truvada change time relative net selling price efavirenz bms respective economic interest joint venture vary annually bms share marketing sale effort second quarter limited number activity jointly manage party long coordinate detail promotional activity united states party begin reduce joint promotional effort launch complera august stribild august party continue collaborate activity manufacture regulatory compliance pharmacovigilance daily operation joint venture govern primary joint committee form bms gilead responsible accounting financial reporting tax reporting manufacturing product distribution joint venture party provide respective bulk active pharmaceutical ingredient joint venture approximate market value agreement continue terminate mutual agreement party addition party terminate party participation collaboration day launch generic version party single agent product double agent product nonterminate party right continue sell atripla obligate pay terminate party certain royalty threeyear period follow effective date termination december joint venture hold efavirenz active pharmaceutical ingredient purchase bms bms estimate net selling price efavirenz market amount include inventory consolidate balance sheet december total asset hold joint venture billion consist primarily cash cash equivalent million account receivable million inventory billion total liability billion consist primarily account payable million accrue expense million december total asset hold joint venture billion consist primarily cash cash equivalent million account receivable million inventory billion total liability billion consist primarily account payable million accrue expense million asset liability amount reflect impact intercompany elimination include consolidated balance sheet consolidate joint venture legal structure joint venture limit recourse creditor general credit asset similarly asset hold joint venture settle obligation joint venture europe gilead sciences limit whollyowne subsidiary ireland bms enter collaboration agreement bms set forth term condition bms commercialize distribute atripla european union iceland liechtenstein norway switzerland collectively european territory party form limited liability company consolidate manufacture atripla distribution european territory efavirenz purchase bms bms estimate net selling price efavirenz european territory responsible product distribution inventory management warehouse local subsidiary primary responsibility order fulfillment collection receivables customer relation handle sale return territory bms promote atripla general party share revenue outofpocket expense proportion net selling price component atripla truvada efavirenz start quarter limited number activity jointly manage party long coordinate detail promotional activity region responsible accounting financial reporting tax reporting collaboration december efavirenz purchase bms bms estimate net selling price efavirenz european territory include inventory consolidate balance sheet party form limited liability company hold marketing authorization atripla europe primary responsibility regulatory activity major market country party agree independently continue use commercially reasonable effort promote atripla roche tamiflu enter development license agreement agreement roche develop commercialize therapy treat prevent viral influenza tamiflu antiviral oral formulation treatment prevention influenza codevelope roche agreement roche exclusive right obligation manufacture sell tamiflu worldwide subject obligation pay percentage net revenue roche generate tamiflu sale turn subject reduction certain define manufacturing cost enter amendment supplement agreement roche amend agreement provide formation joint manufacturing committee review roche manufacturing capacity tamiflu global plan manufacture tamiflu commercial committee evaluate commercial plan strategy tamiflu united states joint supervisory committee evaluate roche overall commercial plan tamiflu global basis case consist representative roche amend agreement option provide specialized sale force supplement roche marketing effort united states tamiflu exercise date agreement roche obligation pay royalty terminate countrybycountry basis patent provide exclusivity tamiflu country expire roche terminate agreement reason case right tamiflu revert party terminate agreement response material breach party royalty payable net sale tamiflu sell roche remain amend agreement follow million worldwide net sale give calendar year million worldwide net sale calendar year worldwide net sale excess million calendar year amend agreement revise provision agreement relate calculation royalty payment give calendar quarter roche pay royalty base actual royalty rate applicable quarter addition amend agreement royalty payable roche long subject cost good sell adjustment provide agreement record total million million million tamiflu royalty respectively ranexa result acquisition therapeutic assume right agreement therapeutic roche exclusive worldwide license ranexa license agreement pay initial license fee obligate certain payment roche receipt second product approval ranexa follow major market country france germany italy united states united kingdom receive fda approval ranexa treatment chronic angina pay million roche accordance agreement receive marketing authorization european medicine agency ema ranexa treatment chronic angina european union member state pay million roche relate approval capitalize longterm asset consolidated balance sheet amortize useful patent life approximately year expiring enter amendment agreement roche relate ranexa amendment provide exclusive worldwide commercial right ranexa potential indication human term amendment upfront payment roche obligate royalty payment roche worldwide net product sale license product addition obligate additional milestone payment achievement certain regulatory approval japan tobacco inc japan tobacco grant exclusive right develop commercialize elvitegravir novel hiv integrase inhibitor country world exclude japan japan tobacco retain right agreement responsible seek regulatory approval territory require use diligent effort commercialize product treatment hiv infection bear cost expense associate commercialization effort term agreement incur upfront license fee million include expense future alternative use technology record million expense relate milestone incur result dose patient phase clinical study record million expense relate milestone pay related dose patient phase clinical study december announce submit marketing authorization application ema marketing approval stribild oncedaily single tablet regimen elvitegravir cobicistat tenofovir disoproxil fumarate emtricitabine record million expense december relate milestone incur connection filing obligate additional payment achievement milestone pay royalty future product sale arise collaboration august capitalize million related milestone incur connection fda approval stribild amortize useful patent life approximately year expire janssen ireland enter license collaboration agreement janssen ireland janssen tibotec pharmaceutical develop commercialize fixeddose combination truvada janssen nonnucleoside reverse transcriptase inhibitor rilpivirine combination approve united states european union sell trade complera united states eviplera european union license collaboration agreement janssen grant exclusive license compleraeviplera administration adult oncedaily oral dosage form worldwide exclude certain middle income develop world country japan party restrict combine drug product drug accordance term agreement obligate reimburse million approximately million development cost incur janssen rilpivirine december record million approximately million million approximately million respectively reimbursable expense incur janssen development rilpivirine reimbursable expense incur janssen responsible manufacturing compleraeviplera lead role registration distribution commercialization combination product license country janssen exercise right codetail combination product country gilead sell party amend agreement include distribution compleraeviplera rest world right distribute product north america europe latin america argentina mexico australia new zealand janssen right distribute product region include japan russia price combination product sum price truvada rilpivirine component cost rilpivirine purchase janssen combination product approximate market price rilpivirine specified percentage major market longterm obligation financing arrangement follow table summarize carry borrowing financing arrangement thousand interest december type borrowing description issue date date rate convertible senior note april convertible senior note july convertible senior note july senior unsecured april note march april senior unsecured december note december december senior unsecured december note december december senior unsecured december note december december senior unsecured december note december december credit facility fiveyear revolver january january variable total debt net current portion total longterm debt net convertible senior note april issue million note private placement pursuant rule securities act amend portion note convert repay million principal balance pay million cash relate conversion spread note represent conversion value excess principal receive million cash convertible note hedge relate note note issue par bear interest rate debt issuance cost million record longterm asset amortize interest expense contractual term note initial conversion rate note share principal note represent initial conversion price approximately share conversion rate subject customary antidilution adjustment note convert subject adjustment follow circumstance calendar quarter begin september closing price common stock trading day consecutive trading day period previous quarter applicable conversion price share specified distribution holder common stock specify corporate transaction occur month prior maturity applicable note conversion holder receive cash equal less principal note conversion value note conversion value exceed principal deliver option cash common stock combination cash common stock conversion value excess principal note convert connection change control require provide premium form increase conversion rate subject state maximum addition event change control holder require purchase portion note purchase price equal principal plus accrue unpaid interest december ifconverte value note exceed principal note million concurrent issuance note purchase convertible note hedge private transaction cost million tax deductible life note sell warrant private transaction acquire million share common stock receive net proceed million sale warrant convertible note hedge warrant intend reduce potential economic dilution future conversion note effectively increase conversion price share note net cost million convertible note hedge warrant transaction record stockholder equity consolidated balance sheet addition contract classify stockholder equity index common stock account derivative convertible note hedge cover subject customary antidilution adjustment million share common stock strike price initially correspond initial conversion price note subject adjustment similar applicable conversion price relate note market value share common stock time conversion note strike price applicable convertible note hedge entitle receive counterpartie transaction share common stock extent correspond election respect relate convertible note cash combination cash share common stock option excess market value common stock strike price convertible note hedge convertible note hedge terminate maturity note note remain outstanding conversion million share common stock underlie warrant subject customary antidilution adjustment warrant strike price share exercisable expiration date market value common stock time exercise applicable warrant exceed strike price require net settle cash share common stock option counterpartie value warrant excess warrant strike price contemporaneously close sale note portion net proceed note issuance proceed warrant transaction repurchase share common stock current accounting guidance bifurcated conversion option note debt instrument classified conversion option equity accrete result debt discount interest expense contractual term note follow table summarize information equity liability component note thousand carry value net carrying unamortized discount equity component liability component liability component december december december convertible senior note year end december recognize million million million respectively interest expense relate contractual coupon rate amortization debt discount note effective interest rate liability component note convertible senior note july issue billion note billion note private placement pursuant rule securities act amend note note issue par bear interest rate respectively debt issuance cost million record longterm asset amortize interest expense contractual term note note aggregate principal note note sell reflect exercise initial purchaser option purchase additional note cover overallotment initial conversion rate note share principal represent initial conversion price approximately share initial conversion rate note share principal represent initial conversion price approximately share conversion rate subject customary antidilution adjustment note note convert prior april april respectively follow circumstance calendar quarter commence september closing price common stock trading day consecutive period consecutive trading day end trading day precede calendar quarter great applicable conversion price applicable trading day business day period measurement period consecutive trading day trading day period trading price principal note product report sale price common stock applicable conversion rate trading day occurrence specify corporate transaction distribution certain stock right cash amount asset shareholder occurrence change control april case note april case note holder convert note time regardless forego circumstance generally conversion holder receive cash equal less principal note conversion value note measure indenture govern relevant note conversion value exceed principal deliver option cash common stock combination cash common stock conversion value excess principal note note convert connection change control require provide premium form increase conversion rate subject state maximum addition event change control holder require purchase portion note purchase price equal principal plus accrue unpaid interest december ifconverte value note note exceed principal amount note million million respectively concurrent issuance note note purchase convertible note hedge private transaction cost million tax deductible life note sell warrant private transaction acquire million share common stock receive net proceed million sale warrant convertible note hedge warrant intend reduce potential economic dilution future conversion note note effectively increase conversion price share note share note net cost million convertible note hedge warrant transaction record stockholder equity consolidated balance sheet addition contract classify stockholder equity index common stock account derivative convertible note hedge cover subject customary antidilution adjustment million share common stock strike price initially correspond initial conversion price note note subject adjustment similar applicable conversion price relate note market value share common stock time conversion note note strike price applicable convertible note hedge entitle receive counterpartie transaction share common stock extent correspond election respect relate convertible note cash combination cash share common stock option excess market value common stock strike price convertible note hedge convertible note hedge terminate maturity note note note note remain outstanding conversion million share common stock underlie warrant subject customary antidilution adjustment warrant strike price share warrant expire share warrant expire exercisable respective expiration date market value common stock time exercise applicable warrant exceed respective strike price require net settle cash share common stock option respective counterpartie value warrant excess warrant strike price net proceed issuance convertible note repurchase share common stock repay exist indebtedness current accounting guidance bifurcated conversion option note note debt instrument classified conversion option equity accrete result debt discount interest expense contractual term note note follow table summarize information equity liability component note note thousand carry value net carrying unamortized discount equity component liability component liability component december december december convertible senior note convertible senior note total convertible senior note year end december recognize million million million respectively interest expense relate contractual coupon rate amortization debt discount note note effective interest rate liability component note note respectively april senior unsecured note march issue april note register offering aggregate principal billion april note mature april pay interest fix annual rate debt issuance cost incur connection issuance debt total approximately million amortize interest expense contractual term april note year end december recognize million million respectively interest expense relate contractual coupon rate amortization debt discount april note april note redeem option time time time redemption price equal great principal note redeem sum determine independent investment banker present value remain schedule payment principal interest note redeem exclusive interest accrue date redemption discount redemption date semiannual basis treasury rate plus basis point plus case accrue unpaid interest note redeem date redemption time january redeem note principal note redeem plus accrue unpaid interest date redemption addition event occurrence change control downgrade rating april note investment grade rating standard poor rating service moody investors service inc holder require purchase portion note price equal principal plus accrue unpaid interest net proceed general corporate purpose include repayment exist indebtedness repurchase common stock december senior unsecured note december issue december note december note december note december note december note register offer million million billion billion respectively aggregate principal billion note mature december pay interest fix annual rate respectively debt issuance cost incur connection issuance debt total approximately million amortize interest expense contractual term respective note year end december recognize million million respectively interest expense relate contractual coupon rate amortization debt discount december note note redeem option time time time redemption price equal great principal note redeem sum determine independent investment banker present value remain schedule payment principal interest note redeem exclusive interest accrue date redemption discount redemption date semiannual basis treasury rate plus basis point case december note december note basis point case december note december notes plus case accrue unpaid interest note redeem date redemption time date month prior maturity date december note redeem note principal note redeem plus accrue unpaid interest date redemption time date month prior maturity date december note redeem note principal note redeem plus accrue unpaid interest date redemption event occurrence change control downgrade rating series note investment grade rating standard poor rating service moody investors service inc holder series note require purchase portion note series price equal aggregate principal note repurchase plus accrue unpaid interest net proceed fund acquisition pharmasset complete january note credit facility eligible borrow aggregate billion revolving credit loan amend restate credit agreement enter credit agreement include subfacility swingline loan letter credit december million letter credit outstanding credit agreement january fully repay outstanding obligation credit agreement terminate credit agreement january conjunction acquisition pharmasset enter fiveyear billion revolve credit facility credit agreement year revolve credit agreement million shortterm revolve credit facility credit agreement shortterm revolve credit agreement billion term loan facility term loan credit agreement borrow million fiveyear revolve credit agreement million shortterm revolve credit agreement billion term loan credit agreement close acquisition fully repay outstanding debt term loan credit agreement shortterm revolve credit agreement time agreement terminate fiveyear revolve credit agreement contain customary representation warranty affirmative negative financial maintenance covenant event default loan bear interest eurodollar rate plus applicable margin base rate plus applicable margin define credit agreement reduce commitment prepay loan time premium penalty require comply certain covenant credit agreement note indenture december compliance covenant fiveyear revolve credit agreement inclusive million swing line loan subfacility million letter credit subfacility december million letter credit outstanding fiveyear revolve credit agreement fiveyear revolve credit agreement terminate amount owe agreement shall payable january commitment contingency lease arrangement enter longterm noncancelable operating lease equipment facility lease facility foster city fremont palo alto san dimas california branford connecticut princeton new jersey durham north carolina seattle washington dublin cork areas ireland london area united kingdom operate lease sale marketing administrative facilities europe canada asia lease expire date lease contain option renew certain facility lease contain rent escalation clause significant lease relate facility seattle washington expire year term lease provide consecutive right extend term lease contain annual percent rent escalation clause lease require pay additional amount operating expense maintenance lease corporate aircraft vary term renewal option expiration lease term lease expense operating lease approximately million million million year end december respectively aggregate noncancelable future minimum rental payment operating lease follow thousand total legal proceeding department justice investigation june receive subpoena attorney office northern district california request document relate manufacture relate quality distribution practice atripla emtriva hepsera letairis truvada viread complera cooperating continue cooperate governmental inquiry estimate possible loss range loss determine litigation generic manufacturer approval process product fda grant new chemical entity nce exclusivity period manufacturer application approval generic version product grant generic manufacturer challenge patent protect product grant exclusivity year prior end exclusivity period generic manufacturer seek continue seek fda approval similar identical drug anda application form typically manufacturer seek approval generic drug receive notice generic manufacturer submit andas manufacture generic version atripla truvada viread hepsera ranexa tamiflu united states atripla truvada viread canada expect begin trial generic manufacturer february gilead teva reach agreement principle settle ongoing patent litigation concern patent protect tenofovir disoproxil fumarate viread truvada atripla product trial litigation adjourn pende completion activity necessary finalize settlement agreement teva allow launch generic version viread december settlement agreement file federal trade commission department justice review final trial relate patent associate ranexa schedule begin april anticipate trial relate patent relate hepsera begin mid trial relate patent protect emtricitabine patent atripla schedule begin october predict ultimate outcome action spend significant resource enforce defend patent unsuccessful lawsuit original claim patent narrow invalidated patent protection atripla truvada viread hepsera ranexa tamiflu united states atripla truvada viread canada substantially shorten patent cover product invalidate fda canadian ministry health approve request manufacture generic version products united states canada respectively prior expiration date patent sale generic version product hepsera early patent expiration significant negative effect revenue result operation matter party legal action arise ordinary course business believe legal action material adverse impact consolidate business financial position result operation commitment normal course business enter firm purchase commitment primarily relate active pharmaceutical ingredient certain inventory relate item december commitment year approximately billion million million million million amount relate active pharmaceutical ingredient represent minimum purchase requirement actual payment purchase relate active pharmaceutical ingredient billion billion million year end december stockholder equity stock repurchase programs january board authorize program repurchase common stock billion open market private block transaction pursuant rule plan privately negotiate purchase mean complete plan time board authorize threeyear billion stock repurchase program december repurchase billion common stock program remain authorize stock repurchase program billion spend total billion repurchase retire million share common stock average purchase price share january board authorize threeyear billion stock repurchase program initiate purchase program september completion stock repurchase program december repurchase billion common stock january stock repurchase program remain authorize stock repurchase plan billion spend total million repurchase retire million share common stock average purchase price share use par value method accounting stock repurchase par value method common stock charge par value share involve excess cost share acquire par value allocate apic base estimate average sale price issue share excess amount charge retain earning follow table summarize reduction common stock apic charge retain earning result stock repurchase millions year end december reduction common stock apic charge retain earning prefer stock share authorize preferred stock issuable series board authorize determine designation power preference right series prefer stock outstanding december right plan september terminate right plan equity incentive plan stockholder approve adopt gilead sciences inc equity incentive plan plan replace exist equity plan prior plan remain share available future grant prior plan transfer plan additionally award grant prior plan expire terminate exercised share common stock reserve award add pool available share common stock plan plan broad base incentive plan provide grant equitybase award include stock option restrict stock unit restrict stock award performance award employee director consultant plan authorize issue maximum share fullvalue award restrict stock restrict stock unit performance share performance unit extent settle common stock phantom share term plan plan authorize issuance total share common stock december share remain available future grant plan stock option plan provide option grant designate nonqualifie incentive stock option prior january grant nonqualified incentive stock option stock option grant january nonqualified stock option plan employee stock option grant prior generally vest year stock option grant start generally vest year option exercisable period exceed contractual term year date stock option issue grant price fair market value common stock grant date stock option exercise settle common stock plan previously authorize available pool share connection acquisition arresto assume arresto equity incentive plan arresto plan option issue outstanding arresto plan convert option purchase common stock effective january number convert option purchase common stock significant share available future grant arresto plan follow table summarize activity stock option plan option grant present table exercise price fair value underlie common stock grant date share thousand weight average share exercise price outstanding december grant assume forfeited expire exercise outstanding december exercisable end year total intrinsic value option exercise year end december million million million respectively total fair value stock option vest year end december million million million respectively weightedaverage grant date fair value stock option grant year end december share respectively december number option outstanding expect vest net estimate future option forfeiture weightedaverage exercise price share aggregate intrinsic value million weightedaverage remain contractual life year aggregate intrinsic value stock option outstanding stock option exercisable december billion billion respectively december weightedaverage remain contractual life option outstanding option exercisable year respectively december million unrecognized compensation cost relate stock option expect recognize estimate weightedaverage period year performance award plan grant performancebase restricted stock unit vest achievement specify market performance goal include achieve total shareholder return compare predetermine peer group achieve revenue target performance share actual number common share ultimately issue calculated multiplying number performance unit payout percentage range performance share vest committee subcommittee board determine specify market performance goal achieve january grant performance share respectively award generally vest period year fair value performance share estimate date grant depend term award fair value date grant determine base monte carlo valuation methodology stock price date grant follow table summarize performance share activity relate information thousand share amount weightedaverage grantdate share fair value share outstanding december grant vest forfeited outstanding december weightedaverage grant date fair value performance share share respectively recognize million million million stockbase compensation expense respectively relate performance share december million unrecognized compensation cost relate performance share expect recognize estimate weightedaverage period year total fair value performance share vest year end december million million million respectively grant performancebase restrict stock award certain employee plan vest award subject achievement specify individual performance goal date number unit grant fair value award significant restrict stock unit grant timebase restrict stock unit rsus certain employee annual employee equity compensation review program new hire employee nonemployee members board rsus share awards entitle holder receive freely tradable share common stock vest award grant prior rsus vest ratably annual basis year date grant start january rsus vest year date grant fair value rsu equal closing price common stock grant date follow table summarize rsu activity relate information thousand share amount weightedaverage grantdate share fair value share outstanding december grant assume vested forfeited outstanding december weightedaverage grant date fair value rsus grant year end december share respectively total fair value rsus vest year end december million million million respectively december million unrecognized compensation cost relate unvested rsus expect recognize weighted average period year employee stock purchase plan employee stock purchase plan amend international employee stock purchase plan espp employee purchase share common stock base percentage compensation subject certain limit purchase price share equal low fair market value common stock offering date purchase date espp offer twoyear lookback feature automatic reset feature provide offer period reset new lowerpriced offering offer price new offering period current offering period espp purchase settle common stock espp previously authorize available pool share share issue espp million total share common stock reserve issuance espp share available issuance espp december december million unrecognized compensation cost relate espp expect recognize estimate weightedaverage period year stockbase compensation follow table summarize stockbase compensation expense include consolidated statement income thousands year end december cost good sell research development expense sell general administrative expense stockbase compensation expense include total cost expense income tax effect stockbase compensation expense net tax year end december capitalize million million million stockbase compensation cost inventory respectively million million million remain inventory december respectively total stockbased compensation year end december include million million sga expense respectively relate acceleration unvested stock option connection acquisition pharmasset close quarter stockbase compensation recognize expense requisite service period consolidate statement income grade vest expense attribution approach unvested stock option grant prior january straightline expense attribution approach stock option grant adoption new guidance sharebase payment employee director january stockbase compensation expense relate stock option recognize adoption new guidance base award ultimately expect vest gross expense reduce estimate forfeiture guidance require forfeiture estimate time grant revise necessary subsequent period actual forfeiture differ estimate estimate forfeiture base historical experience prior adoption guidance pro forma information require disclose include forfeiture occur result guidance adopt january recognize tax benefit stockbase compensation apic incremental tax benefit realize tax attribute currently available utilize addition elect account indirect benefit stockbase compensation research tax credit extraterritorial income deduction consolidate statement income apic valuation assumption fair value option grant plan purchase espp estimate grant purchase date blackschole option valuation model blackschole option valuation model develop use estimate fair value trade option vest restriction fully transferable addition option valuation model require input highly subjective assumption include expect stock price volatility expect award life follow assumption calculate estimate fair value award year end december expect volatility stock option espp expect term year stock option espp riskfree interest rate stock option espp expect dividend yield fair value stock option grant calculate single option approach use blend historical volatility imply volatility trade option common stock determine expect volatility expect term stockbase award represent weightedaverage period award expect remain outstanding estimate weightedaverage expect term base historical cancellation historical exercise datum relate stock option contractual term vest term award riskfree interest rate base observe interest rate appropriate term stockbase award dividend yield base history expectation dividend payout segment information product sale operate business segment primarily focus development commercialization human therapeutic life threaten disease product include segment majority product similar economic characteristic include nature product production process type customer distribution method regulatory environment product sale consist follow thousands year end december antiviral product atripla truvada viread compleraeviplera stribild hepsera emtriva total antiviral product letairis ranexa ambisome product total product sale follow table summarize total revenue external customer collaboration partner geographic region thousand product sale productrelate contract revenue attribute region base shipto location royalty nonproduct relate contract revenue attribute region base location collaboration partner year end december revenues united states europe countrie total revenue follow table summarize revenue customer individually account total revenue percentage total revenue year end december cardinal health inc mckesson corp amerisourcebergen corp property plant equipment december net book value property plant equipment united states ireland canada million million million respectively comprise approximately total net book value property plant equipment december net book value property plant equipment united states ireland canada million million million respectively comprise approximately total net book value property plant equipment income taxis provision income taxis consist follow thousands year end december federal current deferred state current defer foreign current defer provision income taxis foreign pretax income million billion billion respectively cumulative unremitted foreign earning consider indefinitely reinveste foreign subsidiary taxis provide approximately billion billion december respectively residual tax liability amount remit approximately billion billion december respectively difference provision income taxis compute apply federal statutory income tax rate income provision income taxis follow thousands year end december income provision income taxis tax federal statutory rate state taxis net federal benefit foreign earning different rate research credit net unbenefitted stock compensation nondeductible pharmaceutical excise tax provision income taxis defer income taxis reflect net tax effect temporary difference carry amount asset liability financial reporting purpose amount income tax purpose significant component defer tax asset liability follow thousand december defer tax asset net operating loss carryforward stockbase compensation reserve accrual currently deductible defer revenue depreciation relate research credit carryforward net total defer tax asset valuation allowance valuation allowance total defer tax asset defer tax liability intangible unremitted foreign earning total defer tax liability net defer tax asset valuation allowance increase million year end december valuation allowance decrease million year end december increase million year end december conclude base standard set forth fasb accounting standard codification relate income taxis likely realize benefit defer tax asset relate certain state net operating loss credit carryforward december federal net operating loss carryforward approximately million federal net operating loss carryforward start expire utilize federal tax credit carryforward approximately million start expire utilize addition state net operating loss tax credit carryforward approximately billion million respectively state net operating loss tax credit carryforward start expire utilize utilization net operating loss tax credit subject annual limitation ownership change limitation provide internal revenue code amend similar state provision annual limitation result expiration net operating loss credit utilization file federal state foreign income tax return jurisdiction unite states abroad federal income tax purpose statute limitation open onwards certain acquire entity statute limitation open year inception utilization net operating loss credit carry prior year california income tax purpose statute limitation open onwards income tax return audit federal state foreign tax authority currently examination internal revenue service irs tax year state foreign jurisdiction differ interpretation tax law regulation result significant dispute arise tax authority involve issue time deduction allocation income tax jurisdiction periodically evaluate exposure associate tax filing position december total federal state foreign unrecognized tax benefit million million respectively total unrecognized tax benefit million million december respectively recognize reduce effective tax rate period recognition continue classify interest penalty relate unrecognized tax benefit income tax provision consolidate statement income december accrue interest penalty relate unrecognized tax benefit million million respectively december believe reasonably possible unrecognized tax benefit significantly change month expect clarification irs tax authority uncertain tax position follow rollforward total gross unrecognized tax benefit liability year end december thousand december balance beginning period tax position relate current year addition reduction tax position relate prior year addition reduction settlement lapse statute limitation balance end period defer compensation plan maintain retirement saving plan eligible employee defer compensation income tax purpose section internal revenue code gilead plan gilead plan employee contribute eligible annual compensation subject irs plan limit match contribution gilead plan contribute employee contribution annual maximum match annual maximum match total matching contribution expense gilead plan year end december million million million respectively maintain deferred compensation plan director key employee defer compensation income tax purpose defer compensation plan nonqualifie defer compensation plan subject qualification requirement section internal revenue code compensation defer december subject requirement section internal revenue code plan officer senior grade level employee contribute annual salary annual bonus director contribute annual retainer fee effective director defer rsu award amount defer participant deposit rabbi trust record longterm asset consolidate balance sheet begin director elect receive portion annual cash retainer phantom share give participant right receive equal value specify number share specify period time payable share common stock fractional share pay cash establish plan administrator december phantom share outstanding participant elect distribution date event available plan receive defer compensation payment subsequent event acquisition biosciences inc december sign definitive agreement acquire biosciences inc usd share cash approximately million transaction complete february time whollyowne subsidiary quarterly result operation unaudite follow amount thousand share amount quarter quarter quarter quarter total revenue gross profit product sale net income net income attributable gilead net income share attributable gilead common stockholdersbasic net income share attributable gilead common stockholdersdilute total revenue gross profit product sale net income net income attributable gilead net income share attributable gilead common stockholdersbasic net income share attributable gilead common stockholdersdilute net income share period present reflect twoforone stock split effective january fourth quarter record million impairment charge expense relate certain iprd asset acquire cgi gilead sciences inc schedule valuation qualifying account thousand balance begin additionscharged balance end period expense deduction period year end december account receivable allowance valuation allowance defer tax asset year end december account receivable allowance valuation allowance defer tax asset year end december account receivable allowance valuation allowance defer tax asset allowance doubtful account sale return cash discount government chargeback valuation allowance defer tax asset include million million december respectively relate acquisition